<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome - Fraison, E - 2020 | Cochrane Library</title> <meta content="Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome - Fraison, E - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005552.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome - Fraison, E - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005552.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005552.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome" name="citation_title"/> <meta content="Eloise Fraison" name="citation_author"/> <meta content="Hôpital Femme Mère Enfant" name="citation_author_institution"/> <meta content="Elena Kostova" name="citation_author"/> <meta content="Amsterdam UMC, University of Amsterdam" name="citation_author_institution"/> <meta content="Lisa J Moran" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="Sophia Bilal" name="citation_author"/> <meta content="Westmead Hospital" name="citation_author_institution"/> <meta content="Carolyn C Ee" name="citation_author"/> <meta content="Western Sydney University" name="citation_author_institution"/> <meta content="Christos Venetis" name="citation_author"/> <meta content="UNSW Medicine" name="citation_author_institution"/> <meta content="Michael F Costello" name="citation_author"/> <meta content="School of Women's and Children's Health, UNSW and Royal Hospital for Women and IVF Australia" name="citation_author_institution"/> <meta content="mfcostello@unsw.edu.au" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD005552.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/08/13" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005552.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005552.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005552.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acne Vulgaris [drug therapy]; Body Mass Index; Cardiovascular Diseases [prevention &amp; control]; Contraceptives, Oral, Combined [adverse effects, *therapeutic use]; Drug Therapy, Combination; Endometrial Neoplasms [prevention &amp; control]; Hirsutism [*drug therapy]; Hypoglycemic Agents [*therapeutic use]; Menstruation Disturbances [*drug therapy]; Metformin [adverse effects, *therapeutic use]; Polycystic Ovary Syndrome [complications, *drug therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005552.pub3&amp;doi=10.1002/14651858.CD005552.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="JmNqPX1V";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005552\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005552\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005552\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005552\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","th","ko","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005552.pub3",title:"Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome",firstPublishedDate:"Aug 13, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=JmNqPX1V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005552.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005552.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005552.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005552.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005552.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005552.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005552.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005552.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005552.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005552.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>21304 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005552.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-sec-0056"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-sec-0038"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-sec-0050"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/appendices#CD005552-sec-0061"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/table_n/CD005552StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/table_n/CD005552StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/information#CD005552-cr-0004">Eloise Fraison</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/information#CD005552-cr-0005">Elena Kostova</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/information#CD005552-cr-0006">Lisa J Moran</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/information#CD005552-cr-0007">Sophia Bilal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/information#CD005552-cr-0008">Carolyn C Ee</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/information#CD005552-cr-0009">Christos Venetis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005552.pub3/information#CD005552-cr-0010"><i class="icon corresponding-author fa fa-envelope"></i>Michael F Costello</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/information/en#CD005552-sec-0071">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 13 August 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005552.pub3">https://doi.org/10.1002/14651858.CD005552.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005552-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005552-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005552-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005552-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005552-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD005552-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD005552-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005552-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005552-abs-0001" lang="en"> <section id="CD005552-sec-0001"> <h3 class="title" id="CD005552-sec-0001">Background</h3> <p>Metformin has been proposed as possibly a safer and more effective long‐term treatment than the oral contraceptive pill (OCP) in women with polycystic ovary syndrome (PCOS). It is important to directly compare the efficacy and safety of metformin versus OCP in the long‐term treatment of women with PCOS. This is an update of a Cochrane Review comparing insulin sensitising agents with the OCP and only includes studies on metformin. </p> </section> <section id="CD005552-sec-0002"> <h3 class="title" id="CD005552-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of metformin versus the OCP (alone or in combination) in improving clinical, hormonal, and metabolic features of PCOS. </p> </section> <section id="CD005552-sec-0003"> <h3 class="title" id="CD005552-sec-0003">Search methods</h3> <p>In August 2019 we searched the Cochrane Gynaecology and Fertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase and CINAHL, the trial registers, handsearched references of the identified articles, and contacted experts in the field to identify additional studies. </p> </section> <section id="CD005552-sec-0004"> <h3 class="title" id="CD005552-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) of the use of metformin versus the OCP (alone or in combination) for women with PCOS. </p> </section> <section id="CD005552-sec-0005"> <h3 class="title" id="CD005552-sec-0005">Data collection and analysis</h3> <p>We used standard methods recommended by Cochrane. The primary review outcomes were the clinical parameters of hirsutism and adverse events, both severe (requiring stopping of medication), and minor. In the presence of substantial heterogeneity (I<sup>2</sup> statistic &gt; 50), which could be explained by pre‐specified subgroup analyses on the basis of BMI, we reported the subgroups separately. </p> </section> <section id="CD005552-sec-0006"> <h3 class="title" id="CD005552-sec-0006">Main results</h3> <p>This is a substantive update. We identified 38 additional studies. We included 44 RCTs (2253 women), which comprised 39 RCTs on adult women (2047 women) and five RCTs on adolescent women (206 women). Evidence quality ranged from very low to low. The main limitations were risk of bias, imprecision and inconsistency. </p> <p><b>Metformin versus the OCP</b> </p> <p>In adult women, we are uncertain of the effect of metformin compared to the OCP on hirsutism in subgroup body mass index (BMI) &lt; 25 kg/m<sup>2</sup> (mean difference (MD) 0.38, 95% confidence interval (CI) ‐0.44 to 1.19, 3 RCTs, n = 134, I<sup>2</sup> = 50%, very low‐quality evidence) and subgroup BMI &gt; 30 kg/m<sup>2</sup> (MD ‐0.38, 95% CI ‐1.93 to 1.17; 2 RCTs, n = 85, I<sup>2</sup> = 34%, low‐quality evidence). Metformin may be less effective in improving hirsutism compared to the OCP in the subgroup BMI 25 kg/m<sup>2</sup> to 30 kg/m<sup>2</sup> (MD 1.92, 95% CI 1.21 to 2.64, 5 RCTs, n = 254, I<sup>2</sup> = 0%, low‐quality evidence). Metformin may increase severe gastro‐intestinal adverse events rate compared to the OCP (Peto odds ratio (OR) 6.42, 95% CI 2.98 to 13.84, 11 RCTs, n = 602, I<sup>2</sup> = 0%, low‐quality evidence). Metformin may decrease the incidence of severe other adverse events compared to the OCP (Peto OR 0.20, 95% CI 0.09 to 0.44, 8 RCTs, n = 363, I<sup>2</sup> = 0%, low‐quality evidence). There were no trials reporting on minor adverse events.<br/>In adolescents, we are uncertain whether there is a difference between Metformin and the OCP, on hirsutism and adverse events. </p> <p><b>Metformin versus metformin combined with the OCP</b> </p> <p>In adult women, metformin may be less effective in improving hirsutism compared to Metformin combined with the OCP (MD 1.36, 95% CI 0.62 to 2.11, 3 RCTs, n = 135, I<sup>2</sup>= 9%, low‐quality evidence). We are uncertain if there was a difference between metformin and metformin combined with the OCP for severe gastro‐intestinal adverse events (OR 0.74, 95% CI 0.21 to 2.53, 3 RCTs, n = 171, I<sup>2</sup> = 0%, low‐quality evidence), or for severe other adverse events (OR 0.56, 95% CI 0.11 to 2.82, 2 RCTs, n = 109, I<sup>2</sup> = 44%, low‐quality evidence). There were no trials reporting on minor adverse events. In adolescents, there were no trials for this comparison. </p> <p><b>The OCP versus metformin combined with the OCP</b> </p> <p>In adult women, the OCP may be less effective in improving hirsutism compared to metformin combined with the OCP (MD 0.54, 95% CI 0.20 to 0.89, 6 RCTs, n = 389, I<sup>2</sup>= 1%, low‐quality evidence). The OCP may decrease the incidence of severe gastro‐intestinal adverse events compared to metformin combined with the OCP (OR 0.20, 95% CI 0.06 to 0.72, 5 RCTs, n = 228, I<sup>2</sup> = 0%, low‐quality evidence). We are uncertain if there is a difference between the OCP and metformin combined with the OCP for severe other adverse events (OR 1.61, 95% CI 0.49 to 5.37, 4 RCTs, n = 159, I<sup>2</sup> = 12%, low‐quality evidence). The OCP may decrease the incidence of minor (gastro‐intestinal) adverse events compared to metformin combined with the OCP (OR 0.06, 95% CI 0.01 to 0.44, 2 RCTs, n = 98, I<sup>2</sup> = 0%, low‐quality evidence). In adolescents, we are uncertain whether there is a difference between the OCP, compared to metformin combined with the OCP, on hirsutism or adverse events. </p> </section> <section id="CD005552-sec-0007"> <h3 class="title" id="CD005552-sec-0007">Authors' conclusions</h3> <p>In adult women with PCOS, metformin may be less effective in improving hirsutism compared to the OCP in the subgroup BMI 25 kg/m<sup>2</sup> to 30 kg/m<sup>2</sup> but we are uncertain if there was a difference between metformin and the OCP in subgroups BMI &lt; 25 kg/m<sup>2</sup> and BMI &gt; 30kg/m<sup>2</sup>. Compared to the OCP, metformin may increase the incidence of severe gastro‐intestinal adverse events and decrease the incidence of severe other adverse events with no trials reporting on minor adverse events. Either metformin alone or the OCP alone may be less effective in improving hirsutism compared to metformin combined with the OCP. We are uncertain whether there is a difference between the OCP alone and metformin alone compared to metformin combined with the OCP for severe or minor adverse events except for the OCP versus metformin combined with the OCP where the OCP may decrease the incidence of severe and minor gastro‐intestinal adverse events.<br/>In adolescent women with PCOS, we are uncertain whether there is a difference between any of the comparisons for hirsutism and adverse events due to either no evidence or very low‐quality evidence. </p> <p>Further large well‐designed RCTs that stratify for BMI are needed to evaluate metformin versus the OCP and combinations in women with PCOS, in particular adolescent women. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005552-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005552-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005552-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005552-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005552-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD005552-abs-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD005552-abs-0012">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD005552-abs-0010">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005552-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD005552-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD005552-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005552-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD005552-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005552-abs-0002" lang="en"> <h3>Metformin versus the combined oral contraceptive pill for excessive facial/body hair, acne, and menstrual disorders in polycystic ovary syndrome </h3> <p><i><b>Review question</b> </i> </p> <p>Is Metformin more effective and safer than the oral contraceptive pill (OCP) (alone or in combination) in improving clinical, hormonal, and metabolic features (irregular/prolonged menstrual cycles, excessive facial and body hair, acne, obesity) in women with polycystic ovary syndrome (PCOS)? </p> <p><i><b>Background</b> </i> </p> <p>PCOS is a common hormonal and metabolic problem affecting approximately 1 in 10 women of childbearing age, often resulting in infrequent menstrual periods, excess body and facial hair, acne and polycystic ovaries (enlarged ovaries due to numerous small collections of fluid (follicles)). The OCP has long been a proven effective treatment for women with PCOS who are not trying to fall pregnant. More recently, metformin (a medication that lowers insulin and blood sugar levels and often used to treat type 2 diabetes) has been advocated as possibly a more effective and safer long‐term treatment than the OCP in women with PCOS. Therefore, it is important to directly compare the benefits and risks of these two treatments in women with PCOS. </p> <p><i><b>Study characteristics</b> </i> </p> <p>We found 44 randomised controlled trials (RCTs) comparing metformin versus the OCP (alone or in combination) in a total of 2253 women with PCOS which comprised 39 RCTs on adult women (2047 women) and five RCTs on adolescent women (206 women). We combined results from the studies and assessed the quality of the studies to judge how confident we could be in their results. The evidence is current to August 2019. </p> <p><i><b>Key results</b> </i> </p> <p>In adult women, when we compared metformin to the OCP in terms of improving excessive facial and body hair, metformin may be less effective in women with PCOS with a body mass index (BMI) between 25 kg/m<sup>2</sup> to 30 kg/m<sup>2,</sup> but we are uncertain of the effect with BMI less than 25 kg/m<sup>2</sup> or greater than 30 kg/m<sup>2</sup>. In terms of severe adverse events (requiring stopping of medication), metformin may result in a higher incidence of gastro‐intestinal (i.e. nausea, vomiting, diarrhoea), but a lower incidence of other adverse events. Evidence suggests that if the severe gastro‐intestinal adverse event rate following the OCP is 0.3%, then the severe gastro‐intestinal adverse event rate after metformin would be between 1% and 4.5%. Evidence also suggests that if the severe other adverse event rate following the OCP is 12%, the severe other adverse event rate after metformin would between 1% and 6%. </p> <p>Either metformin alone or the OCP alone may be less effective in improving excessive facial and body hair compared to the combination of the OCP with metformin. In terms of severe adverse events, we are uncertain if there was a difference between metformin and metformin combined with the OCP for gastro‐intestinal or other adverse events. If the severe gastro‐intestinal adverse event rate following metformin combined with the OCP is 7%, then the corresponding rate after metformin would be between 2% and 17%, and if the severe other adverse event rate following metformin combined with the OCP is 6%, the corresponding rate after metformin would be between 0.7% and 15%. </p> <p>When comparing the OCP to metformin combined with the OCP in terms of severe adverse events, there may be a lower incidence of gastro‐intestinal adverse events with the OCP, but we are uncertain if there is a difference in other adverse events. If the severe gastro‐intestinal adverse event rate is 10% following metformin combined with the OCP, the corresponding rate following the OCP would be between 1% and 7%. If the severe other adverse event rate is 4% following Metformin combined with the OCP, the corresponding rate following the OCP would be between 2% and 18%. </p> <p>In adolescent women, we are uncertain as to whether there is a difference between any of the three comparisons in this review in terms of hirsutism and adverse events (both severe requiring stopping medication and minor) due to either a lack of evidence or very low‐quality evidence based on one trial. </p> <p><i><b>Quality of the evidence</b> </i> </p> <p>The evidence was of very low to low quality. The main limitations in the evidence were poor reporting of study methods and a lack of both precision and consistency in the results. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005552-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005552-sec-0056"></div> <h3 class="title" id="CD005552-sec-0057">Implications for practice</h3> <section id="CD005552-sec-0057"> <p>In adult women with PCOS, metformin may be less effective in improving hirsutism compared to the oral contraceptive pill (OCP) in the subgroup body mass index (BMI) &gt; 25 /kg2 &lt; BMI 30 kg/m<sup>2</sup>,but we are uncertain if there was a difference between metformin and the OCP in subgroup BMI &lt; 25 kg/m<sup>2</sup> and subgroup BMI &gt; 30 kg/m<sup>2</sup>. Compared to the OCP, metformin may result in a higher incidence of severe gastro‐intestinal adverse events and lower incidence of severe other adverse events with no trials reporting on minor adverse events. Either metformin alone or the OCP alone may be less effective in improving hirsutism compared to metformin combined with the OCP. We are uncertain as to whether there is a difference between the OCP alone and metformin alone compared to metformin combined with the OCP for adverse events (severe or minor; gastro‐intestinal or other), except for the OCP versus metformin combined with the OCP where the OCP may result in a lower incidence of severe and minor gastro‐intestinal adverse events . </p> <p>In adolescent women with PCOS, we are uncertain as to whether there is a difference between any of the three comparisons for this review for the primary outcomes of hirsutism and adverse events (both severe requiring stopping medication and minor) due to either no evidence or very low‐quality evidence, primarily due to very serious imprecision as the evidence for all reported primary outcomes derived from a single randomised controlled trial (RCT). Further large well‐designed and conducted RCTs that stratify for BMI are needed to evaluate metformin versus the OCP and combinations of these interventions in women with PCOS, in particular adolescent women. </p> </section> <h3 class="title" id="CD005552-sec-0058">Implications for research</h3> <section id="CD005552-sec-0058"> <p>The evidence quality for this review ranged from very low to low based on GRADE assessment with the vast majority of the evidence quality being low or very low limiting the certainty of all of the results in this review. Therefore, further high‐quality adequately‐powered RCTs are required comparing metformin versus the OCP, metformin versus metformin combined with the OCP, and the OCP versus metformin combined with the OCP in adult and adolescent women with PCOS stratified by BMI to assess the important clinical outcomes of hirsutism, improvement of menstrual pattern, acne, BMI, diagnosis of type 2 diabetes and adverse events in order to increase the quality of the body of evidence on these comparisons and outcomes, and provide more certainty in the benefit and harms of these long‐term medical treatment interventions. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005552-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005552-sec-0008"></div> <div class="table" id="CD005552-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Metformin compared to oral contraceptive pill (OCP) for hirsutism, acne, and menstrual pattern in adult women with polycystic ovary syndrome (PCOS)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Metformin compared to OCP for hirsutism, acne, and menstrual pattern in adult women with PCOS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult women with PCOS<br/><b>Setting:</b> Hospital or University Clinics<br/><b>Intervention:</b> metformin<br/><b>Comparison:</b> OCP </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with OCP</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with metformin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Hirsutism ‐ Clinical F‐G score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI ≤ 25kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean hirsutism ‐ Clinical F‐G score was 7.5</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.38 higher<br/>(0.44 lower to 1.19 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI &gt; 25 kg/m<sup>2</sup> &lt; 30 kg/m<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean hirsutism ‐ Clinical F‐G score was 6.44</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 1.92 higher<br/>(1.21 higher to 2.64 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>254 (5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>LOW<sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI ≥ 30 kg/m<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean hirsutism ‐ Clinical F‐G score was 6.05</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 0.38 lower<br/>(1.93 lower to 1.17 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>LOW<sup>1,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events ‐ Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1 000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1 000<br/>(10 to 45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 6.42<br/>(2.98 to 13.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>602<br/>(11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>122 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>27 per 1000</p> <p>(12 to 57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.20<br/>(0.09 to 0.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>363<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>6,7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse events ‐ Minor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse events ‐ Minor ‐ Gastro‐intestinal"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse events ‐ Minor ‐ Others"</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Improved menstrual pattern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shortening of intermenstrual days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improved menstrual pattern (ie. shortening of intermenstrual days) was 32.4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 6.05 higher<br/>(2.37 higher to 9.74 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝⊝<br/>LOW <sup>4,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An initiation of menses or cycle regularity) ‐ ≤<br/>25 kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1 000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1 000<br/>(1000 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.07<br/>(0.01 to 0.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An initiation of menses or cycle regularity)‐ BMI &gt; 25 kg/m<sup>2</sup> &lt; 30 kg/m<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>931 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>669 per 1000 (486 to 817)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.15 (0.07 to 0.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>VERY LOW <sup>7,8,9</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An initiation of menses or cycle regularity) ‐ BMI ≥ 30 kg/m<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1000 per 1 000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1000 per 1 000<br/>(1000 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.09 (0.01 to 1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>6,10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An initiation of menses or cycle regularity) ‐ BMI not stated</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>500 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>661 per 1000 (281 to 906)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.95 (0.39 to 9.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>VERY LOW <sup>8,10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne ‐ Visual analogue scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean acne ‐ Visual analogue scale was 1</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.90 higher<br/>(0.40 lower to 2.20 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>11</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>BMI (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI ≤ 25 kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BMI (kg/m<sup>2</sup>) was 22.7 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.59 lower<br/>(1.02 lower to 0.17 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>451<br/>(9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>VERY LOW</p> <p><sup>1,12,13</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI &gt; 25 kg/m<sup>2</sup> &lt; 30 kg/m<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean BMI (kg/m<sup>2</sup>) was 27.4 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 0.11 higher<br/>(0.48 lower to 0.7 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>353 (8 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>VERY LOW</p> <p><sup>1,14,15</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI ≥ 30 kg/m<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean BMI (kg/m<sup>2</sup>) was 35.1 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 2.31 lower<br/>(4.40 lower to 0.21 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>VERY LOW</p> <p><sup>1, 15,16</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI:</b> body mass index; <b>CI:</b> Confidence interval; <b>F‐G:</b> Ferriman‐Gallwey score; <b>MD:</b> Mean difference; <b>OR:</b> Odds ratio; <b>RCT:</b> Randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Evidence downgraded by one level for serious risk of bias ‐ the majority of the RCTs have unclear or high risk of bias<br/><sup>2</sup> Evidence downgraded by one level for serious inconsistency (I<sup>2</sup> = 50%) as unexplained heterogeneity (i.e. heterogeneity not explained by subgrouping of data according to mean study BMI) </p> <p><sup>3</sup> Evidence downgraded by one level for serious imprecision – 95% CI includes both appreciable effect and little or no effect and low number of participants (total number of participants &lt; 400) </p> <p><sup>4</sup> Evidence downgraded by one level for serious imprecision – low number of participants (total number of participants &lt; 400) </p> <p><sup>5</sup> Evidence downgraded by one level for serious imprecision ‐ low number of participants (total number of participants &lt; 400) and 95% CI includes both appreciable benefit and harm </p> <p><sup>6</sup> Evidence downgraded by one level for serious risk of bias ‐ the majority of the RCTs have unclear risk of bias </p> <p><sup>7</sup> Evidence downgraded by one level for serious imprecision – low number of events (total number of events &lt; 300) </p> <p><sup>8</sup> Evidence downgraded by one level for serious risk of bias ‐ the majority of the RCTs have high risk of bias </p> <p><sup>9</sup> Evidence downgraded by one level for serious inconsistency (I<sup>2</sup> = 51%) as unexplained heterogeneity (i.e. heterogeneity not explained by subgrouping of data according to mean study BMI) </p> <p><sup>10</sup> Evidence downgraded by two levels for very serious imprecision – 95% CI includes both appreciable benefit and harm or no effect and very low number of events (total number of events &lt; 300) </p> <p><sup>11</sup> Evidence downgraded by two levels for serious imprecision – 95% CI includes both appreciable benefit and harm or no effect and low number of participants (total number of participants &lt; 400) </p> <p><sup>12</sup> Evidence downgraded by one level for serious inconsistency (I<sup>2</sup> = 76%) as unexplained heterogeneity (i.e. heterogeneity not explained by subgrouping of data according to mean study BMI) </p> <p><sup>13</sup> Evidence downgraded by one level for serious imprecision – 95% CI includes both appreciable effect and little or no effect </p> <p><sup>14</sup> Evidence downgraded by one level for serious inconsistency (I<sup>2</sup> = 72%) as unexplained heterogeneity (i.e. heterogeneity not explained by subgrouping of data according to mean study BMI) </p> <p><sup>15</sup> Evidence downgraded by one level for serious imprecision ‐ low number of participants (total number of participants &lt; 400) and 95% CI includes both appreciable effect and little or no effect </p> <p><sup>16</sup> Evidence downgraded by one level for serious inconsistency (I<sup>2</sup> = 52%) as unexplained heterogeneity (i.e. heterogeneity not explained by subgrouping of data according to mean study BMI) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005552-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Metformin compared to metformin combined with oral contraceptive pill (OCP) for hirsutism, acne, and menstrual pattern in adult women with polycystic ovary syndrome (PCOS)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Metformin compared to metformin combined with OCP for hirsutism, acne, and menstrual pattern in adult women with PCOS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population: a</b> dult women with PCOS<br/><b>Setting:</b> Hospital or University Clinics<br/><b>Intervention:</b> metformin<br/><b>Comparison:</b> metformin combined with OCP </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Metformin combined with OCP</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with metformin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hirsutism ‐ Clinical F‐G score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean hirsutism ‐ Clinical F‐G score was 5.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.36 higher<br/>(0.62 higher to 2.11 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events ‐ Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1 000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1 000<br/>(17 to 168) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.74<br/>(0.21 to 2.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>60 per 1 000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>35 per 1 000<br/>(7 to 153) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.56<br/>(0.11 to 2.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>109<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse events ‐ Minor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse events ‐ Minor ‐ Gastro‐intestinal"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse events ‐ Minor ‐ Others"</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Improved menstrual pattern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shortening of intermenstrual days</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trials reported on outcome "Improved menstrual pattern (i.e. shortening of intermenstrual days)" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An initiation of menses or cycle regularity</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trials reported on outcome "Improved menstrual pattern (i.e. an initiation of menses or cycle regularity)" </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne ‐ Visual analogue scale/Clinical acne score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trials reported either on outcome "Acne ‐ Visual analogue scale" or "Acne ‐ Clinical acne score" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean Body Mass Index (kg/m<sup>2</sup>) was 25.49 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 1.47 lower<br/>(2.27 lower to 0.66 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>199<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI: Body mass index; CI:</b> Confidence interval; <b>F‐G:</b> Ferriman‐Gallwey score; <b>MD:</b> Mean difference; <b>OR:</b> Odds ratio; <b>RCT:</b> Randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Evidence downgraded by one level for serious risk of bias ‐ the majority of the RCTs have unclear risk of bias<br/><sup>2</sup> Evidence downgraded by one level for serious imprecision – low number of participants (total number of participants &lt; 400)<br/><sup>3</sup> Evidence downgraded by one level for serious imprecision – low number of events (total number of events &lt; 300) and 95% CI includes both appreciable benefit and harm </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005552-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oral contraceptive pill (OCP) compared to metformin combined with OCP for hirsutism, acne, and menstrual pattern in adult women with polycystic ovary syndrome (PCOS)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>OCP compared to Metformin combined with OCP for hirsutism, acne, and menstrual pattern in adult women with polycystic ovary syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> aAdult women with PCOS<br/><b>Setting:</b> Hospital or University Clinics<br/><b>Intervention:</b> OCP<br/><b>Comparison:</b> metformin combined with OCP </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with metformin combined with OCP</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with OCP</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hirsutism ‐ Clinical F‐G score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean hirsutism ‐ Clinical F‐G score was 5.57</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.54 higher<br/>(0.20 higher to 0.89 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>389<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse events ‐ Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>98 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>21 per 1000<br/>(6 to 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.20<br/>(0.06 to 0.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>228<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000<br/>(19 to 179) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.61<br/>(0.49 to 5.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events ‐ Minor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>260 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/>(4 to 134) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.06<br/>(0.01 to 0.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse events ‐ Minor ‐ Others"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Improved menstrual pattern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shortening of inter menstrual days</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Improved menstrual pattern (i.e. shortening of inter menstrual days)" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An initiation of menses or cycle regularity</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Improved menstrual pattern (i.e. an initiation of menses or cycle regularity)" </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne ‐ Clinical acne score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean acne ‐ Clinical acne score was 0.54</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.09 lower<br/>(0.10 lower to 0.08 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMI (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BMI (kg/m<sup>2</sup>) was 28.6 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.21 lower<br/>(0.53 lower to 0.12 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>661<br/>(13 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI:</b> body mass index; <b>CI:</b> Confidence interval; <b>F‐G:</b> Ferriman‐Gallwey score; <b>MD:</b> Mean difference; <b>OR:</b> Odds ratio; <b>RCT:</b> Randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Evidence downgraded by one level for serious risk of bias ‐ the majority of the RCTs have unclear risk of bias<br/><sup>2</sup> Evidence downgraded by one level for serious imprecision – low number of participants (total number of participants &lt; 400) and 95% CI includes both appreciable effect and little or no effect<br/><sup>3</sup> Evidence downgraded by one level for serious imprecision ‐ low number of events (total number of events &lt; 300)<br/><sup>4</sup> Evidence downgraded by one level for serious imprecision – low number of events (total number of events &lt; 300) and 95% CI includes both appreciable benefit and harm<br/><sup>5</sup> Evidence downgraded by one level for serious risk of bias ‐ the majority of the RCTs have high risk of bias<br/><sup>6</sup> Evidence downgraded by one level for serious imprecision – low number of events (total number of events &lt; 300)<br/><sup>7</sup>Evidence downgraded by one level for serious imprecision – very low number of participants (total number of participants &lt; 400; i.e n = 82; single RCT) and/or 95% CI includes both appreciable effect and little or no effect<br/><sup>8</sup>Evidence downgraded by one level for serious inconsistency ‐ substantial heterogeneity was detected which was not explained by the difference in effect of the interventions between the BMI subgroups (test for subgroup difference: P = 0.64, I<sup>2</sup> = 0%) </p> <p><sup>9</sup> Evidence downgraded by one level for serious imprecision ‐ 95% CI includes both appreciable effect and little or no effect </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005552-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Metformin compared to oral contraceptive pill (OCP) for hirsutism, acne, and menstrual pattern in adolescent women with polycystic ovary syndrome (PCOS)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Metformin compared to OCP for hirsutism, acne, and menstrual pattern in adolescent women with PCOS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> adolescent women with PCOS<br/><b>Setting:</b> Hospital or University Clinics<br/><b>Intervention: m</b> etformin<br/><b>Comparison:</b> OCP </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with OCP</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with metformin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hirsutism ‐ Clinical F‐G score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean hirsutism ‐ Clinical F‐G score was 8.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.40 lower<br/>(3.42 lower to 2.62 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse event ‐ Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse event ‐ Severe ‐ Gastro‐intestinal"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1 000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1 000<br/>(27 to 300) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.63<br/>(0.16 to 2.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse event ‐ Minor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1 000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1 000<br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 11.67<br/>(0.53 to 258.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were only 3 events in the arm metformin and 0 in the arm OCP</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse event ‐ Minor ‐ Others"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Improved menstrual pattern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shortening of inter menstrual days</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Improved menstrual pattern (i.e. shortening of inter menstrual days)" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An initiation of menses or cycle regularity</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 000 per 1 000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1 000<br/>(1 000 to 1 000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.10<br/>(0.01 to 1.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>3,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 out of 40 participants had improved menstrual patter in the OCP group compared to 36 out of 40 in the metformin group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne ‐ Visual analogue scale or Clinical acne score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported either on outcome "Acne ‐ Visual analogue scale" or "Acne ‐ Clinical acne score" </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMI (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BMI (kg/m<sup>2</sup>) was 36 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.45 lower<br/>(5.08 lower to 2.17 </p> <p>higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>7,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI:</b> body mass index; <b>CI:</b> Confidence interval; <b>F‐G:</b> Ferriman‐Gallwey score; <b>MD:</b> Mean difference; <b>OR:</b> Odds ratio; <b>RCT:</b> Randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Evidence downgraded by one level for serious risk of bias – a single RCT which has unclear risk of bias<br/><sup>2</sup> Evidence downgraded by two levels for very serious imprecision – very low number of participants (total number of participants &lt; 400 i.e. n = 16 participants) and 95% CI includes both appreciable benefit and appreciable harm<br/><sup>3</sup> Evidence downgraded by one level for serious risk of bias – a single RCT which has high risk of bias<br/><sup>4</sup> Evidence downgraded by two levels for very serious imprecision – very low number of events (total number of events &lt; 300 i.e. n = 10 events) and 95% CI includes both appreciable benefit and appreciable harm<br/><sup>5</sup> Evidence downgraded by two levels for very serious imprecision – very low number of events (total number of events &lt; 300 i.e. n = 3 events) and 95% CI includes both appreciable benefit and appreciable harm<br/><sup>6</sup> Evidence downgraded by two levels for very serious imprecision – very low number of events (total number of events &lt; 300 i.e. n = 76 events) and 95% CI includes both appreciable benefit and appreciable harm<br/><sup>7</sup> Evidence downgraded by one level for serious risk of bias ‐ the majority of the RCTs have unclear risk of bias<br/><sup>8</sup> Evidence downgraded by two levels for very serious imprecision – very low number of participants (total number of participants &lt; 400 i.e. n = 69 participants) and 95% CI includes both appreciable benefit and appreciable harm </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005552-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Metformin compared to metformin combined with oral contraceptive pill (OCP) for hirsutism, acne and menstrual pattern in adolescent women with polycystic ovary syndrome (PCOS)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Metformin compared to metformin combined with OCP for hirsutism, acne and menstrual pattern in adolescent women with PCOS</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> adolescent women with PCOS<br/><b>Setting:</b> Hospital or University Clinics<br/><b>Intervention:</b> metformin<br/><b>Comparison:</b> metformin combined with OCP </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with metformin combined with OCP</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with metformin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hirsutism ‐ Clinical F‐G score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Hirsutism ‐ Clinical F‐G score"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse event ‐ Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse event ‐ Severe ‐ Gastro‐intestinal"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse event ‐ Severe ‐ Others"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse event ‐ Minor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse event ‐ Minor ‐ Gastro‐intestinal"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse event ‐ Minor ‐ Others"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Improved menstrual pattern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shortening of inter menstrual day</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Improved menstrual pattern (i.e. shortening of intermenstrual days)" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An initiation of menses or cycle regularity</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Improved menstrual pattern (i.e. an initiation of menses or cycle regularity)" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne ‐ Visual analogue scale or Clinical acne score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported either on outcome "Acne ‐ Visual analogue scale" or "Acne ‐ Clinical acne score" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "BMI"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI:</b> body mass index; <b>CI:</b> Confidence interval; <b>F‐G:</b> Ferriman‐Gallwey score; <b>MD:</b> Mean difference; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD005552-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Oral contraceptive pill (OCP) compared to metformin combined with OCP for hirsutism, acne, and menstrual pattern in adolescent women with polycystic ovary syndrome PCOS</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>OCP compared to metformin combined with OCP for hirsutism, acne, and menstrual pattern in adolescent women with PCOS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> adolescent women with PCOS<br/><b>Setting:</b> Hospital or University Clinics<br/><b>Intervention:</b> OCP<br/><b>Comparison:</b> metformin combined with OCP </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with metformin combined with OCP</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with OCP</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hirsutism ‐ Clinical F‐G score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean hirsutism ‐ Clinical F‐G score was 6.2</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.80 higher<br/>(1.19 lower to 2.79 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events ‐ Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1 000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1 000<br/>(4 to 505) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00<br/>(0.06 to 17.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse events ‐ Severe ‐ Others"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse events ‐ Minor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse events ‐ Minor ‐ Gastro‐intestinal"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse events ‐ Minor ‐ Others"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Improved menstrual pattern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shortening of intermenstrual days</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Improved menstrual pattern (i.e. shortening of intermenstrual days)" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An initiation of menses or cycle regularity</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Improved menstrual pattern (i.e. an initiation of menses or cycle regularity)" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne ‐ Visual analogue scale or Clinical acne score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported either on outcome "Acne ‐ Visual analogue scale" or "Acne ‐ Clinical acne score" </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMI (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BMI (kg/m<sup>2</sup>) was 32.4 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.5 higher<br/>(1.63 lower to 4.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI:</b> body mass index; <b>CI:</b> Confidence interval; <b>F‐G:</b> Ferriman‐Gallwey score; <b>MD:</b> Mean difference; <b>OR:</b> Odds ratio; <b>RCT:</b> Randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Evidence downgraded by one level for serious risk of bias – a single RCT which has unclear risk of bias<br/><sup>2</sup> Evidence downgraded by two levels for very serious imprecision – very low number of participants (total number of participants &lt; 400 i.e. n = 32 participants) and 95% CI includes both appreciable benefit and appreciable harm<br/><sup>3</sup> Evidence downgraded by two levels for very serious imprecision – very low number of events (total number of events &lt; 300 i.e. n = 2 events) and 95% CI includes both appreciable benefit and appreciable harm </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005552-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005552-sec-0009"></div> <section id="CD005552-sec-0010"> <h3 class="title" id="CD005552-sec-0010">Description of the condition</h3> <p>Polycystic ovary syndrome (PCOS) is characterised by chronic anovulation (failure or absence of ovulation) and hyperandrogenism (excessive production of male hormones in women) with clinical manifestations of irregular menstrual cycles (periods), infertility (failure to conceive), hirsutism (excessive hairiness) and acne (pimples). This condition is the most common endocrinopathy in women, affecting approximately 8% to 18% of women of reproductive age (<a href="./references#CD005552-bbs2-0116" title="TeedeH , DeeksA , MoranL . Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Medicine2010;8:41.">Teede 2010a</a>; <a href="./references#CD005552-bbs2-0117" title="TeedeHJ , MissoML , CostelloMF , DokrasA , LavenJ , MoranL , et al, International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction2018;33(9):1602-18.">Teede 2018</a>). PCOS is a heterogenous condition, both clinically and biochemically. Women with PCOS are at increased risk of a number of metabolic disturbances, including gestational diabetes, impaired glucose tolerance (IGT), type 2 diabetes mellitus (T2DM) and metabolic syndrome. However, it remains unclear whether women with PCOS have a higher risk of cardiovascular disease (CVD) (<a href="./references#CD005552-bbs2-0100" title="FauserBC , TarlatzisBC , RebarRW , LegroRS , BalenAH , LoboR , et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril2012;97:28-38.e25.">Fauser 2012</a>; <a href="./references#CD005552-bbs2-0112" title="OvalleF , AzzizR . Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertility and Sterility2002;77:1095-105.">Ovalle 2002</a>; <a href="./references#CD005552-bbs2-0116" title="TeedeH , DeeksA , MoranL . Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Medicine2010;8:41.">Teede 2010a</a>; <a href="./references#CD005552-bbs2-0117" title="TeedeHJ , MissoML , CostelloMF , DokrasA , LavenJ , MoranL , et al, International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction2018;33(9):1602-18.">Teede 2018</a>; <a href="./references#CD005552-bbs2-0120" title="WildRA . Long-term health consequences of PCOS. Human Reproduction Update2002;8:231-41.">Wild 2002a</a>; <a href="./references#CD005552-bbs2-0121" title="WildRA . Polycystic ovary syndrome: a risk for coronary artery disease?American Journal of Obstetrics &amp; Gynaecology2002;186:35-43.">Wild 2002b</a>). </p> <p>Recent international evidence‐based guidelines for the assessment, diagnosis and management of polycystic ovary syndrome have been published (<a href="./references#CD005552-bbs2-0117" title="TeedeHJ , MissoML , CostelloMF , DokrasA , LavenJ , MoranL , et al, International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction2018;33(9):1602-18.">Teede 2018</a>). The guidelines recommend that all clinicians and investigators now use an internationally agreed definition of PCOS according to Rotterdam criteria (<a href="./references#CD005552-bbs2-0114" title="The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction2004;19:41-7.">Rotterdam ESHRE 2004</a>). Therefore, the diagnosis of PCOS in adult women requires that at least two of the following three criteria are met: (1) oligo‐ or anovulation (infrequent or no ovulation); (2) clinical and/or biochemical signs of hyperandrogenism; (3) polycystic ovaries on ultrasound. However, ultrasound is not indicated for adolescent patients due to overlap with normal reproductive physiology. Other causes for hyperandrogenism which mimic PCOS (such as congenital adrenal hyperplasia, Cushing's syndrome, or androgen‐secreting tumours) and amenorrhoea (such as thyroid disease or hyperprolactinaemia) should be excluded. These guidelines also recommend that standardised visual scales are preferred when assessing hirsutism, and one such scale is the Ferriman‐Gallwey (F‐G) score (<a href="./references#CD005552-bbs2-0111" title="MartinKA , AndersonRR , ChangRJ , EhrmannDA , LoboRA , MuradMH , et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society* Clinical Practice Guideline. Journal of Clinical and Endocrinology Metabolism2018;103(4):1–25.">Martin 2018</a>; <a href="./references#CD005552-bbs2-0117" title="TeedeHJ , MissoML , CostelloMF , DokrasA , LavenJ , MoranL , et al, International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction2018;33(9):1602-18.">Teede 2018</a>). </p> <p>The exact pathophysiological mechanism (body characteristics) leading to the characteristic PCOS phenotype remains unclear. Some investigators explain it as primarily an intrinsic ovarian problem (excess ovarian production of androgens), others as adrenal (excess adrenal gland production of androgens), and again others as hypothalamic‐pituitary dysfunction (exaggerated gonadotropin‐releasing hormone pulsatility that results in hypersecretion of luteinising hormone). Insulin resistance (IR) (defined as a reduced glucose response to a given amount of insulin) seems to be one of the key pathophysiological feature of PCOS leading to both reproductive and metabolic disorders. Evidence of decreased insulin sensitivity is seen in both lean (30% incidence) and obese women (75% incidence) with PCOS; but IR accompanied by compensatory hyperinsulinaemia is most marked when there is an interaction between obesity and the syndrome (<a href="./references#CD005552-bbs2-0092" title="ConwayGS , JacobsHS , HollyJM , WassJA . Effects of luteinizing hormone, insulin, insulin-like growth factor-1 and insulin-like growth factor small binding protein-1 in the polycystic ovary syndrome. Clinical Endocrinology1990;33:593-603.">Conway 1990</a>; <a href="./references#CD005552-bbs2-0096" title="Diamanti-KandarakisE , DunaifA . Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Reviews2012;33(6):981–1030.">Diamanti‐Kandarakis 2012</a>; <a href="./references#CD005552-bbs2-0097" title="DunaifA , SegalKR , FutterweitW , DobrjanskyA . Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes1989;38:1165-74.">Dunaif 1989</a>; <a href="./references#CD005552-bbs2-0098" title="DunaifA . Molecular mechanisms of insulin resistance in the polycystic ovary syndrome. Seminars in Reproductive Endocrinology1994;12:15-20.">Dunaif 1994</a>). Hyperinsulinaemia directly stimulates both ovarian and adrenal androgen secretion and suppresses liver sex hormone‐binding globulin (SHBG) synthesis, resulting in an increase in free, biologically‐active androgens. This excess in local ovarian androgen production, augmented by hyperinsulinaemia, causes premature follicular atresia (the breakdown of the ovarian follicles) and anovulation along with the other clinical manifestations of hyperandrogenism such as hirsutism and acne (<a href="./references#CD005552-bbs2-0093" title="CostelloMF , EdenJA . A systematic review of the reproductive system effects of Metformin in patients with polycystic ovary syndrome. Fertility and Sterility2003;79(1):1-13.">Costello 2003</a>; <a href="./references#CD005552-bbs2-0119" title="UtigerR . Insulin and the polycystic ovary syndrome. New England Journal of Medicine1996;335:657-8.">Utiger 1996</a>). </p> </section> <section id="CD005552-sec-0011"> <h3 class="title" id="CD005552-sec-0011">Description of the intervention</h3> <p>Metformin, an insulin‐sensitising drug (ISD), has been advocated as a long‐term treatment given the importance of hyperinsulinaemia in the development of hyperandrogenism and disrupted folliculogenesis in PCOS. Metformin may be useful in the restoration of normal endocrinological and clinical parameters of PCOS by lowering insulin secretion (<a href="./references#CD005552-bbs2-0104" title="HasegawaI , MurakawaH , SuzukiM , YamamotoY , KurabayashiT , TanakaK . Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertility and Sterility1999;71:323-7.">Hasegawa 1999</a>). The most common side effects of metformin include gastrointestinal complaints such as nausea, diarrhoea, and abdominal cramping. These occur in up to 50% of treated patients, usually improving or completely subsiding with continued treatment (<a href="./references#CD005552-bbs2-0108" title="HundalRS , InzucchiSE . Metformin: new understandings, new uses. Drugs2003;63(18):1879-94.">Hundal 2003</a>). </p> <p>Oral contraceptive pills (OCP) have been the traditional therapy for the long‐term treatment of PCOS to regularise and lighten menses, improve hirsutism and acne by reducing ovarian androgen production and to provide endometrial protection. It has been advocated that the OCP may reduce insulin sensitivity, glucose tolerance in women with PCOS, and increase triglycerides in women with PCOS (<a href="./references#CD005552-bbs2-0095" title="Diamanti-KandarakisE , Baillargeon, JP, IuornoMJ , JakubowiczDJ , NestlerJE . A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. Journal of Clinical Endocrinology &amp; Metabolism2003;88:1927-32.">Diamanti‐Kandarakis 2003</a>; <a href="./references#CD005552-bbs2-0101" title="Freitas de MedeirosS . Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome. Reproductive Biology and Endocrinology2017;15:93-109.">Freitas de Medeiros 2017</a>). The most common side effects in women taking the OCP include headache, mood changes, gastrointestinal disturbances, and breast pain (<a href="./references#CD005552-bbs2-0102" title="GalloMF , NandaK , GrimesDA , LopezLM , SchulzKF . 20 µg versus &gt;20 µg estrogen combined oral contraceptives for contraception.. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD003989. [DOI: 10.1002/14651858.CD003989.pub5]">Gallo 2013</a>). </p> <p>Oral contraceptive pills have been demonstrated to be effective therapy for hirsutism and acne, whilst the evidence for such efficacy with metformin for these outcomes is less so and inconsistent (<a href="./references#CD005552-bbs2-0091" title="BuzneyE , D, SheuJ , BuzneyC , ReynoldsRV . Polycystic ovary syndrome: a review for dermatologists Part II. Treatment. Journal of the American Academy of Dermatology.2014;71(5):859.e1-859.e15; quiz 873-4.">Buzney 2014</a>; <a href="./references#CD005552-bbs2-0111" title="MartinKA , AndersonRR , ChangRJ , EhrmannDA , LoboRA , MuradMH , et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society* Clinical Practice Guideline. Journal of Clinical and Endocrinology Metabolism2018;103(4):1–25.">Martin 2018</a>; <a href="./references#CD005552-bbs2-0117" title="TeedeHJ , MissoML , CostelloMF , DokrasA , LavenJ , MoranL , et al, International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction2018;33(9):1602-18.">Teede 2018</a>). </p> </section> <section id="CD005552-sec-0012"> <h3 class="title" id="CD005552-sec-0012">How the intervention might work</h3> <p>Metformin, improves insulin sensitivity, reduces insulin and consequently androgen levels, and therefore could improve menstrual cyclicity, acne and hirsutism (<a href="./references#CD005552-bbs2-0109" title="KatsikiN , HatzitoliosAI . Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update. Current Opinion in Obstetrics &amp; Gynecology2010;22(6):466-76.">Katsiki 2010</a>). OCPs contain oestrogen and progestin components allowing a regularisation of the menstrual cycle. OCP therapy reduces hyperandrogenism via a number of mechanisms, including the following: suppression of luteinising hormone secretion (and therefore ovarian androgen secretion), stimulation of hepatic production of sex hormone binding globulin (thereby increasing androgen binding in serum and reducing serum free androgen concentrations), and a slight reduction in both adrenal androgen secretion and binding of androgens to their receptor. Consequently, there is a reduction of androgen production and action yielding an improvement in hirsutism and acne (<a href="./references#CD005552-bbs2-0111" title="MartinKA , AndersonRR , ChangRJ , EhrmannDA , LoboRA , MuradMH , et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society* Clinical Practice Guideline. Journal of Clinical and Endocrinology Metabolism2018;103(4):1–25.">Martin 2018</a>). </p> </section> <section id="CD005552-sec-0013"> <h3 class="title" id="CD005552-sec-0013">Why it is important to do this review</h3> <p>The OCP has been the traditional therapy for the long‐term treatment of women with PCOS not seeking fertility treatment in terms of the reproductive features of menstrual dysfunction and hyperandrogenic symptoms such as hirsutism and acne. However, metformin has more recently been proposed and used as an alternative therapy to the OCP for these reproductive manifestations with perhaps more favourable effect on the metabolic features of PCOS. It is therefore important to directly compare these two interventions in terms of both efficacy and adverse events to help guide clinical practice in the management of women with PCOS. Therefore, the overall aim of this review was to compare the efficacy and safety of metformin versus the OCP (alone or in combination) in improving clinical, hormonal, and metabolic features of PCOS. </p> <p>This review is a substantive update of a previous Cochrane Review (<a href="./references#CD005552-bbs2-0123" title="CostelloMF , ShresthaB , EdenJ , JohnsonN , MoranLJ . Insulin‐sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD005552. [DOI: 10.1002/14651858.CD005552.pub2]">Costello 2007</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005552-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005552-sec-0014"></div> <p>To assess the effectiveness and safety of metformin versus the oral contraceptive pill (OCP) (alone or in combination) for the long‐term treatment of women with polycystic ovary syndrome (PCOS). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005552-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005552-sec-0015"></div> <section id="CD005552-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005552-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered randomised controlled trials (RCTs) for inclusion in the review. Cross‐over trials were not eligible for inclusion unless phase‐one data (i.e. pre‐cross‐over) were available. </p> </section> <section id="CD005552-sec-0018"> <h4 class="title">Types of participants</h4> <p>Women (adults or adolescents) with PCOS based on clinical (ovulatory dysfunction, hirsutism, acne, androgen dependent alopecia), biochemical (hyperandrogaenemia), or ultrasound (polycystic ovaries) evidence as defined by included studies. </p> <p>Note was taken as to whether the participants of the included studies met the internationally agreed definitions of PCOS (<a href="./references#CD005552-bbs2-0099" title="The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction2004;19:41-7.">ESHRE/ASRM 2004</a>), which were endorsed as the diagnostic criteria for PCOS in the recently published international guidelines on PCOS (<a href="./references#CD005552-bbs2-0117" title="TeedeHJ , MissoML , CostelloMF , DokrasA , LavenJ , MoranL , et al, International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction2018;33(9):1602-18.">Teede 2018</a>). </p> <p>Note was also taken of whether any of the participants had diabetes mellitus or were taking any other medications which might alter insulin sensitivity. </p> <p>The RCTs of adult women with PCOS were analysed separately to those involving adolescent women with PCOS. </p> </section> <section id="CD005552-sec-0019"> <h4 class="title">Types of interventions</h4> <p>(a) Metformin versus the combined oral contraceptive pill (MET versus OCP).</p> <p>(b) Metformin versus metformin in combination with the combined oral contraceptive pill (MET versus MET + the OCP). </p> <p>(c) Combined oral contraceptive pill versus metformin in combination with the combined oral contraceptive pill (the OCP versus MET + the OCP). </p> </section> <section id="CD005552-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Outcomes measures were defined as primary (clinical) outcomes and secondary (clinical, hormonal, and metabolic) outcomes. </p> <p>This review considered trials with a minimum length of follow‐up of three months.</p> <section id="CD005552-sec-0021"> <h5 class="title">Primary outcomes</h5> <p><i>(a) Clinical parameters</i> </p> <p>1. Hirsutism as assessed clinically by a trained observer (using a scoring system such as the Ferriman and Gallwey (F‐G) score or a Visual Analogue Scale (VAS)), or participant self‐scoring of subjective improvement or not.<br/>2. Adverse events (gastro‐intestinal and other): severe (requiring stopping of medication), and minor. </p> </section> <section id="CD005552-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p><i>(a) Clinical parameters</i> </p> <p>3. Improved menstrual pattern (i.e. an initiation of menses or cycle regularity or significant shortening of intermenstrual days). </p> <p>4. Acne as assessed clinically by a trained observer (using a scoring system such as a VAS, or participant self‐scoring of subjective improvement or not. </p> <p>5. Diagnosis of type 2 diabetes mellitus<br/>6. Body weight (kg)<br/>7. Body mass index (BMI) (kg/m<sup>2</sup>)<br/>8. Blood pressure systolic (mmHg)<br/>9 Blood pressure diastolic (mmHg) </p> <p><i>(b) Hormonal parameters</i> </p> <p>10. Serum total testosterone (nmol/L)<br/>11. Free androgen index (FAI) (%) </p> <p><i>(c) Metabolic parameters</i> </p> <p>12. Fasting insulin (mLU/L)<br/>13. Fasting glucose (mmol/L)<br/>14. Fasting total cholesterol (mmol/L)<br/>15. Fasting high‐density lipoprotein (HDL) cholesterol (mmol/L)<br/>16. Fasting low‐density lipoprotein (LDL) cholesterol (mmol/L)<br/>17. Fasting triglycerides (mmol/L) </p> </section> </section> </section> <section id="CD005552-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all published and unpublished RCTs on the use of metformin and the OCP (alone or in combination) in women with PCOS, without language restriction and in consultation with the Gynaecology and Fertility Group Information Specialist. </p> <section id="CD005552-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases for relevant trials:</p> <p>(1) The Cochrane Gynaecology and Fertility Group (CGF) Specialised Register of Controlled Trials; PROCITE platform (searched 15 August 2019) (<a href="./appendices#CD005552-sec-0062">Appendix 1</a>) </p> <p>(2) The Cochrane Central Register of Controlled Trials; Ovid platform (searched 15 August 2019, Issue July 2019) (<a href="./appendices#CD005552-sec-0063">Appendix 2</a>) </p> <p>(3) MEDLINE (Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations); Ovid platform (searched from 1946 to 15 August 2019) (<a href="./appendices#CD005552-sec-0064">Appendix 3</a>) </p> <p>(4) Embase; Ovid platform (searched from 1980 to 15 August 2019) (<a href="./appendices#CD005552-sec-0065">Appendix 4</a>) </p> <p>(5) PsycINFO; Ovid platform (searched from 1806 to 15 August 2019) (<a href="./appendices#CD005552-sec-0066">Appendix 5</a>) </p> <p>(6) CINAHL (Cumulative Index to Nursing and Allied Health Literature); EBSCO platform (searched from 1961 to 15 August 2019) (<a href="./appendices#CD005552-sec-0067">Appendix 6</a>) </p> </section> <section id="CD005552-sec-0025"> <h4 class="title">Searching other resources</h4> <p>(7) Reference lists of included studies, other relevant review articles and textbooks were handsearched. </p> <p>(8) Trial registers for ongoing and registered trials were checked and authors contacted if required. </p> <p>(9) We contacted experts in the field to identify additional studies.</p> </section> </section> <section id="CD005552-sec-0026"> <h3 class="title" id="CD005552-sec-0026">Data collection and analysis</h3> <p>We conducted data collection and analysis in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005552-bbs2-0106" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 5.2 (updated 2017). The Cochrane Collaboration, 2011. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). </p> <section id="CD005552-sec-0027"> <h4 class="title">Selection of studies</h4> <p>After an initial screen of titles and abstracts retrieved by the search, conducted by review authors EF, LM, CV, and MC, the full texts of all potentially eligible studies were retrieved. Three review authors (LM, EF and MC) independently examined these full‐text articles for compliance with the inclusion criteria and selected eligible studies. If papers contained insufficient information to make a decision about eligibility, we contacted the authors of those papers in order to seek further information to clarify study eligibility. Disagreements were resolved by discussion. </p> <p>Studies from non‐English language journals were translated if necessary. The selection process is documented in the PRISMA flow chart (<a href="#CD005552-fig-0001">Figure 1</a>). We provide a list of excluded studies, showing the reasons for exclusion in the <a href="./references#CD005552-sec-0079" title="">Characteristics of excluded studies</a> table. </p> <div class="figure" id="CD005552-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD005552-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD005552-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Four review authors (EF, LM, CE and SB) independently extracted data from eligible studies using a data extraction form designed and pilot‐tested by the authors. Any disagreements were resolved by discussion. Data extracted included study characteristics and outcome data. Unit conversion factors are shown in <a href="#CD005552-tbl-0007">Table 1</a>. Where studies had multiple publications, we collated multiple reports of the same under a single study ID with multiple references. We corresponded with study investigators for further data on methods or results, or both, when required. In multiple‐arm studies; data from arms that did not meet the inclusion criteria were not used. </p> <div class="table" id="CD005552-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Conversion Factors</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Convert from</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Convert to</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Conversion factor</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Androstenedione</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cholesterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.026</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence intervals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence intervals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(upper limit ‐ lower limit)/3.92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glucose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.056</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mIU/L (= microIU/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1667</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sex hormone‐binding globulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mcg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sqrt n</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Testosterone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pg/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Triglycerides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.011</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </section> <section id="CD005552-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Four review authors (EF, LM, CE and MC) independently assessed the included studies for risk of bias using the Cochrane 'Risk of bias' assessment tool (<a href="./references#CD005552-bbs2-0106" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 5.2 (updated 2017). The Cochrane Collaboration, 2011. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). We assessed selection (random sequence generation and allocation concealment); performance (blinding of participants and personnel); detection (blinding of outcome assessors); attrition (incomplete outcome data); reporting (selective reporting) bias; and other bias (other potential bias), and summarised our judgements in the 'Risk of bias' tables, <a href="#CD005552-fig-0002">Figure 2</a> and <a href="#CD005552-fig-0003">Figure 3</a>. Judgements were assigned as low, high or unclear risk using the criteria from the <i>Cochrane Handbook Table</i> 8.5.d: 'Criteria for judging risk bias' in the 'Risk of bias' assessment tool (<a href="./references#CD005552-bbs2-0106" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 5.2 (updated 2017). The Cochrane Collaboration, 2011. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). Disagreements were resolved by discussion. All judgements were fully described and the conclusions are presented in the 'Risk of Bias' table, and incorporated into the interpretation of review findings by means of sensitivity analyses where indicated. </p> <div class="figure" id="CD005552-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies" data-id="CD005552-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD005552-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study ." data-id="CD005552-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study . </p> </div> </div> </div> </section> <section id="CD005552-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data, results for each study were expressed as odds ratios (ORs) with 95% confidence intervals (CIs) and combined for meta‐analysis with Review Manager software using the fixed‐effect model (Peto method). The goal was to calculate a pooled estimate of treatment effect for each outcome across studies. </p> <p>For continuous data, we measured the mean post‐treatment or intervention values and standard deviations for each group and calculated the weighted mean differences (MDs) with 95% CIs. If different scales measured the same continuous data outcome, we planned to measure the mean post‐treatment or intervention values and standard deviations for each group and to calculate the standardised mean difference (SMD) with 95% CI. </p> </section> <section id="CD005552-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We took into account the level at which the randomisation occurred in each trials.</p> <p>We considered whether in each study:</p> <p> <ol id="CD005552-list-0001"> <li> <p>groups of individuals were randomised together to the same intervention (i.e. cluster‐ randomised trials); </p> </li> <li> <p>or each individual was individually randomised to one of the intervention groups;</p> </li> <li> <p>or if individuals underwent more than one intervention (e.g. in cross‐over trial). Only first‐phase data from cross‐over trials were included. </p> </li> </ol> </p> <p>The analysis was by woman randomised.</p> </section> <section id="CD005552-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>If data were missing from included studies, we contacted the investigators to request the relevant missing data. </p> <p>If this was not possible, we analysed the data on an intention‐to‐treat basis as far as possible (i.e. including all randomised participants in analysis, in the groups to which they were randomised). Otherwise, available data were analysed<b>.</b> </p> <p>If studies reported sufficient detail to calculate mean differences (MD), but no information on associated standard deviation, we assumed the outcome to have a standard deviation equal to the highest standard deviation from other studies within the same analysis. </p> </section> <section id="CD005552-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity reflects any type of variability among the studies in a systematic review. The clinical and methodological characteristics of the included studies were considered in order to check if they were sufficiently similar for meta‐analysis to provide a clinically‐meaningful summary. A consistent treatment effect among the included studies suggests there is sufficient homogeneity for pooled analysis. Heterogeneity (inconsistency) between the results of different studies was examined by inspecting the scatter in the data points on the graph and the overlap in their confidence intervals on the forest plot and, more formally, by checking the results of the Chi<sup>2</sup> tests and the measure of the I<sup>2</sup> statistic (<a href="./references#CD005552-bbs2-0105" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557–60.">Higgins 2003</a>). An I<sup>2</sup> statistic greater than 50% was taken to indicate substantial heterogeneity (<a href="./references#CD005552-bbs2-0094" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>). </p> <p>Substantial heterogeneity for the review outcomes was explored (investigated) with subgroup and sensitivity analyses by consideration of factors such as study quality, differences in population, interventions and outcomes (see below section '<a href="#CD005552-sec-0036">Subgroup analysis and investigation of heterogeneity</a>'. </p> </section> <section id="CD005552-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data. If there were 10 or more studies in an analysis, we used a funnel plot for the main review outcomes to explore the possibility of small‐study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies). </p> </section> <section id="CD005552-sec-0035"> <h4 class="title">Data synthesis</h4> <p>Studies were sufficiently similar in order to combine the data using a fixed‐effect model in the following comparisons. </p> <p>(a) Metformin versus the combined oral contraceptive pill (MET versus the OCP).</p> <p>(b) Metformin versus the combined oral contraceptive pill in combination with metformin (MET versus the OCP + MET). </p> <p>(c) Combined oral contraceptive pill versus the combined oral contraceptive pill in combination with metformin (the OCP versus the OCP + MET). </p> <p>Statistical analysis was performed using Review manager 5.3 in accordance with the guidelines for statistical analysis developed by Cochrane (<a href="./references#CD005552-bbs2-0113" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> <p>For all outcomes, where data were available, we stratified comparisons by subgroups of studies of women with different mean body mass index (BMI) (e.g. BMI ≤ 25 kg/m<sup>2</sup>, BMI &gt; 25 kg/m<sup>2</sup> but &lt; 30 kg/m<sup>2</sup>, BMI ≥ 30 kg/m<sup>2</sup>) with an additional stratum for studies in which BMI was not reported, apart from the outcome of adverse events (which were divided into gastro‐intestinal and other adverse events). </p> </section> <section id="CD005552-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where data were available, we conducted pre‐specified subgroup analyses to determine the separate evidence within the following subgroups for all outcomes. </p> <p>All outcomes (apart from the outcome of adverse events) were divided or subgrouped according to studies of women with different mean BMI (e.g. BMI ≤ 25 kg/m<sup>2</sup>, BMI &gt; 25 kg/m<sup>2</sup> but &lt; 30 kg/m<sup>2</sup>, BMI ≥ 30 kg/m<sup>2</sup>) in order to assess any differences in intervention effect between these subgroups and to assess whether any substantial heterogeneity, if detected, could be explained by such subgroup analysis according to BMI (i.e. whether BMI is an important effect modifier). The rationale for pre‐specifying BMI for subgroup analysis was that metformin is an insulin‐sensitising agent and insulin resistance in PCOS is exacerbated by obesity (see <a href="#CD005552-sec-0009">Background</a> section), and therefore it is clinically plausible for metformin to possibly have a larger (or different) relative effect with increasing BMI. </p> <p>The assessment of whether there was a statistically significant difference between the subgroups was performed by comparing the different subgroups directly with each other using the "statistical test for subgroup differences" (I<sup>2</sup> statistic &gt; 50 and/or P value &lt; 0.05) in the forest plot graph. </p> <p>If substantial heterogeneity could be explained by such pre‐specified subgroup analyses (i.e. explained substantial heterogeneity), we analysed/reported the subgroups separately (and did not analyse/report the pooled results). </p> <p>If substantial heterogeneity was detected, which could not be explained by such pre‐specified subgroup analyses (i.e. unexplained substantial heterogeneity), we conducted sensitivity analyses to determine whether the conclusions are robust to arbitrary decisions made regarding the eligibility and analysis. These analyses included consideration of whether the review conclusions would have differed if (i) eligibility was restricted to studies at low risk of bias (defined as low risk of selection bias (both random sequence generation and allocation concealment) and not at high risk of bias in any domain) for the main review outcomes and if (ii) a random‐effects model had been adopted for all outcomes. If the random‐effects model and the fixed‐effect model produced substantially different pooled estimates, then this is an excellent indication of heterogeneity and the random‐effects model is the preferred model and as such was used. If the two models yielded similar pooled estimates then the fixed‐effect model is preferred and as such was used, because usually it will have a narrower confidence interval; that is, it is more precise than the random‐effects model (<a href="./references#CD005552-bbs2-0115" title="RyanR , Cochrane Consumers and Communication Review Group. Cochrane Consumers and Communication Group: meta-analysis. http://cccrg.cochrane.org accessed December 2016.">Ryan 2016</a>). Unexplained substantial heterogeneity was taken into account when assessing the quality of the evidence using GRADE in terms of inconsistency and interpreting the results, especially when there was variation in the direction of effect. </p> </section> <section id="CD005552-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses to determine whether the conclusions are robust to arbitrary decisions made regarding the eligibility and analysis. These analyses included consideration of whether the review conclusions would have differed if eligibility was restricted to studies at low risk of bias (defined as low risk of selection bias (both random sequence generation and allocation concealment) and not at high risk of bias in any domain) for the main review outcomes and if a random‐effects model had been adopted in the presence of unexplained substantial heterogeneity for all outcomes. </p> <p><b>Overall quality of the body of the evidence: 'Summary of findings' table</b> </p> <p>We generated 'Summary of findings' tables using GRADEpro software and Cochrane methods (<a href="./references#CD005552-bbs2-0103" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed 6 August 2019. Available at gradepro.org.">GRADEpro GDT</a>). This tables evaluated the overall quality of the body of the evidence for the main review outcomes (hirsutism, improvement in menstrual pattern, acne assessed clinically (as opposed to subjectively) by either visual analogue scale (VAS) or clinical acne score, BMI and adverse events (severe and minor) (subgrouped according to type of adverse event: gastro‐intestinal or other)) for the main review comparisons (metformin versus the OCP, metformin versus metformin in combination with the OCP, and the OCP versus metformin in combination with the OCP). We assessed the quality of the evidence using GRADE criteria: risk of bias, inconsistency, imprecision, indirectness and publication bias). Judgements about evidence quality (high, moderate, low or very low) were made by three review authors (EF, EK and MC) working independently, with disagreements resolved by discussion. Judgements were justified, documented and incorporated into reporting of results for each main review outcome. Unexplained substantial heterogeneity was taken into account when assessing the quality of the evidence using GRADE in terms of inconsistency and interpreting the results, especially when there was variation in the direction of effect. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005552-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005552-sec-0038"></div> <section id="CD005552-sec-0039"> <h3 class="title">Description of studies</h3> <section id="CD005552-sec-0040"> <h4 class="title">Results of the search</h4> <p>The previous version of this review included six trials (<a href="./references#CD005552-bbs2-0123" title="CostelloMF , ShresthaB , EdenJ , JohnsonN , MoranLJ . Insulin‐sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD005552. [DOI: 10.1002/14651858.CD005552.pub2]">Costello 2007</a>). The search for the current review update resulted in the retrieval of 77 full‐text papers and abstracts (<a href="#CD005552-fig-0001">Figure 1</a>). We included 38 new studies, 37 full‐text papers and one abstract (<a href="./references#CD005552-sec-0078" title="">Characteristics of included studies</a>). Three included studies from non‐English language journals required translation (<a href="./references#CD005552-bbs2-0018" title="JinLN , YuQ , Ma LK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/ Ethinyl Estradiol in PCOS patients. Chinese Journal of Postgraduate Medicine2006;29:10-5. ">Jin 2006</a>; <a href="./references#CD005552-bbs2-0025" title="LiuJX , DangJM , WuYZ , ZhengN , WuXK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/Ethynil Estradiol on PCOS patients. Chinese Journal of Postgraduate Medicine2006;19:530-3. ">Liu 2006</a>;<a href="./references#CD005552-bbs2-0042" title="TengYQ , ZhengJH , HanXY . Evaluation of clinical efficacy of Metformin in treating polycystic ovary syndrome. Journal of Harbin Medical University2007;41:405-6. ">Teng 2007</a>). We excluded 38 new studies (<a href="./references#CD005552-sec-0079" title="">Characteristics of excluded studies</a>). Four new studies are awaiting classification (<a href="./references#CD005552-sec-0080" title="">Characteristics of studies awaiting classification</a>); we have contacted the authors and still await a response. We one study from awaiting classification to included studies (<a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>), and another study from awaiting classification to excluded studies (<a href="./references#CD005552-bbs2-0075" title="NCT02866786. The effect of OCP and Metformin on Clinical, hormonal, metabolic and ultrasonographic characteristics in PCOS. clinicaltrials.gov/show/NCT02866786 (first received 15 August 2016). ">NCT02866786</a>). We classified three new studies as ongoing (<a href="./references#CD005552-bbs2-0087" title="OCP vs metformin for Improvement in clinical symptoms and metabolic markers in Indian PCOS women (OCP). Ongoing study. 04/2016. Contact author for more information.">NCT02744131</a>; <a href="./references#CD005552-bbs2-0088" title="Comparing the effects of oral contraceptive pills versus metformin (COMET-PCOS). Ongoing study. Juillet 2017. Contact author for more information.">NCT03229057</a>;<a href="./references#CD005552-bbs2-0089" title="Relative desirability of metformin vs. birth control pill in treating PCOS in women of later reproductive age. Ongoing study. March 2020. Contact author for more information.">NCT03905941</a>), (<a href="./references#CD005552-sec-0081" title="">Characteristics of ongoing studies</a>). </p> </section> <section id="CD005552-sec-0041"> <h4 class="title">Included studies</h4> <p><b>Study design and setting</b> </p> <p>In this 2020 updated review, we included 44 randomised controlled trials ( RCTs) consisting of 43 parallel‐designed RCTs and 1 cross‐over RCT (in which only pre‐cross over data were used). The updated review includes 37 full‐text articles, one abstract and six full‐text references from the former review. </p> <p>The studies were performed in different locations around the world.</p> <p> <ul id="CD005552-list-0002"> <li> <p>Australia (<a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>; <a href="./references#CD005552-bbs2-0033" title="MoranLJ , MeyerC , HutchisonSK , ZoungasS , TeedeHJ . Novel inflammatory markers in overweight women with or without polycystic ovary syndrome and following pharmacological intervention. Journal of Endocrinological Investigation2010;33:258-65. ">Moran 2010</a>) </p> </li> <li> <p>Czech Republic (<a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>) </p> </li> <li> <p>China (<a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0018" title="JinLN , YuQ , Ma LK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/ Ethinyl Estradiol in PCOS patients. Chinese Journal of Postgraduate Medicine2006;29:10-5. ">Jin 2006</a>; <a href="./references#CD005552-bbs2-0023" title="KuekS , Wang W-J, Gui S-Q. Efficacy of chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial. Journal of Chinese Integrative Medicine2011;9:965-72. ">Kuek 2011</a>; <a href="./references#CD005552-bbs2-0025" title="LiuJX , DangJM , WuYZ , ZhengN , WuXK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/Ethynil Estradiol on PCOS patients. Chinese Journal of Postgraduate Medicine2006;19:530-3. ">Liu 2006</a>; <a href="./references#CD005552-bbs2-0030" title="LvL , LiuY , SunY , TanK . Effects of Metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. Journal of Huazhong University of Science and Technology2005;25:194-7. ">Lv 2005</a>; <a href="./references#CD005552-bbs2-0041" title="SongJ , RuanX , GuM , WangL , WangH , MueckAO . Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological Endocrinology2018;34:413-7. ">Song 2017</a>; <a href="./references#CD005552-bbs2-0039" title="RuanX , SongJ , GuM , WangL , WangH , Mueck AO. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Archives of Gynecology and Obstetrics2018;297:1557-63. ">Ruan 2018</a>; <a href="./references#CD005552-bbs2-0042" title="TengYQ , ZhengJH , HanXY . Evaluation of clinical efficacy of Metformin in treating polycystic ovary syndrome. Journal of Harbin Medical University2007;41:405-6. ">Teng 2007</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>) </p> </li> <li> <p>Denmark (<a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>) </p> </li> <li> <p>Egypt (<a href="./references#CD005552-bbs2-0010" title="El MaghrabyHA , NafeeT , GuiziryD , ElnasharA . Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 months follow up period. Middle East Fertility Society Journal2015;20:131-7. ">El Maghraby 2015</a>) </p> </li> <li> <p>Finland (<a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0038" title="RautioK , TapanainenJS , RuokonenA , Morin-PapunenLC . Effects of metformin and ethinyl-estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. European Journal of Endocrinology2005;152:269-75. ">Rautio 2005</a>) </p> </li> <li> <p>Greece (<a href="./references#CD005552-bbs2-0007" title="ChristakouC , KolliasA , PiperiC , KatsikisI , PanidisD , Diamanti-KandarakisE . The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. Hormones2014;13:488-97. ">Christakou 2014</a>) </p> </li> <li> <p>Italy (<a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>) </p> </li> <li> <p>India (<a href="./references#CD005552-bbs2-0004" title="Bhattacharya SM , BiswasB , BasuA . Comparative study of the therapeutic effects of drospirenone (DRSP, 3mg) with ethinyl estradiol (EE, 20 mcg) pill with or without metformin 500 mg in polycystic ovary syndrome (PCOS). In: Fertility and Sterility. 2016, poster P-401:e257. ">Bhattacharya 2016</a> (abstract); <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>) </p> </li> <li> <p>Iran (<a href="./references#CD005552-bbs2-0001" title="AghamohammadzadehN , AliasgarzadehA , BaglarL , AbdollahifardS , BahramiA , NajafipourF , et al. Comparison of metformin and cyproterone-estrodiol compound effect on HS C-reactive protein and serum androgen levels in patients with polycystic ovary syndrome. Pakistan Journal of Medical Science2010;26(2):347-51. ">Aghamohammadzadeh 2010</a>) </p> </li> <li> <p>Iraq (<a href="./references#CD005552-bbs2-0032" title="MhaoNS , Al-HilliSA , HadiNR , JamilDA , Al-AubaidyHA . A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews2015;10S:S95-S98. ">Mhao 2015</a>) </p> </li> <li> <p>Poland (<a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>) </p> </li> <li> <p>Scotland (<a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>) </p> </li> <li> <p>Spain (<a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0027" title="Luque-RamirezM , Alvarez-BlascoF , Botella-Carretero JI , SanchonR , San MillanJL , Escobar-MorrealeHF . Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care 09/2007;30:2309-13. ">Luque‐Ramirez 2007b</a>; <a href="./references#CD005552-bbs2-0028" title="Luque-RamirezM , Alvarez-BlascoF , Uriol RiveraMG , Escobar-MorrealeHF . Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. Human Reproduction2008;23:1594-601. ">Luque‐Ramirez 2008a</a>; <a href="./references#CD005552-bbs2-0029" title="Luque-RamirezM , Mendieta-AzconaC , Alvarez-BlascoF , Escobar-MorrealeHF . Effects of Metformin versus Ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertility and Sterility2008;91:2527-36. ">Luque‐Ramirez 2009b</a>) </p> </li> <li> <p>Turkey (<a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0011" title="ElterK , ImirG , DurmusogluF . Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction2002;17(7):1729-37. ">Elter 2002</a>; <a href="./references#CD005552-bbs2-0019" title="KayaMG , YildirimS , CalapkorurB , AkpekM , UnluhizarciK , KelestimurF . Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecological Endocrinology2015;31:401-5. ">Kaya 2015</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0021" title="BilgirO , KebapcilarL , TanerC , BilgirF , KebapcilarA , BozkayaG , et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). International Medicine2009;48:1193-9. KebapcilarL , YukselA , BozkayaG , TanerCE , KebapcilarAG , BilgirO , et al. Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome. Central European Journal of Medicine2009;4:423-7. ">Kebapcilar 2009b</a>; <a href="./references#CD005552-bbs2-0022" title="KilicS , YilmazN , ZulfikarogluE , ErdoganG , AydinM , BatiogluS . Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecological Endocrinology2011;27(9):622-9. ">Kilic 2011</a>; <a href="./references#CD005552-bbs2-0037" title="OzgurtasT , OktenliC , DedeM , TapanS , KenarL , SanisogluSY , et al. Metformin and oral contraceptive treatment reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis2008;200:336-44. ">Ozgurtas 2008</a>) </p> </li> <li> <p>USA (<a href="./references#CD005552-bbs2-0002" title="AllenHF , MazzoniC , HeptullaRA , MurrayMA , MillerN , KoenigsL , et al. Randomized controlled trial evaluating response to Metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism2005;18:761-8. ">Allen 2005</a>; <a href="./references#CD005552-bbs2-0003" title="Al-ZubeidiH , KleinKO . Randomized clinical trial evaluating Metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome. Journal of Pediatric Endocrinology and Metabolism2015;28:853-8. ">Al‐Zubeidi 2015</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>; <a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>). </p> </li> </ul> </p> <p><b>Participants</b> </p> <p>The studies included 2253 women with polycystic ovary syndrome (PCOS).</p> <p> <ul id="CD005552-list-0003"> <li> <p>43/44 studies fulfilled the Rotterdam PCOS criteria (<a href="./references#CD005552-bbs2-0004" title="Bhattacharya SM , BiswasB , BasuA . Comparative study of the therapeutic effects of drospirenone (DRSP, 3mg) with ethinyl estradiol (EE, 20 mcg) pill with or without metformin 500 mg in polycystic ovary syndrome (PCOS). In: Fertility and Sterility. 2016, poster P-401:e257. ">Bhattacharya 2016</a>; <a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0010" title="El MaghrabyHA , NafeeT , GuiziryD , ElnasharA . Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 months follow up period. Middle East Fertility Society Journal2015;20:131-7. ">El Maghraby 2015</a>; <a href="./references#CD005552-bbs2-0011" title="ElterK , ImirG , DurmusogluF . Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction2002;17(7):1729-37. ">Elter 2002</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0018" title="JinLN , YuQ , Ma LK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/ Ethinyl Estradiol in PCOS patients. Chinese Journal of Postgraduate Medicine2006;29:10-5. ">Jin 2006</a>; <a href="./references#CD005552-bbs2-0019" title="KayaMG , YildirimS , CalapkorurB , AkpekM , UnluhizarciK , KelestimurF . Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecological Endocrinology2015;31:401-5. ">Kaya 2015</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0021" title="BilgirO , KebapcilarL , TanerC , BilgirF , KebapcilarA , BozkayaG , et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). International Medicine2009;48:1193-9. KebapcilarL , YukselA , BozkayaG , TanerCE , KebapcilarAG , BilgirO , et al. Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome. Central European Journal of Medicine2009;4:423-7. ">Kebapcilar 2009b</a>; <a href="./references#CD005552-bbs2-0022" title="KilicS , YilmazN , ZulfikarogluE , ErdoganG , AydinM , BatiogluS . Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecological Endocrinology2011;27(9):622-9. ">Kilic 2011</a>; <a href="./references#CD005552-bbs2-0023" title="KuekS , Wang W-J, Gui S-Q. Efficacy of chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial. Journal of Chinese Integrative Medicine2011;9:965-72. ">Kuek 2011</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0030" title="LvL , LiuY , SunY , TanK . Effects of Metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. Journal of Huazhong University of Science and Technology2005;25:194-7. ">Lv 2005</a>; <a href="./references#CD005552-bbs2-0032" title="MhaoNS , Al-HilliSA , HadiNR , JamilDA , Al-AubaidyHA . A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews2015;10S:S95-S98. ">Mhao 2015</a>; <a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0037" title="OzgurtasT , OktenliC , DedeM , TapanS , KenarL , SanisogluSY , et al. Metformin and oral contraceptive treatment reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis2008;200:336-44. ">Ozgurtas 2008</a>; <a href="./references#CD005552-bbs2-0038" title="RautioK , TapanainenJS , RuokonenA , Morin-PapunenLC . Effects of metformin and ethinyl-estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. European Journal of Endocrinology2005;152:269-75. ">Rautio 2005</a>; <a href="./references#CD005552-bbs2-0041" title="SongJ , RuanX , GuM , WangL , WangH , MueckAO . Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological Endocrinology2018;34:413-7. ">Song 2017</a>; <a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>; <a href="./references#CD005552-bbs2-0039" title="RuanX , SongJ , GuM , WangL , WangH , Mueck AO. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Archives of Gynecology and Obstetrics2018;297:1557-63. ">Ruan 2018</a>; <a href="./references#CD005552-bbs2-0042" title="TengYQ , ZhengJH , HanXY . Evaluation of clinical efficacy of Metformin in treating polycystic ovary syndrome. Journal of Harbin Medical University2007;41:405-6. ">Teng 2007</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>); including 12/44 studies which fulfilled the stricter National Institutes of Health (NIH) PCOS criteria (<a href="./references#CD005552-bbs2-0001" title="AghamohammadzadehN , AliasgarzadehA , BaglarL , AbdollahifardS , BahramiA , NajafipourF , et al. Comparison of metformin and cyproterone-estrodiol compound effect on HS C-reactive protein and serum androgen levels in patients with polycystic ovary syndrome. Pakistan Journal of Medical Science2010;26(2):347-51. ">Aghamohammadzadeh 2010</a>; <a href="./references#CD005552-bbs2-0002" title="AllenHF , MazzoniC , HeptullaRA , MurrayMA , MillerN , KoenigsL , et al. Randomized controlled trial evaluating response to Metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism2005;18:761-8. ">Allen 2005</a>; <a href="./references#CD005552-bbs2-0003" title="Al-ZubeidiH , KleinKO . Randomized clinical trial evaluating Metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome. Journal of Pediatric Endocrinology and Metabolism2015;28:853-8. ">Al‐Zubeidi 2015</a>; <a href="./references#CD005552-bbs2-0007" title="ChristakouC , KolliasA , PiperiC , KatsikisI , PanidisD , Diamanti-KandarakisE . The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. Hormones2014;13:488-97. ">Christakou 2014</a>; <a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>; <a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>; <a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>; <a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0027" title="Luque-RamirezM , Alvarez-BlascoF , Botella-Carretero JI , SanchonR , San MillanJL , Escobar-MorrealeHF . Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care 09/2007;30:2309-13. ">Luque‐Ramirez 2007b</a>; <a href="./references#CD005552-bbs2-0028" title="Luque-RamirezM , Alvarez-BlascoF , Uriol RiveraMG , Escobar-MorrealeHF . Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. Human Reproduction2008;23:1594-601. ">Luque‐Ramirez 2008a</a>; <a href="./references#CD005552-bbs2-0029" title="Luque-RamirezM , Mendieta-AzconaC , Alvarez-BlascoF , Escobar-MorrealeHF . Effects of Metformin versus Ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertility and Sterility2008;91:2527-36. ">Luque‐Ramirez 2009b</a>; <a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>); and including 1/44 studies fulfilled either NIH or Rotterdam PCOS criteria (<a href="./references#CD005552-bbs2-0033" title="MoranLJ , MeyerC , HutchisonSK , ZoungasS , TeedeHJ . Novel inflammatory markers in overweight women with or without polycystic ovary syndrome and following pharmacological intervention. Journal of Endocrinological Investigation2010;33:258-65. ">Moran 2010</a>). </p> </li> <li> <p>1/44 studies did not described any diagnostic criteria (<a href="./references#CD005552-bbs2-0025" title="LiuJX , DangJM , WuYZ , ZhengN , WuXK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/Ethynil Estradiol on PCOS patients. Chinese Journal of Postgraduate Medicine2006;19:530-3. ">Liu 2006</a>). </p> </li> </ul> </p> <p>The mean age of the women ranged across studies from 12 to 40 years.</p> <p> <ul id="CD005552-list-0004"> <li> <p>5/44 studies (206 women analysed) recruited adolescent women (<a href="./references#CD005552-bbs2-0002" title="AllenHF , MazzoniC , HeptullaRA , MurrayMA , MillerN , KoenigsL , et al. Randomized controlled trial evaluating response to Metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism2005;18:761-8. ">Allen 2005</a>; <a href="./references#CD005552-bbs2-0003" title="Al-ZubeidiH , KleinKO . Randomized clinical trial evaluating Metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome. Journal of Pediatric Endocrinology and Metabolism2015;28:853-8. ">Al‐Zubeidi 2015</a>; <a href="./references#CD005552-bbs2-0010" title="El MaghrabyHA , NafeeT , GuiziryD , ElnasharA . Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 months follow up period. Middle East Fertility Society Journal2015;20:131-7. ">El Maghraby 2015</a>; <a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>; <a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>). </p> </li> <li> <p>39/44 studies (2047 women analysed) recruited adult women (<a href="./references#CD005552-bbs2-0001" title="AghamohammadzadehN , AliasgarzadehA , BaglarL , AbdollahifardS , BahramiA , NajafipourF , et al. Comparison of metformin and cyproterone-estrodiol compound effect on HS C-reactive protein and serum androgen levels in patients with polycystic ovary syndrome. Pakistan Journal of Medical Science2010;26(2):347-51. ">Aghamohammadzadeh 2010</a>; <a href="./references#CD005552-bbs2-0004" title="Bhattacharya SM , BiswasB , BasuA . Comparative study of the therapeutic effects of drospirenone (DRSP, 3mg) with ethinyl estradiol (EE, 20 mcg) pill with or without metformin 500 mg in polycystic ovary syndrome (PCOS). In: Fertility and Sterility. 2016, poster P-401:e257. ">Bhattacharya 2016</a>; <a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0007" title="ChristakouC , KolliasA , PiperiC , KatsikisI , PanidisD , Diamanti-KandarakisE . The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. Hormones2014;13:488-97. ">Christakou 2014</a>; <a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0011" title="ElterK , ImirG , DurmusogluF . Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction2002;17(7):1729-37. ">Elter 2002</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0018" title="JinLN , YuQ , Ma LK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/ Ethinyl Estradiol in PCOS patients. Chinese Journal of Postgraduate Medicine2006;29:10-5. ">Jin 2006</a>; <a href="./references#CD005552-bbs2-0019" title="KayaMG , YildirimS , CalapkorurB , AkpekM , UnluhizarciK , KelestimurF . Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecological Endocrinology2015;31:401-5. ">Kaya 2015</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0021" title="BilgirO , KebapcilarL , TanerC , BilgirF , KebapcilarA , BozkayaG , et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). International Medicine2009;48:1193-9. KebapcilarL , YukselA , BozkayaG , TanerCE , KebapcilarAG , BilgirO , et al. Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome. Central European Journal of Medicine2009;4:423-7. ">Kebapcilar 2009b</a>; <a href="./references#CD005552-bbs2-0022" title="KilicS , YilmazN , ZulfikarogluE , ErdoganG , AydinM , BatiogluS . Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecological Endocrinology2011;27(9):622-9. ">Kilic 2011</a>; <a href="./references#CD005552-bbs2-0023" title="KuekS , Wang W-J, Gui S-Q. Efficacy of chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial. Journal of Chinese Integrative Medicine2011;9:965-72. ">Kuek 2011</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0025" title="LiuJX , DangJM , WuYZ , ZhengN , WuXK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/Ethynil Estradiol on PCOS patients. Chinese Journal of Postgraduate Medicine2006;19:530-3. ">Liu 2006</a>; <a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0027" title="Luque-RamirezM , Alvarez-BlascoF , Botella-Carretero JI , SanchonR , San MillanJL , Escobar-MorrealeHF . Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care 09/2007;30:2309-13. ">Luque‐Ramirez 2007b</a>; <a href="./references#CD005552-bbs2-0028" title="Luque-RamirezM , Alvarez-BlascoF , Uriol RiveraMG , Escobar-MorrealeHF . Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. Human Reproduction2008;23:1594-601. ">Luque‐Ramirez 2008a</a>; <a href="./references#CD005552-bbs2-0029" title="Luque-RamirezM , Mendieta-AzconaC , Alvarez-BlascoF , Escobar-MorrealeHF . Effects of Metformin versus Ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertility and Sterility2008;91:2527-36. ">Luque‐Ramirez 2009b</a>; <a href="./references#CD005552-bbs2-0030" title="LvL , LiuY , SunY , TanK . Effects of Metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. Journal of Huazhong University of Science and Technology2005;25:194-7. ">Lv 2005</a>; <a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>; <a href="./references#CD005552-bbs2-0032" title="MhaoNS , Al-HilliSA , HadiNR , JamilDA , Al-AubaidyHA . A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews2015;10S:S95-S98. ">Mhao 2015</a>; <a href="./references#CD005552-bbs2-0033" title="MoranLJ , MeyerC , HutchisonSK , ZoungasS , TeedeHJ . Novel inflammatory markers in overweight women with or without polycystic ovary syndrome and following pharmacological intervention. Journal of Endocrinological Investigation2010;33:258-65. ">Moran 2010</a>; <a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0037" title="OzgurtasT , OktenliC , DedeM , TapanS , KenarL , SanisogluSY , et al. Metformin and oral contraceptive treatment reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis2008;200:336-44. ">Ozgurtas 2008</a>; <a href="./references#CD005552-bbs2-0038" title="RautioK , TapanainenJS , RuokonenA , Morin-PapunenLC . Effects of metformin and ethinyl-estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. European Journal of Endocrinology2005;152:269-75. ">Rautio 2005</a>; <a href="./references#CD005552-bbs2-0041" title="SongJ , RuanX , GuM , WangL , WangH , MueckAO . Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological Endocrinology2018;34:413-7. ">Song 2017</a>; <a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>; <a href="./references#CD005552-bbs2-0039" title="RuanX , SongJ , GuM , WangL , WangH , Mueck AO. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Archives of Gynecology and Obstetrics2018;297:1557-63. ">Ruan 2018</a>; <a href="./references#CD005552-bbs2-0042" title="TengYQ , ZhengJH , HanXY . Evaluation of clinical efficacy of Metformin in treating polycystic ovary syndrome. Journal of Harbin Medical University2007;41:405-6. ">Teng 2007</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> </li> </ul> </p> <p><b>Interventions</b> </p> <p> <ul id="CD005552-list-0005"> <li> <p>26/44 studies compared metformin (MET) versus the combined oral contraceptive (OCP) (<a href="./references#CD005552-bbs2-0001" title="AghamohammadzadehN , AliasgarzadehA , BaglarL , AbdollahifardS , BahramiA , NajafipourF , et al. Comparison of metformin and cyproterone-estrodiol compound effect on HS C-reactive protein and serum androgen levels in patients with polycystic ovary syndrome. Pakistan Journal of Medical Science2010;26(2):347-51. ">Aghamohammadzadeh 2010</a>; <a href="./references#CD005552-bbs2-0002" title="AllenHF , MazzoniC , HeptullaRA , MurrayMA , MillerN , KoenigsL , et al. Randomized controlled trial evaluating response to Metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism2005;18:761-8. ">Allen 2005</a>; <a href="./references#CD005552-bbs2-0003" title="Al-ZubeidiH , KleinKO . Randomized clinical trial evaluating Metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome. Journal of Pediatric Endocrinology and Metabolism2015;28:853-8. ">Al‐Zubeidi 2015</a>; <a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0007" title="ChristakouC , KolliasA , PiperiC , KatsikisI , PanidisD , Diamanti-KandarakisE . The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. Hormones2014;13:488-97. ">Christakou 2014</a>; <a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0010" title="El MaghrabyHA , NafeeT , GuiziryD , ElnasharA . Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 months follow up period. Middle East Fertility Society Journal2015;20:131-7. ">El Maghraby 2015</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>; <a href="./references#CD005552-bbs2-0018" title="JinLN , YuQ , Ma LK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/ Ethinyl Estradiol in PCOS patients. Chinese Journal of Postgraduate Medicine2006;29:10-5. ">Jin 2006</a>; <a href="./references#CD005552-bbs2-0022" title="KilicS , YilmazN , ZulfikarogluE , ErdoganG , AydinM , BatiogluS . Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecological Endocrinology2011;27(9):622-9. ">Kilic 2011</a>; <a href="./references#CD005552-bbs2-0023" title="KuekS , Wang W-J, Gui S-Q. Efficacy of chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial. Journal of Chinese Integrative Medicine2011;9:965-72. ">Kuek 2011</a>; <a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0027" title="Luque-RamirezM , Alvarez-BlascoF , Botella-Carretero JI , SanchonR , San MillanJL , Escobar-MorrealeHF . Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care 09/2007;30:2309-13. ">Luque‐Ramirez 2007b</a>; <a href="./references#CD005552-bbs2-0028" title="Luque-RamirezM , Alvarez-BlascoF , Uriol RiveraMG , Escobar-MorrealeHF . Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. Human Reproduction2008;23:1594-601. ">Luque‐Ramirez 2008a</a>; <a href="./references#CD005552-bbs2-0029" title="Luque-RamirezM , Mendieta-AzconaC , Alvarez-BlascoF , Escobar-MorrealeHF . Effects of Metformin versus Ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertility and Sterility2008;91:2527-36. ">Luque‐Ramirez 2009b</a>; <a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>; <a href="./references#CD005552-bbs2-0032" title="MhaoNS , Al-HilliSA , HadiNR , JamilDA , Al-AubaidyHA . A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews2015;10S:S95-S98. ">Mhao 2015</a>; <a href="./references#CD005552-bbs2-0033" title="MoranLJ , MeyerC , HutchisonSK , ZoungasS , TeedeHJ . Novel inflammatory markers in overweight women with or without polycystic ovary syndrome and following pharmacological intervention. Journal of Endocrinological Investigation2010;33:258-65. ">Moran 2010</a>; <a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0037" title="OzgurtasT , OktenliC , DedeM , TapanS , KenarL , SanisogluSY , et al. Metformin and oral contraceptive treatment reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis2008;200:336-44. ">Ozgurtas 2008</a>; <a href="./references#CD005552-bbs2-0038" title="RautioK , TapanainenJS , RuokonenA , Morin-PapunenLC . Effects of metformin and ethinyl-estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. European Journal of Endocrinology2005;152:269-75. ">Rautio 2005</a>; <a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>; <a href="./references#CD005552-bbs2-0042" title="TengYQ , ZhengJH , HanXY . Evaluation of clinical efficacy of Metformin in treating polycystic ovary syndrome. Journal of Harbin Medical University2007;41:405-6. ">Teng 2007</a>). </p> </li> <li> <p>11/44 studies compared MET versus MET + the OCP (<a href="./references#CD005552-bbs2-0004" title="Bhattacharya SM , BiswasB , BasuA . Comparative study of the therapeutic effects of drospirenone (DRSP, 3mg) with ethinyl estradiol (EE, 20 mcg) pill with or without metformin 500 mg in polycystic ovary syndrome (PCOS). In: Fertility and Sterility. 2016, poster P-401:e257. ">Bhattacharya 2016</a>; <a href="./references#CD005552-bbs2-0011" title="ElterK , ImirG , DurmusogluF . Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction2002;17(7):1729-37. ">Elter 2002</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>; <a href="./references#CD005552-bbs2-0019" title="KayaMG , YildirimS , CalapkorurB , AkpekM , UnluhizarciK , KelestimurF . Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecological Endocrinology2015;31:401-5. ">Kaya 2015</a>; <a href="./references#CD005552-bbs2-0021" title="BilgirO , KebapcilarL , TanerC , BilgirF , KebapcilarA , BozkayaG , et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). International Medicine2009;48:1193-9. KebapcilarL , YukselA , BozkayaG , TanerCE , KebapcilarAG , BilgirO , et al. Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome. Central European Journal of Medicine2009;4:423-7. ">Kebapcilar 2009b</a>; <a href="./references#CD005552-bbs2-0030" title="LvL , LiuY , SunY , TanK . Effects of Metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. Journal of Huazhong University of Science and Technology2005;25:194-7. ">Lv 2005</a>; <a href="./references#CD005552-bbs2-0041" title="SongJ , RuanX , GuM , WangL , WangH , MueckAO . Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological Endocrinology2018;34:413-7. ">Song 2017</a>; <a href="./references#CD005552-bbs2-0039" title="RuanX , SongJ , GuM , WangL , WangH , Mueck AO. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Archives of Gynecology and Obstetrics2018;297:1557-63. ">Ruan 2018</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>). </p> </li> <li> <p>7/44 studies compared MET versus the OCP versus MET + the OCP (<a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0025" title="LiuJX , DangJM , WuYZ , ZhengN , WuXK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/Ethynil Estradiol on PCOS patients. Chinese Journal of Postgraduate Medicine2006;19:530-3. ">Liu 2006</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> </li> </ul> </p> <p>(See <a href="./references#CD005552-sec-0078" title="">Characteristics of included studies</a> table). </p> <p><b>Outcomes</b> </p> <p> <ul id="CD005552-list-0006"> <li> <p>18/44 studies reported hirsutism by woman randomised (<a href="./references#CD005552-bbs2-0004" title="Bhattacharya SM , BiswasB , BasuA . Comparative study of the therapeutic effects of drospirenone (DRSP, 3mg) with ethinyl estradiol (EE, 20 mcg) pill with or without metformin 500 mg in polycystic ovary syndrome (PCOS). In: Fertility and Sterility. 2016, poster P-401:e257. ">Bhattacharya 2016</a>; <a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0010" title="El MaghrabyHA , NafeeT , GuiziryD , ElnasharA . Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 months follow up period. Middle East Fertility Society Journal2015;20:131-7. ">El Maghraby 2015</a>; <a href="./references#CD005552-bbs2-0011" title="ElterK , ImirG , DurmusogluF . Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction2002;17(7):1729-37. ">Elter 2002</a>; <a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>; <a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>; <a href="./references#CD005552-bbs2-0018" title="JinLN , YuQ , Ma LK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/ Ethinyl Estradiol in PCOS patients. Chinese Journal of Postgraduate Medicine2006;29:10-5. ">Jin 2006</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>; <a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> </li> <li> <p>17/44 studies reported adverse events (severe or minor) by woman randomised (<a href="./references#CD005552-bbs2-0001" title="AghamohammadzadehN , AliasgarzadehA , BaglarL , AbdollahifardS , BahramiA , NajafipourF , et al. Comparison of metformin and cyproterone-estrodiol compound effect on HS C-reactive protein and serum androgen levels in patients with polycystic ovary syndrome. Pakistan Journal of Medical Science2010;26(2):347-51. ">Aghamohammadzadeh 2010</a>; <a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0007" title="ChristakouC , KolliasA , PiperiC , KatsikisI , PanidisD , Diamanti-KandarakisE . The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. Hormones2014;13:488-97. ">Christakou 2014</a>; <a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0010" title="El MaghrabyHA , NafeeT , GuiziryD , ElnasharA . Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 months follow up period. Middle East Fertility Society Journal2015;20:131-7. ">El Maghraby 2015</a>; <a href="./references#CD005552-bbs2-0011" title="ElterK , ImirG , DurmusogluF . Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction2002;17(7):1729-37. ">Elter 2002</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>; <a href="./references#CD005552-bbs2-0022" title="KilicS , YilmazN , ZulfikarogluE , ErdoganG , AydinM , BatiogluS . Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecological Endocrinology2011;27(9):622-9. ">Kilic 2011</a>; <a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>). </p> </li> <li> <p>7/44 studies reported improved menstrual pattern by woman randomised (<a href="./references#CD005552-bbs2-0010" title="El MaghrabyHA , NafeeT , GuiziryD , ElnasharA . Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 months follow up period. Middle East Fertility Society Journal2015;20:131-7. ">El Maghraby 2015</a>; <a href="./references#CD005552-bbs2-0018" title="JinLN , YuQ , Ma LK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/ Ethinyl Estradiol in PCOS patients. Chinese Journal of Postgraduate Medicine2006;29:10-5. ">Jin 2006</a>; <a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0032" title="MhaoNS , Al-HilliSA , HadiNR , JamilDA , Al-AubaidyHA . A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews2015;10S:S95-S98. ">Mhao 2015</a>; <a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>). </p> </li> <li> <p>6/44 studies reported acne (<a href="./references#CD005552-bbs2-0004" title="Bhattacharya SM , BiswasB , BasuA . Comparative study of the therapeutic effects of drospirenone (DRSP, 3mg) with ethinyl estradiol (EE, 20 mcg) pill with or without metformin 500 mg in polycystic ovary syndrome (PCOS). In: Fertility and Sterility. 2016, poster P-401:e257. ">Bhattacharya 2016</a>; <a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0018" title="JinLN , YuQ , Ma LK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/ Ethinyl Estradiol in PCOS patients. Chinese Journal of Postgraduate Medicine2006;29:10-5. ">Jin 2006</a>; <a href="./references#CD005552-bbs2-0032" title="MhaoNS , Al-HilliSA , HadiNR , JamilDA , Al-AubaidyHA . A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews2015;10S:S95-S98. ">Mhao 2015</a>). </p> </li> <li> <p>39/44 studies reported body mass index (BMI) by woman randomised (<a href="./references#CD005552-bbs2-0001" title="AghamohammadzadehN , AliasgarzadehA , BaglarL , AbdollahifardS , BahramiA , NajafipourF , et al. Comparison of metformin and cyproterone-estrodiol compound effect on HS C-reactive protein and serum androgen levels in patients with polycystic ovary syndrome. Pakistan Journal of Medical Science2010;26(2):347-51. ">Aghamohammadzadeh 2010</a>; <a href="./references#CD005552-bbs2-0002" title="AllenHF , MazzoniC , HeptullaRA , MurrayMA , MillerN , KoenigsL , et al. Randomized controlled trial evaluating response to Metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism2005;18:761-8. ">Allen 2005</a>; <a href="./references#CD005552-bbs2-0003" title="Al-ZubeidiH , KleinKO . Randomized clinical trial evaluating Metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome. Journal of Pediatric Endocrinology and Metabolism2015;28:853-8. ">Al‐Zubeidi 2015</a>; <a href="./references#CD005552-bbs2-0004" title="Bhattacharya SM , BiswasB , BasuA . Comparative study of the therapeutic effects of drospirenone (DRSP, 3mg) with ethinyl estradiol (EE, 20 mcg) pill with or without metformin 500 mg in polycystic ovary syndrome (PCOS). In: Fertility and Sterility. 2016, poster P-401:e257. ">Bhattacharya 2016</a>; <a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0007" title="ChristakouC , KolliasA , PiperiC , KatsikisI , PanidisD , Diamanti-KandarakisE . The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. Hormones2014;13:488-97. ">Christakou 2014</a>; <a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0011" title="ElterK , ImirG , DurmusogluF . Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction2002;17(7):1729-37. ">Elter 2002</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>; <a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>; <a href="./references#CD005552-bbs2-0018" title="JinLN , YuQ , Ma LK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/ Ethinyl Estradiol in PCOS patients. Chinese Journal of Postgraduate Medicine2006;29:10-5. ">Jin 2006</a>; <a href="./references#CD005552-bbs2-0019" title="KayaMG , YildirimS , CalapkorurB , AkpekM , UnluhizarciK , KelestimurF . Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecological Endocrinology2015;31:401-5. ">Kaya 2015</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0021" title="BilgirO , KebapcilarL , TanerC , BilgirF , KebapcilarA , BozkayaG , et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). International Medicine2009;48:1193-9. KebapcilarL , YukselA , BozkayaG , TanerCE , KebapcilarAG , BilgirO , et al. Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome. Central European Journal of Medicine2009;4:423-7. ">Kebapcilar 2009b</a>; <a href="./references#CD005552-bbs2-0022" title="KilicS , YilmazN , ZulfikarogluE , ErdoganG , AydinM , BatiogluS . Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecological Endocrinology2011;27(9):622-9. ">Kilic 2011</a>; <a href="./references#CD005552-bbs2-0023" title="KuekS , Wang W-J, Gui S-Q. Efficacy of chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial. Journal of Chinese Integrative Medicine2011;9:965-72. ">Kuek 2011</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0025" title="LiuJX , DangJM , WuYZ , ZhengN , WuXK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/Ethynil Estradiol on PCOS patients. Chinese Journal of Postgraduate Medicine2006;19:530-3. ">Liu 2006</a>; <a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0030" title="LvL , LiuY , SunY , TanK . Effects of Metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. Journal of Huazhong University of Science and Technology2005;25:194-7. ">Lv 2005</a>; <a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>; <a href="./references#CD005552-bbs2-0032" title="MhaoNS , Al-HilliSA , HadiNR , JamilDA , Al-AubaidyHA . A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews2015;10S:S95-S98. ">Mhao 2015</a>; <a href="./references#CD005552-bbs2-0033" title="MoranLJ , MeyerC , HutchisonSK , ZoungasS , TeedeHJ . Novel inflammatory markers in overweight women with or without polycystic ovary syndrome and following pharmacological intervention. Journal of Endocrinological Investigation2010;33:258-65. ">Moran 2010</a>; <a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0037" title="OzgurtasT , OktenliC , DedeM , TapanS , KenarL , SanisogluSY , et al. Metformin and oral contraceptive treatment reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis2008;200:336-44. ">Ozgurtas 2008</a>; <a href="./references#CD005552-bbs2-0041" title="SongJ , RuanX , GuM , WangL , WangH , MueckAO . Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological Endocrinology2018;34:413-7. ">Song 2017</a>; <a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>; <a href="./references#CD005552-bbs2-0039" title="RuanX , SongJ , GuM , WangL , WangH , Mueck AO. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Archives of Gynecology and Obstetrics2018;297:1557-63. ">Ruan 2018</a>; <a href="./references#CD005552-bbs2-0042" title="TengYQ , ZhengJH , HanXY . Evaluation of clinical efficacy of Metformin in treating polycystic ovary syndrome. Journal of Harbin Medical University2007;41:405-6. ">Teng 2007</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> </li> </ul> </p> </section> <section id="CD005552-sec-0042"> <h4 class="title">Excluded studies</h4> <p>We excluded 38 trials from this review, 36 full texts (<a href="./references#CD005552-bbs2-0045" title="AlpanesM , Alvarez-BlascoF , Fernandez-DuranE , Luque-RamirezM , Escobar-MorrealeHF . Combined oral contraceptives plus spironolactone compared with Metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. European Journal of Endocrinology2017;177:399-408. ">Alpanes 2017</a>; <a href="./references#CD005552-bbs2-0046" title="AltinokML , RavnP , AndersenM , GlintoborgD . Effect of 12-months treatment with metformin and/or oral contraceptives on health-related quality of life in polycystic ovary syndrome. Gynecological Endocrinology2018;34(10):859-63. ">Altinok 2018</a>; <a href="./references#CD005552-bbs2-0047" title="BachaniS , Ganju MallaV . Identifying risk factors and screening tests for extent of metabolic risk in urban adolescent girls in a developing nation. International journal of child and adolescent health2016;9(3):347-53. ">Bachani 2016</a>; <a href="./references#CD005552-bbs2-0048" title="BattacharyaSM , JhaA . Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertility and sterility2012;98(4):1053-9. ">Bhattacharya 2012</a>; <a href="./references#CD005552-bbs2-0049" title="BredellaMA , McManusS , MisraM . Impact of metformin monotherapy versus metformin with oestrogen-progesterone on lipids in adolescent girls with polycystic ovarian syndrome. Clinical Endocrinology2013;79(2):199-203. ">Bredella 2013</a>; <a href="./references#CD005552-bbs2-0050" title="BurchallGF , PivaTJ , LindenMD , Gibson-HelmME , RanasinhaS , TeedeHJ . Comprehensive assessment of the hemostatic system in polycystic ovarian syndrome. Seminars in Thrombosis and Hemostasis2016;42:55-62. ">Burchall 2015</a>; <a href="./references#CD005552-bbs2-0051" title="CakirogluY , VuralB , IsgorenS . The effects of drospirenone-ethinyl estradiol and drospirenone-ethinyl estradiol + metformin on ovarian ultrasonographic markers, body fat mass index, leptin, and ghrelin. Archive of Gynecology and Obstetrics2013;288:213-20. ">Cakiroglu 2013</a>; <a href="./references#CD005552-bbs2-0052" title="DiazM , Gallego-EscuredoJM , deZegherF . Effect of ethinylestradiol-cyproterone acetate vs. pioglitazone-flutamide-metformin on plasma FGF21 levels in adolescent girls with androgen excess. Diabetes and Metabolism2016;42:196-9. ">Diaz 2016</a>; <a href="./references#CD005552-bbs2-0053" title="GlintborgD , MummH , AltinokML , RichelsenB , BruunJM , AndersenM . Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-months randomized treatment with metformin and/or contraceptives in polycystic ovary syndrome. Journal of Endocrinal Investigation2014;37:757-64. ">Glintborg 2014b</a>; <a href="./references#CD005552-bbs2-0054" title="GlintborgD , SidelmannJJ , AltinokML , MummH , AndersenM . Increased thrombin generation in women with polycystic ovary syndrome. A pilot study on the effect of metformin and oral contraceptives. Metabolism2015;64:1272-8. ">Glintborg 2015</a>; <a href="./references#CD005552-bbs2-0055" title="GlintborgD , MummH , HolstJJ , AndersenM . Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycemia in polycystic ovary syndrome. Endocrine connections2017;6:267-277. ">Glintborg 2017</a>; <a href="./references#CD005552-bbs2-0056" title="Hadziomerovic-PekicD , WildtL , WeissJM , MoellerK , MattleV , SeeberBE . Metformin, naltrexone, or the combination of prednisolone and antiandrogenic oral contraceptives as first-line therapy in hyperinsulinemic women with polycystic ovary syndrome. Fertility and Sterility2010;94(6):2385-8. ">Hadziomerovic‐Pekic 2010</a>; <a href="./references#CD005552-bbs2-0057" title="Harris-GlockerM , DavidsonK , KochmanL , GuzickD , HoegerK . Improvement in quality of life questionnaire measures (PCOSQ) in obese adolescent females with PCOS treated with Lifestyle changes and oral contraceptives, with or without Metformin. Fertility and Sterility2009;93(3):1016-9. ">Harris‐Glocker 2009</a>; <a href="./references#CD005552-bbs2-0058" title="HuZ , WangY , QiaoJ , LiM , ChiH , ChenX . The role of family history in clinical symptoms and therapeutic outcomes of women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:35-9. ">Hu 2010</a>; <a href="./references#CD005552-bbs2-0059" title="HutchisonSK , HarrisonC , SteptoN , MeyerC , TeedeHJ . Retinol-binding protein 4 and insulin resistance in polycystic ovary syndrome. Cardiovascular and Metabolic Risk2008;31:1427-32. ">Hutchison 2008</a>; <a href="./references#CD005552-bbs2-0060" title="IbanezL , Lopez-BermejoA , DiazM , EnriquezG , delRioL , deZegherF . Low-dose pioglitazone, flutamide, metformin plus an oestro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months. Gynecological Endocrinology2010;26(12):869-73. ">Ibanez 2010</a>; <a href="./references#CD005552-bbs2-0061" title="IbanezL , delRioL , DiazM , SebastianiG , PozoOJ , Lopez-BermejoA , et al. Normalizing ovulation rate by preferential reduction of hepato-visceral fat in adolescent girls with polycystic ovary syndrome. Journal of Adolescent Health2017;61:446-53. ">Ibanez 2017</a>; <a href="./references#CD005552-bbs2-0062" title="KebapcilarL , KebapcilarAG , BilgirO , TanerCE , BozkayaG , YilidizY , et al. Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients. Gynecological Endocrinology2010;27(2):91-5. ">Kebapcilar 2010</a>; <a href="./references#CD005552-bbs2-0063" title="Kim C-H, Jeon G-H, Kim S-R, Kim S-H, Chae H-D, Kang B-M. Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2010;94:236-41. ">Kim 2010</a>; <a href="./references#CD005552-bbs2-0064" title="LadsonG , DodsonWC , SweetSD , ArchibongAE , KunselmanAR , DemersLM , et al. Effects of metformin in adolescents with polycystic ovary syndrome undertaking lifestyle therapy: a pilot randomized double-blind study. Fertility and Sterility2011;95(8):2595-8. ">Ladson 2011</a>; <a href="./references#CD005552-bbs2-0065" title="LazaroI , DiazM , CabreA , MasanaL , IbanezL . Fatty acid-blinding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess. Gynecological Endocrinology2011;27(11):935-9. ">Lazaro 2011</a>; <a href="./references#CD005552-bbs2-0066" title="LemayA , DodinS , TurcotL , DéchêneF , Forest J-C. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Human Reproduction2006;21(1):121-8. ">Lemay 2006</a>; <a href="./references#CD005552-bbs2-0067" title="Luque-RamirezM , Alvarez-BlascoF , Escobar-MorrealeHF . Antiandrogenic contraceptives increase serum adiponectin in obese polycystic ovary syndrome patients. Obesity2008;17(1):3-9. ">Luque‐Ramirez 2008c</a>; <a href="./references#CD005552-bbs2-0068" title="Luque-RamirezM , Mendieta-AzconaC , delRey SanchezJM , MatiesM , Escobar-MorrealeHF . Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking. European Journal of Endocrinology2009;160:469-80. ">Luque‐Ramirez 2009</a>; <a href="./references#CD005552-bbs2-0069" title="Luque-RamirezM , Escobar-MorrealeHF . Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with decrease of serum interleukine-6 concentrations. Hormone and Metabolic Research2010;42:815-20. ">Luque‐Ramirez 2010a</a>; <a href="./references#CD005552-bbs2-0070" title="Luque-RamirezM , Alvarez-BlascoF , AlpanesM , Escobar-MorrealeHF . Role of decreased circulating hepcidin concentrations in the iron excess of women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2011;96(3):846-52. ">Luque‐Ramirez 2011</a>; <a href="./references#CD005552-bbs2-0071" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences2016;21:7. ">Mehrabian 2016</a>; <a href="./references#CD005552-bbs2-0072" title="MitkovM , PehlivanovB , TerzievaD . Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. European Journal of Obstetrics and Gynecology and Reproductive Biology2005;118:209-13. ">Mitkov 2005</a>; <a href="./references#CD005552-bbs2-0075" title="NCT02866786. The effect of OCP and Metformin on Clinical, hormonal, metabolic and ultrasonographic characteristics in PCOS. clinicaltrials.gov/show/NCT02866786 (first received 15 August 2016). ">NCT02866786</a>; <a href="./references#CD005552-bbs2-0076" title="OrbetzovaMM , PehlivanovBK , MitkoMM , AtanassovaIB , KamenovZA , KolarovGB , et al. Effect of short-term standard therapeutic regimens on neuropeptide Y and adipose tissue hormones in overweight insulin-resistant women with polycystic ovary syndrome. Folia Medica2011;53(3):15-24. ">Orbetzova 2011</a>; <a href="./references#CD005552-bbs2-0077" title="PanidisD , GeorgopoulosNA , PioukaA , KatsikisI , SaltamavrosAD , DecavalasG , et al. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. Gynecological Endocrinology2011;27(8):587-92. ">Panidis 2011</a>; <a href="./references#CD005552-bbs2-0078" title="PedersenAJ , StageTB , GlintborgD , AndersenM , ChristensenMM . The pharmacogenetics of metformin in women with polycystic ovary syndrome: a randomized trial. Basic and Clinical Pharmacology and Toxicology2018;122:239-44. ">Pedersen 2018</a>; <a href="./references#CD005552-bbs2-0079" title="RomualdiD , GiulianiM , CristelloF , FulghesuAM , SelvaggiL , LanzoneA , et sl. Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome; a randomized double-blind placebo-controlled clinical trial. Fertility and Sterility2010;93(7):2303-10. ">Romualdi 2010</a>; <a href="./references#CD005552-bbs2-0080" title="SuvarnaY , MaityN , KalraP , ShivamurthyMC . Comparison of efficacy of metformin and oral contraceptive combination of ethinyl estradiol and drospirenone in polycystic ovary syndrome. Journal of the Turkish-German Gynecological Association2016;17:6-9. ">Suvarna 2016</a>; <a href="./references#CD005552-bbs2-0081" title="TeedeHJ , MeyerC , HutchisonSK , ZoungasS , McGrathBP , MoranLJ . Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. Fertility and Sterility2010;93(1):184-91. ">Teede 2010b</a>; <a href="./references#CD005552-bbs2-0082" title="Wang Q-Y, SongY , HuangW , XiaoL , Wang Q-S, Feng G-M. Comparison of drospirenone with cyproterone acetate containing oral contraceptives, combined with metformin and lifestyle modifications in women with polycystic ovary syndrome and metabolic disorders: a prospective randomized control trial. Chinese Medical Journal2016;129(8):883-90. ">Wang 2016</a>) and two abstract articles (<a href="./references#CD005552-bbs2-0073" title="MoghtadaeiP , SardariF . Metabolic and endocrine effect of metformin and metformin plus cyclic dydrogestrel in women with polycystic ovarian syndrome. Cell Journal2009;11:67-8. ">Moghtadaei 2009</a>; <a href="./references#CD005552-bbs2-0074" title="MorettiCG , GuccioneL , di GiacintoP , CannucciaA , MelecaC , LanzollaG , et al. Efficacy and safety of myo-inositol supplementation in the treatment of obese hirsute PCOS women: comparative evaluation with OCP+bicalutamide therapy. In: Endocrine Society Journal, poster SUN-153. 2016. ">Moretti 2016</a>). The primary reasons for exclusion of the studies were no randomisation, other interventions, or other outcome of interest . </p> <p>(See <a href="./references#CD005552-sec-0079" title="">Characteristics of excluded studies</a> table). </p> </section> </section> <section id="CD005552-sec-0043"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD005552-sec-0044"> <h4 class="title">Allocation</h4> <p>Twenty‐four studies were at low risk of selection bias in relation to random sequence generation. These 24 studies used a computer random number generator or a random number table. In the remaining 20 studies, insufficient information about the random sequence generation was given and therefore were rated at unclear risk of bias for this domain (<a href="#CD005552-fig-0003">Figure 3</a>). </p> <p>Ten studies were at low risk of selection bias in relation to allocation concealment. These 10 studies used central allocation, sequentially numbered drug containers of identical appearance or sequentially numbered, opaque, sealed envelopes. The other 34 studies did not describe allocation concealment sufficiently and therefore were rated at unclear risk of bias for this domain (<a href="#CD005552-fig-0003">Figure 3</a>). </p> </section> <section id="CD005552-sec-0045"> <h4 class="title">Blinding</h4> <p>In relation to the blinding of all outcomes:</p> <p> <ul id="CD005552-list-0007"> <li> <p>participants (performance bias): three out of 44 studies described the blinding of participants and were thus rated at low risk of performance bias. Thirty‐one out of 44 studies did not report on blinding of participants and were rated at unclear risk of performance bias. Ten out of 44 studies described no blinding for participants and were rated at high risk of performance bias (<a href="#CD005552-fig-0003">Figure 3</a>) </p> </li> <li> <p>personnel (performance bias): one out of 44 studies described the blinding of personnel and were thus rated at low risk of performance bias. Thirty‐two out of 44 studies did not mention blinding of personnel and were rated at unclear risk of performance bias. Eleven out of 44 studies described no blinding for personnel and were rated at high risk of performance bias (<a href="#CD005552-fig-0003">Figure 3</a>) </p> </li> <li> <p>outcome assessor (detection bias): Five out of 44 studies described the blinding of outcome assessor and were thus rated at low risk of detection bias. Thirty‐five out of 44 studies did not mention blinding of outcome assessor and were rated at unclear risk of detection bias. Four out of 44 studies described no blinding for outcome assessor and were rated at high risk of detection bias (<a href="#CD005552-fig-0003">Figure 3</a>) </p> </li> </ul> </p> </section> <section id="CD005552-sec-0046"> <h4 class="title">Incomplete outcome data</h4> <p>Thirteen out of 44 studies had no missing outcome data and were rated at low risk of attrition bias. </p> <p>Twenty six out of 44 studies were rated at unclear risk of attrition bias. In 20 of these studies the reasons for missing data were judged as unclear: no show, unreachable, declined treatment, regrets, loss of follow up, personal reason, not stated, discontinued treatment, protocol violation, voluntary drop off, wanted the other intervention, and incomplete data (<a href="./references#CD005552-bbs2-0002" title="AllenHF , MazzoniC , HeptullaRA , MurrayMA , MillerN , KoenigsL , et al. Randomized controlled trial evaluating response to Metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism2005;18:761-8. ">Allen 2005</a>; <a href="./references#CD005552-bbs2-0003" title="Al-ZubeidiH , KleinKO . Randomized clinical trial evaluating Metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome. Journal of Pediatric Endocrinology and Metabolism2015;28:853-8. ">Al‐Zubeidi 2015</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>; <a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>; <a href="./references#CD005552-bbs2-0022" title="KilicS , YilmazN , ZulfikarogluE , ErdoganG , AydinM , BatiogluS . Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecological Endocrinology2011;27(9):622-9. ">Kilic 2011</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0027" title="Luque-RamirezM , Alvarez-BlascoF , Botella-Carretero JI , SanchonR , San MillanJL , Escobar-MorrealeHF . Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care 09/2007;30:2309-13. ">Luque‐Ramirez 2007b</a>; <a href="./references#CD005552-bbs2-0028" title="Luque-RamirezM , Alvarez-BlascoF , Uriol RiveraMG , Escobar-MorrealeHF . Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. Human Reproduction2008;23:1594-601. ">Luque‐Ramirez 2008a</a>; <a href="./references#CD005552-bbs2-0029" title="Luque-RamirezM , Mendieta-AzconaC , Alvarez-BlascoF , Escobar-MorrealeHF . Effects of Metformin versus Ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertility and Sterility2008;91:2527-36. ">Luque‐Ramirez 2009b</a>; <a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>; <a href="./references#CD005552-bbs2-0033" title="MoranLJ , MeyerC , HutchisonSK , ZoungasS , TeedeHJ . Novel inflammatory markers in overweight women with or without polycystic ovary syndrome and following pharmacological intervention. Journal of Endocrinological Investigation2010;33:258-65. ">Moran 2010</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0037" title="OzgurtasT , OktenliC , DedeM , TapanS , KenarL , SanisogluSY , et al. Metformin and oral contraceptive treatment reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis2008;200:336-44. ">Ozgurtas 2008</a>; <a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>). In one study the number or patient randomised was unclear (states n = 100, n = 99, n=94) (<a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>). In two studies no information was provided after randomisation and the authors were contacted without success (<a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0030" title="LvL , LiuY , SunY , TanK . Effects of Metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. Journal of Huazhong University of Science and Technology2005;25:194-7. ">Lv 2005</a>). In two studies the number of dropouts were considered quite important (50% for MET group and 37.5% for the OCP group), and it was unclear whether this could have had a clinically relevant impact on the intervention effect estimate (<a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0038" title="RautioK , TapanainenJS , RuokonenA , Morin-PapunenLC . Effects of metformin and ethinyl-estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. European Journal of Endocrinology2005;152:269-75. ">Rautio 2005</a>). In one study, there was a discrepancy between the figure and the text regarding number and reason for withdrawal (<a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p>Five out of 44 studies were rated at high risk of attrition bias. In four of these studies, the reason for missing data were imbalanced and related to intervention (<a href="./references#CD005552-bbs2-0001" title="AghamohammadzadehN , AliasgarzadehA , BaglarL , AbdollahifardS , BahramiA , NajafipourF , et al. Comparison of metformin and cyproterone-estrodiol compound effect on HS C-reactive protein and serum androgen levels in patients with polycystic ovary syndrome. Pakistan Journal of Medical Science2010;26(2):347-51. ">Aghamohammadzadeh 2010</a>; <a href="./references#CD005552-bbs2-0007" title="ChristakouC , KolliasA , PiperiC , KatsikisI , PanidisD , Diamanti-KandarakisE . The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. Hormones2014;13:488-97. ">Christakou 2014</a>; <a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>). In one of these studies, the manner in which the use of imputation was performed was not appropriate (<a href="./references#CD005552-bbs2-0004" title="Bhattacharya SM , BiswasB , BasuA . Comparative study of the therapeutic effects of drospirenone (DRSP, 3mg) with ethinyl estradiol (EE, 20 mcg) pill with or without metformin 500 mg in polycystic ovary syndrome (PCOS). In: Fertility and Sterility. 2016, poster P-401:e257. ">Bhattacharya 2016</a>) (<a href="#CD005552-fig-0003">Figure 3</a>). </p> </section> <section id="CD005552-sec-0047"> <h4 class="title">Selective reporting</h4> <p>Fifteen out of 44 studies reported the outcomes that were stated in the methods section and thus were judged as low risk of reporting bias. </p> <p>In 20 out of 44 studies, insufficient information was available to permit a judgement of 'low risk' or 'high risk' and therefore we rated them at unclear risk of reporting bias. In 19 of these studies, some secondary outcomes (BMI, BP, fasting glucose, weight, menstrual pattern, lipid profile, testosterone level, acne) were described in the methods section but not in the results and the study protocol was not available (<a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>; <a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>; <a href="./references#CD005552-bbs2-0021" title="BilgirO , KebapcilarL , TanerC , BilgirF , KebapcilarA , BozkayaG , et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). International Medicine2009;48:1193-9. KebapcilarL , YukselA , BozkayaG , TanerCE , KebapcilarAG , BilgirO , et al. Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome. Central European Journal of Medicine2009;4:423-7. ">Kebapcilar 2009b</a>; <a href="./references#CD005552-bbs2-0022" title="KilicS , YilmazN , ZulfikarogluE , ErdoganG , AydinM , BatiogluS . Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecological Endocrinology2011;27(9):622-9. ">Kilic 2011</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0032" title="MhaoNS , Al-HilliSA , HadiNR , JamilDA , Al-AubaidyHA . A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews2015;10S:S95-S98. ">Mhao 2015</a>; <a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0037" title="OzgurtasT , OktenliC , DedeM , TapanS , KenarL , SanisogluSY , et al. Metformin and oral contraceptive treatment reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis2008;200:336-44. ">Ozgurtas 2008</a>; <a href="./references#CD005552-bbs2-0038" title="RautioK , TapanainenJS , RuokonenA , Morin-PapunenLC . Effects of metformin and ethinyl-estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. European Journal of Endocrinology2005;152:269-75. ">Rautio 2005</a>; <a href="./references#CD005552-bbs2-0041" title="SongJ , RuanX , GuM , WangL , WangH , MueckAO . Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological Endocrinology2018;34:413-7. ">Song 2017</a>; <a href="./references#CD005552-bbs2-0039" title="RuanX , SongJ , GuM , WangL , WangH , Mueck AO. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Archives of Gynecology and Obstetrics2018;297:1557-63. ">Ruan 2018</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). In two of these studies, the outcome measurements were not described in the methods section and the protocol was not available (<a href="./references#CD005552-bbs2-0019" title="KayaMG , YildirimS , CalapkorurB , AkpekM , UnluhizarciK , KelestimurF . Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecological Endocrinology2015;31:401-5. ">Kaya 2015</a>; <a href="./references#CD005552-bbs2-0021" title="BilgirO , KebapcilarL , TanerC , BilgirF , KebapcilarA , BozkayaG , et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). International Medicine2009;48:1193-9. KebapcilarL , YukselA , BozkayaG , TanerCE , KebapcilarAG , BilgirO , et al. Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome. Central European Journal of Medicine2009;4:423-7. ">Kebapcilar 2009b</a>). </p> <p>Nine out of 44 studies were rated at high risk of reporting bias. In four of these studies, hirsutism (which was a primary outcome) was described in the methods section but not reported in the results (<a href="./references#CD005552-bbs2-0002" title="AllenHF , MazzoniC , HeptullaRA , MurrayMA , MillerN , KoenigsL , et al. Randomized controlled trial evaluating response to Metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism2005;18:761-8. ">Allen 2005</a>; <a href="./references#CD005552-bbs2-0003" title="Al-ZubeidiH , KleinKO . Randomized clinical trial evaluating Metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome. Journal of Pediatric Endocrinology and Metabolism2015;28:853-8. ">Al‐Zubeidi 2015</a>; <a href="./references#CD005552-bbs2-0010" title="El MaghrabyHA , NafeeT , GuiziryD , ElnasharA . Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 months follow up period. Middle East Fertility Society Journal2015;20:131-7. ">El Maghraby 2015</a>; <a href="./references#CD005552-bbs2-0018" title="JinLN , YuQ , Ma LK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/ Ethinyl Estradiol in PCOS patients. Chinese Journal of Postgraduate Medicine2006;29:10-5. ">Jin 2006</a>). In the other three of these studies, some of the primary outcomes were reported in the results without being prespecified in the methods section (<a href="#CD005552-fig-0003">Figure 3</a>). </p> </section> <section id="CD005552-sec-0048"> <h4 class="title">Other potential sources of bias</h4> <p>In six studies there were substantial baseline imbalances between the two intervention groups and thus we deemed the risk of other bias to be high (<a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0018" title="JinLN , YuQ , Ma LK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/ Ethinyl Estradiol in PCOS patients. Chinese Journal of Postgraduate Medicine2006;29:10-5. ">Jin 2006</a>; <a href="./references#CD005552-bbs2-0022" title="KilicS , YilmazN , ZulfikarogluE , ErdoganG , AydinM , BatiogluS . Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecological Endocrinology2011;27(9):622-9. ">Kilic 2011</a>; <a href="./references#CD005552-bbs2-0023" title="KuekS , Wang W-J, Gui S-Q. Efficacy of chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial. Journal of Chinese Integrative Medicine2011;9:965-72. ">Kuek 2011</a>; <a href="./references#CD005552-bbs2-0032" title="MhaoNS , Al-HilliSA , HadiNR , JamilDA , Al-AubaidyHA . A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews2015;10S:S95-S98. ">Mhao 2015</a>). In one study the use of laser and waxing was considered a source of bias in terms of the evaluation of hirsutism (<a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>), and therefore rated at high risk of other bias. In two studies there were substantial baseline differences in clinical and biochemical hyperandrogenism between the two intervention groups and we judged them at high risk of other bias (<a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>; <a href="./references#CD005552-bbs2-0033" title="MoranLJ , MeyerC , HutchisonSK , ZoungasS , TeedeHJ . Novel inflammatory markers in overweight women with or without polycystic ovary syndrome and following pharmacological intervention. Journal of Endocrinological Investigation2010;33:258-65. ">Moran 2010</a>). We found no potential sources of other bias in the other 35 studies (<a href="#CD005552-fig-0003">Figure 3</a>). </p> </section> </section> <section id="CD005552-sec-0049"> <h3 class="title" id="CD005552-sec-0049">Effects of interventions</h3> <p>See: <a href="./full#CD005552-tbl-0001"><b>Summary of findings 1</b> Metformin compared to oral contraceptive pill (OCP) for hirsutism, acne, and menstrual pattern in adult women with polycystic ovary syndrome (PCOS)</a>; <a href="./full#CD005552-tbl-0002"><b>Summary of findings 2</b> Metformin compared to metformin combined with oral contraceptive pill (OCP) for hirsutism, acne, and menstrual pattern in adult women with polycystic ovary syndrome (PCOS)</a>; <a href="./full#CD005552-tbl-0003"><b>Summary of findings 3</b> Oral contraceptive pill (OCP) compared to metformin combined with OCP for hirsutism, acne, and menstrual pattern in adult women with polycystic ovary syndrome (PCOS)</a>; <a href="./full#CD005552-tbl-0004"><b>Summary of findings 4</b> Metformin compared to oral contraceptive pill (OCP) for hirsutism, acne, and menstrual pattern in adolescent women with polycystic ovary syndrome (PCOS)</a>; <a href="./full#CD005552-tbl-0005"><b>Summary of findings 5</b> Metformin compared to metformin combined with oral contraceptive pill (OCP) for hirsutism, acne and menstrual pattern in adolescent women with polycystic ovary syndrome (PCOS)</a>; <a href="./full#CD005552-tbl-0006"><b>Summary of findings 6</b> Oral contraceptive pill (OCP) compared to metformin combined with OCP for hirsutism, acne, and menstrual pattern in adolescent women with polycystic ovary syndrome PCOS</a> </p> <p><b>1. Metformin compared to the combined oral contraceptive pill (OCP) in adult women (clinical parameters)</b> </p> <p><a href="./full#CD005552-tbl-0001">summary of findings Table 1</a> </p> <p>Twenty‐eight randomised controlled trials (RCTs) including 1403 adult women compared metformin with the OCP (<a href="./references#CD005552-bbs2-0001" title="AghamohammadzadehN , AliasgarzadehA , BaglarL , AbdollahifardS , BahramiA , NajafipourF , et al. Comparison of metformin and cyproterone-estrodiol compound effect on HS C-reactive protein and serum androgen levels in patients with polycystic ovary syndrome. Pakistan Journal of Medical Science2010;26(2):347-51. ">Aghamohammadzadeh 2010</a>; <a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0007" title="ChristakouC , KolliasA , PiperiC , KatsikisI , PanidisD , Diamanti-KandarakisE . The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. Hormones2014;13:488-97. ">Christakou 2014</a>; <a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0018" title="JinLN , YuQ , Ma LK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/ Ethinyl Estradiol in PCOS patients. Chinese Journal of Postgraduate Medicine2006;29:10-5. ">Jin 2006</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0022" title="KilicS , YilmazN , ZulfikarogluE , ErdoganG , AydinM , BatiogluS . Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecological Endocrinology2011;27(9):622-9. ">Kilic 2011</a>; <a href="./references#CD005552-bbs2-0023" title="KuekS , Wang W-J, Gui S-Q. Efficacy of chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial. Journal of Chinese Integrative Medicine2011;9:965-72. ">Kuek 2011</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0027" title="Luque-RamirezM , Alvarez-BlascoF , Botella-Carretero JI , SanchonR , San MillanJL , Escobar-MorrealeHF . Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care 09/2007;30:2309-13. ">Luque‐Ramirez 2007b</a>; <a href="./references#CD005552-bbs2-0028" title="Luque-RamirezM , Alvarez-BlascoF , Uriol RiveraMG , Escobar-MorrealeHF . Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. Human Reproduction2008;23:1594-601. ">Luque‐Ramirez 2008a</a>; <a href="./references#CD005552-bbs2-0029" title="Luque-RamirezM , Mendieta-AzconaC , Alvarez-BlascoF , Escobar-MorrealeHF . Effects of Metformin versus Ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertility and Sterility2008;91:2527-36. ">Luque‐Ramirez 2009b</a>; <a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>; <a href="./references#CD005552-bbs2-0032" title="MhaoNS , Al-HilliSA , HadiNR , JamilDA , Al-AubaidyHA . A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews2015;10S:S95-S98. ">Mhao 2015</a>; <a href="./references#CD005552-bbs2-0033" title="MoranLJ , MeyerC , HutchisonSK , ZoungasS , TeedeHJ . Novel inflammatory markers in overweight women with or without polycystic ovary syndrome and following pharmacological intervention. Journal of Endocrinological Investigation2010;33:258-65. ">Moran 2010</a>; <a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0037" title="OzgurtasT , OktenliC , DedeM , TapanS , KenarL , SanisogluSY , et al. Metformin and oral contraceptive treatment reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis2008;200:336-44. ">Ozgurtas 2008</a>; <a href="./references#CD005552-bbs2-0038" title="RautioK , TapanainenJS , RuokonenA , Morin-PapunenLC . Effects of metformin and ethinyl-estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. European Journal of Endocrinology2005;152:269-75. ">Rautio 2005</a>; <a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>; <a href="./references#CD005552-bbs2-0042" title="TengYQ , ZhengJH , HanXY . Evaluation of clinical efficacy of Metformin in treating polycystic ovary syndrome. Journal of Harbin Medical University2007;41:405-6. ">Teng 2007</a>, <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p><b>Primary outcomes</b> </p> <p><b>1.1 Hirsutism ‐ Clinical Ferriman‐Gallwey (F‐G) score</b> </p> <p>Ten trials including 473 women compared metformin versus the OCP and reported hirsutism clinically using the Ferriman‐Gallwey (F‐G) score (<a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>; <a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p>Substantial heterogeneity was detected, which may be explained by the difference in effect of the interventions between the mean study body mass index (BMI) subgroups (test for subgroup difference: P = 0.003, I<sup>2</sup> = 82.9%). Therefore, we analysed the results per mean BMI subgroup. </p> <p>We are uncertain if there was a difference between metformin and the OCP on F‐G score in subgroup BMI &lt; 25 kg/m<sup>2</sup> (mean difference (MD) 0.38, 95% confidence interval (CI) ‐0.44 to 1.19; 3 RCTs; n = 134; I<sup>2</sup> = 50%; very low‐quality evidence, <a href="#CD005552-fig-0004">Figure 4</a>, <a href="./references#CD005552-fig-0007" title="">Analysis 1.1</a>). This suggests that for a mean F‐G score of 7.5 following the OCP, the mean F‐G score following metformin would be between 0.44 lower to 1.19 higher. </p> <div class="figure" id="CD005552-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Adult ‐ metformin versus OCP (Clinical parameters), outcome: 1.1 Hirsutism ‐ Clinical F‐G score." data-id="CD005552-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Adult ‐ metformin versus OCP (Clinical parameters), outcome: 1.1 Hirsutism ‐ Clinical F‐G score. </p> </div> </div> </div> <p>Metformin may be less effective in improving F‐G score compared to the OCP in the subgroup BMI &gt; 25 /kg2 &lt; BMI 30 kg/m<sup>2</sup> (MD 1.92, 95% CI 1.21 to 2.64; 5 RCTs; n = 254; I<sup>2</sup> = 0%; low‐quality evidence, <a href="#CD005552-fig-0004">Figure 4</a>, <a href="./references#CD005552-fig-0007" title="">Analysis 1.1</a> ). This suggests that for a mean F‐G score of 6.44 following the OCP, the mean F‐G score following metformin would be between 1.21 higher to 2.64 higher. </p> <p>We are uncertain if there was a difference between metformin and the OCP on F‐G score in subgroup BMI &gt; 30 kg/m<sup>2</sup> (MD ‐0.38, 95% CI ‐1.93 to 1.17; 2 RCTs; n = 85; I<sup>2</sup> = 34%; low‐quality evidence, <a href="#CD005552-fig-0004">Figure 4</a>, <a href="./references#CD005552-fig-0007" title="">Analysis 1.1</a>). This suggests that for a mean F‐G score of 6.05 following the OCP, the mean F‐G score following metformin would be between 1.93 lower to 1.17 higher. </p> <p>Sensitivity analysis restricting studies to low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>') was unable to be performed due to no RCTs having a low risk of bias. </p> <p>The funnel plot (n = 10 studies) was asymmetrical indicating that our findings might be influenced by publication bias although asymmetrical funnel plots can also be due to true heterogeneity (<a href="#CD005552-fig-0005">Figure 5</a>, <a href="./references#CD005552-fig-0007" title="">Analysis 1.1</a>). </p> <div class="figure" id="CD005552-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Adult ‐ metformin versus OCP (Clinical parameters), outcome: 1.1 Hirsutism ‐ Clinical F‐G score." data-id="CD005552-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Adult ‐ metformin versus OCP (Clinical parameters), outcome: 1.1 Hirsutism ‐ Clinical F‐G score. </p> </div> </div> </div> <p><b>1.2 Hirsutism ‐ Subjective visual analogue scale (VAS)</b> </p> <p>One trial including 34 women compared metformin versus the OCP and reported hirsutism subjectively (patient self‐assessed) using a VAS ranging from 0 to 10. All the participants in this trial had hirsutism (F‐G score &gt; 8) (<a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>). </p> <p>Metformin resulted in an improvement of hirsutism compared to the OCP (MD ‐2.70, 95% CI ‐4.41 to ‐0.99, 1 RCT, n = 34, <a href="./references#CD005552-fig-0008" title="">Analysis 1.2</a>). </p> <p><b>1.3</b> <b>Hirsutism ‐ Subjective improvement</b> </p> <p>One trial including 25 women compared metformin versus the OCP and reported on hirsutism subjective improvement (not reported if patient self‐assessed or clinician assessed) (<a href="./references#CD005552-bbs2-0018" title="JinLN , YuQ , Ma LK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/ Ethinyl Estradiol in PCOS patients. Chinese Journal of Postgraduate Medicine2006;29:10-5. ">Jin 2006</a>). </p> <p>There was insufficient evidence to determine whether there was a difference between metformin and the OCP for subjective improvement of hirsutism (odds ratio (OR) 0.64, 95% CI 0.04 to 11.63, 1 RCT, n = 25, <a href="./references#CD005552-fig-0009" title="">Analysis 1.3</a>). </p> <p>One trial including 28 women compared metformin versus the OCP and reported an improvement of acne and hirsutism with both metformin and the OCP in the Discussion, but did not report supporting data and therefore could not be included in any meta‐analysis for this review (<a href="./references#CD005552-bbs2-0023" title="KuekS , Wang W-J, Gui S-Q. Efficacy of chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial. Journal of Chinese Integrative Medicine2011;9:965-72. ">Kuek 2011</a>). </p> <p><b>1.4 Adverse events: severe (requiring stopping of medication) (gastro‐intestinal and others)</b> </p> <p>Twelve trials including 965 women compared metformin versus the OCP and reported severe adverse events (<a href="./references#CD005552-bbs2-0001" title="AghamohammadzadehN , AliasgarzadehA , BaglarL , AbdollahifardS , BahramiA , NajafipourF , et al. Comparison of metformin and cyproterone-estrodiol compound effect on HS C-reactive protein and serum androgen levels in patients with polycystic ovary syndrome. Pakistan Journal of Medical Science2010;26(2):347-51. ">Aghamohammadzadeh 2010</a>; <a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0007" title="ChristakouC , KolliasA , PiperiC , KatsikisI , PanidisD , Diamanti-KandarakisE . The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. Hormones2014;13:488-97. ">Christakou 2014</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0022" title="KilicS , YilmazN , ZulfikarogluE , ErdoganG , AydinM , BatiogluS . Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecological Endocrinology2011;27(9):622-9. ">Kilic 2011</a>; <a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p>Findings were not influenced by sensitivity analyses restricting studies to low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>'). </p> <p>The funnel plot (n = 12 studies) was symmetrical indicating that our findings might not be influenced by publication bias (funnel plot not shown). </p> <p><b>1.4.1 Gastro‐intestinal</b> </p> <p>Eleven trials including 602 women compared metformin versus the OCP and reported severe gastro‐intestinal adverse events (<a href="./references#CD005552-bbs2-0001" title="AghamohammadzadehN , AliasgarzadehA , BaglarL , AbdollahifardS , BahramiA , NajafipourF , et al. Comparison of metformin and cyproterone-estrodiol compound effect on HS C-reactive protein and serum androgen levels in patients with polycystic ovary syndrome. Pakistan Journal of Medical Science2010;26(2):347-51. ">Aghamohammadzadeh 2010</a>; <a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0007" title="ChristakouC , KolliasA , PiperiC , KatsikisI , PanidisD , Diamanti-KandarakisE . The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. Hormones2014;13:488-97. ">Christakou 2014</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0022" title="KilicS , YilmazN , ZulfikarogluE , ErdoganG , AydinM , BatiogluS . Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecological Endocrinology2011;27(9):622-9. ">Kilic 2011</a>; <a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p>Metformin resulted in a higher incidence of severe gastro‐intestinal adverse events compared to the OCP (Peto OR 6.42, 95% CI 2.98 to 13.84, 11 RCTs, n = 602, I<sup>2</sup> = 0%; low‐quality evidence, <a href="#CD005552-fig-0006">Figure 6</a>, <a href="./references#CD005552-fig-0010" title="">Analysis 1.4</a>) This suggests that if the severe gastro‐intestinal adverse event rate following the OCP is 0.3%, then the severe gastro‐intestinal adverse event rate after metformin would be between 1% and 4.5%. </p> <div class="figure" id="CD005552-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Adult ‐ metformin versus OCP (Clinical parameters), outcome: 1.4 Adverse events ‐ severe." data-id="CD005552-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Adult ‐ metformin versus OCP (Clinical parameters), outcome: 1.4 Adverse events ‐ severe. </p> </div> </div> </div> <p>Findings were not influenced by sensitivity analysis restricting to the one study with low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>') (<a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>). </p> <p><b>1.4.2 Others</b> </p> <p>Eight trials including 363 women compared metformin versus the OCP and reported other severe adverse events (<a href="./references#CD005552-bbs2-0001" title="AghamohammadzadehN , AliasgarzadehA , BaglarL , AbdollahifardS , BahramiA , NajafipourF , et al. Comparison of metformin and cyproterone-estrodiol compound effect on HS C-reactive protein and serum androgen levels in patients with polycystic ovary syndrome. Pakistan Journal of Medical Science2010;26(2):347-51. ">Aghamohammadzadeh 2010</a>; <a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>. </p> <p>Metformin may result in a lower incidence of severe other adverse events compared to the OCP (Peto OR 0.20, 95% CI 0.09 to 0.44, 8 RCTs, n = 363, I<sup>2</sup> = 0%, low‐quality evidence, <a href="#CD005552-fig-0006">Figure 6</a>;<a href="./references#CD005552-fig-0010" title="">Analysis 1.4</a>). This suggests that if the severe other adverse event rate following the OCP is 12%, then the severe other adverse event rate after metformin would between 1% and 6%. </p> <p>Findings were not influenced by sensitivity analysis restricting to the one study with low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>') (<a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>). </p> <p>One trial including 101 women compared metformin versus the OCP and reported severe adverse events with both metformin and the OCP, but did not report supporting data and therefore could not be included in any meta‐analysis for this review (<a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>). </p> <p>One trial including 24 women compared metformin versus the OCP and reported minor adverse events with metformin only, but did not report supporting data and therefore could not be included in any meta‐analysis for this review (<a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>). </p> <p><b>Adverse events ‐ minor (gastro‐intestinal and others)</b> </p> <p>No RCT reported on this outcome.</p> <p><b>Secondary outcomes</b> </p> <p><b>1.5</b> <b>Improved menstrual pattern: i.e. significant shortening of intermenstrual days</b> </p> <p>Two trials including 153 women compared metformin versus the OCP and reported improvement in menstrual pattern (<a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>; <a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>). </p> <p>Overall, metformin may be less effective in improving menstrual pattern compared to the OCP (MD 6.05, 95% CI 2.37 to 9.74, 2 RCTs, n = 153, I<sup>2</sup>= 0%; low‐quality evidence,<a href="./references#CD005552-fig-0011" title="">Analysis 1.5</a>). This suggests that for a mean Improved menstrual pattern (i.e. significant shortening of intermenstrual days) of 32.4 following the OCP, the mean Improved menstrual pattern following metformin would be between 2.37 higher to 9.74 higher. </p> <p>Subgroup analysis showed insufficient evidence to suggest a difference in effect by mean study BMI (test for subgroup difference: P = 0.73, I<sup>2</sup> = 0%). </p> <p>Sensitivity analysis restricting studies to low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>') was unable to be performed due to no RCTs having a low risk of bias. </p> <p><b>1.6 Improved menstrual pattern: i.e. an initiation of menses or cycle regularity</b> </p> <p>Six trials including 189 women compared metformin versus the OCP and reported improvement in menstrual pattern (<a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0018" title="JinLN , YuQ , Ma LK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/ Ethinyl Estradiol in PCOS patients. Chinese Journal of Postgraduate Medicine2006;29:10-5. ">Jin 2006</a>, <a href="./references#CD005552-bbs2-0027" title="Luque-RamirezM , Alvarez-BlascoF , Botella-Carretero JI , SanchonR , San MillanJL , Escobar-MorrealeHF . Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care 09/2007;30:2309-13. ">Luque‐Ramirez 2007b</a>; <a href="./references#CD005552-bbs2-0032" title="MhaoNS , Al-HilliSA , HadiNR , JamilDA , Al-AubaidyHA . A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews2015;10S:S95-S98. ">Mhao 2015</a>; <a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>). </p> <p>Substantial heterogeneity was detected which may be explained by the difference in effect of the interventions between the mean BMI subgroups (test for subgroup difference: P = 0.03, I<sup>2</sup> = 67.8%) (<a href="./references#CD005552-fig-0012" title="">Analysis 1.6</a>). Therefore, we analysed the results per mean BMI subgroup. </p> <p>Metformin compared to the OCP may be less effective in improving menstrual pattern in subgroup BMI ≤ 25 kg/m<sup>2</sup> (Peto OR 0.07, 95% CI 0.01 to 0.65; 1 RCT; n = 17; low‐quality evidence). </p> <p>We are uncertain if metformin is less effective in improving menstrual pattern compared to the OCP in subgroup BMI &gt; 25 kg/m<sup>2</sup> &lt; 30kg/m<sup>2</sup> (Peto OR 0.15, 95% CI 0.07 to 0.33; 3 RCTs; n = 129; I<sup>2</sup> = 51%; verylLow‐quality evidence). </p> <p>We are uncertain of the effect of metformin compared to the OCP on menstrual pattern in subgroup BMI ≥30 kg/m<sup>2</sup> (Peto OR 0.09, 95% CI 0.01 to 1.62; 1 RCT; n = 18; very low‐quality evidence). </p> <p>We are uncertain of the effect of metformin compared to the OCP on menstrual pattern in subgroup BMI not stated (Peto OR 1.95, 95% CI 0.39 to 9.65; 1 RCT; n = 25; very low‐quality evidence). </p> <p>Sensitivity analysis restricting studies to low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>') was unable to be performed due to no RCTs having a low risk of bias. </p> <p>One trial including 60 women compared metformin versus the OCP and reported improvement in menstrual pattern in both group but did not report supporting and therefore could not be included in any meta‐analysis in this review (<a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p><b>1.7 Acne ‐ visual analogue scale (VAS)</b> </p> <p>One trial including 34 women compared metformin versus the OCP and reported acne subjectively (patient self assessed) using a VAS ranging from 0 to 10. (<a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>). </p> <p>There was uncertainty as to whether there was a difference between metformin and the OCP for acne (patient self‐assessed) (MD 0.90, 95% CI ‐0.40 to 2.20, 1 RCT, n = 34, low‐quality evidence;<a href="./references#CD005552-fig-0013" title="">Analysis 1.7</a>). This suggests that for a mean acne ‐ VAS of 1 following the OCP, the mean acne ‐ VAS following metformin would be between 0.40 lower to 2.2 higher. </p> <p><b>1.8 Acne ‐ Subjective improvement</b> </p> <p>Three trials including 131 women compared metformin versus the OCP and reported acne subjectively (<a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0018" title="JinLN , YuQ , Ma LK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/ Ethinyl Estradiol in PCOS patients. Chinese Journal of Postgraduate Medicine2006;29:10-5. ">Jin 2006</a>, <a href="./references#CD005552-bbs2-0032" title="MhaoNS , Al-HilliSA , HadiNR , JamilDA , Al-AubaidyHA . A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews2015;10S:S95-S98. ">Mhao 2015</a>). </p> <p>Metformin was less effective in improving subjective improvement of acne compared to the OCP (OR 0.30, 95% CI 0.11 to 0.79; 3 RCTs; n = 131; I<sup>2</sup> = 18%) (<a href="./references#CD005552-fig-0014" title="">Analysis 1.8</a>). </p> <p>One trial including 28 women compared metformin versus the OCP and reported an improvement of acne and hirsutism with both metformin and the OCP in the Discussion but did not report supporting data and therefore could not be included in any meta‐analysis in this review (<a href="./references#CD005552-bbs2-0023" title="KuekS , Wang W-J, Gui S-Q. Efficacy of chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial. Journal of Chinese Integrative Medicine2011;9:965-72. ">Kuek 2011</a>). </p> <p><b>1.9 Diagnosis of Type II diabetes mellitus</b> </p> <p>One trial including 18 women compared metformin versus the OCP and reported on diagnosis of T2DM (<a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>). </p> <p>There was insufficient evidence to determine whether there was a difference between metformin and the OCP for the diagnosis of T2DM. (Peto OR 0.17, 95% CI 0.00 to 8.54, 1 RCT, n = 18, <a href="./references#CD005552-fig-0015" title="">Analysis 1.9</a>). </p> <p><b>1.10 Body weight (kg)</b> </p> <p>Seven trials including 358 women compared metformin versus the OCP and reported on body weight (<a href="./references#CD005552-bbs2-0001" title="AghamohammadzadehN , AliasgarzadehA , BaglarL , AbdollahifardS , BahramiA , NajafipourF , et al. Comparison of metformin and cyproterone-estrodiol compound effect on HS C-reactive protein and serum androgen levels in patients with polycystic ovary syndrome. Pakistan Journal of Medical Science2010;26(2):347-51. ">Aghamohammadzadeh 2010</a>; <a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0023" title="KuekS , Wang W-J, Gui S-Q. Efficacy of chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial. Journal of Chinese Integrative Medicine2011;9:965-72. ">Kuek 2011</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0033" title="MoranLJ , MeyerC , HutchisonSK , ZoungasS , TeedeHJ . Novel inflammatory markers in overweight women with or without polycystic ovary syndrome and following pharmacological intervention. Journal of Endocrinological Investigation2010;33:258-65. ">Moran 2010</a>). </p> <p>Overall, there was insufficient evidence to determine whether there was a difference between metformin and the OCP for body weight (MD ‐0.93, 95% CI ‐2.93 to 1.08, 7 RCTs, n = 358, I<sup>2</sup> = 30%, <a href="./references#CD005552-fig-0016" title="">Analysis 1.10</a>). </p> <p>Subgroup analysis showed sufficient evidence to suggest a difference in effect by mean study BMI (test for subgroup difference: P = 0.03, I<sup>2</sup> = 70.5%). </p> <p><b>1.11 Body Mass Index (BMI) (kg/m<sup>2</sup>)</b> </p> <p>Nineteen trials including 923 women compared metformin versus the OCP and reported on BMI (<a href="./references#CD005552-bbs2-0001" title="AghamohammadzadehN , AliasgarzadehA , BaglarL , AbdollahifardS , BahramiA , NajafipourF , et al. Comparison of metformin and cyproterone-estrodiol compound effect on HS C-reactive protein and serum androgen levels in patients with polycystic ovary syndrome. Pakistan Journal of Medical Science2010;26(2):347-51. ">Aghamohammadzadeh 2010</a>; <a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0007" title="ChristakouC , KolliasA , PiperiC , KatsikisI , PanidisD , Diamanti-KandarakisE . The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. Hormones2014;13:488-97. ">Christakou 2014</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0022" title="KilicS , YilmazN , ZulfikarogluE , ErdoganG , AydinM , BatiogluS . Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecological Endocrinology2011;27(9):622-9. ">Kilic 2011</a>; <a href="./references#CD005552-bbs2-0023" title="KuekS , Wang W-J, Gui S-Q. Efficacy of chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial. Journal of Chinese Integrative Medicine2011;9:965-72. ">Kuek 2011</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0032" title="MhaoNS , Al-HilliSA , HadiNR , JamilDA , Al-AubaidyHA . A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews2015;10S:S95-S98. ">Mhao 2015</a>; <a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>; <a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0037" title="OzgurtasT , OktenliC , DedeM , TapanS , KenarL , SanisogluSY , et al. Metformin and oral contraceptive treatment reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis2008;200:336-44. ">Ozgurtas 2008</a>; <a href="./references#CD005552-bbs2-0042" title="TengYQ , ZhengJH , HanXY . Evaluation of clinical efficacy of Metformin in treating polycystic ovary syndrome. Journal of Harbin Medical University2007;41:405-6. ">Teng 2007</a>; <a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p>Substantial heterogeneity was detected which may be explained by the difference in effect of the interventions between the mean BMI subgroups (test for subgroup difference: P = 0.03, I<sup>2</sup> = 70.9%) (<a href="./references#CD005552-fig-0017" title="">Analysis 1.11</a>). Therefore, we analysed the results per mean BMI subgroup. </p> <p>We are uncertain if metformin decreases BMI compared to the OCP in subgroup BMI &lt; 25 kg/m<sup>2</sup> (MD ‐0.59, 95% CI ‐1.02 to ‐0.17; 9 RCTs; n = 451; I<sup>2</sup> = 76%, very low‐quality evidence). This suggests that for a mean BMI of 22.7 following the OCP, the mean BMI following metformin would be between 1.02 lower to 0.17 lower. </p> <p>We are uncertain of the effect of metformin compared to the OCP on BMI in subgroup BMI &gt; 25 kg/m<sup>2</sup> &lt; 30 kg/m<sup>2</sup>.(MD 0.11, 95% CI ‐0.48 to 0.70; 8 RCTs; n = 353; I<sup>2</sup> = 72%, very low‐quality evidence). This suggests that for a mean BMI of 27.4 following the OCP, the mean BMI following metformin would be between 0.48 lower to 0.7 higher. </p> <p>We are uncertain if metformin decreases BMI compared to the OCP in subgroup BMI &gt; 30 kg/m<sup>2</sup> (MD ‐2.31, 95% CI ‐4.40 to ‐0.21; 3 RCTs; n = 119; I<sup>2</sup> = 52%), very low‐quality evidence). This suggests that for a mean BMI of 35.1 following the OCP, the mean BMI following metformin would be between 4.4 lower to 0.21 lower. </p> <p>Findings were not influenced by sensitivity analysis restricting to the one study with low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>') (<a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>). </p> <p>The funnel plot (n = 19 studies) was asymmetrical indicating that our findings might be influenced by publication bias although asymmetrical funnel plots can also be due to true heterogeneity (funnel plot not shown). </p> <p><b>1.12 Blood pressure ‐ systolic (mmHg)</b> </p> <p>Five trials including 209 women compared metformin versus the OCP and reported on systolic blood pressure (<a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0029" title="Luque-RamirezM , Mendieta-AzconaC , Alvarez-BlascoF , Escobar-MorrealeHF . Effects of Metformin versus Ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertility and Sterility2008;91:2527-36. ">Luque‐Ramirez 2009b</a>; <a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>). </p> <p>Overall, metformin resulted in an improvement in systolic blood pressure compared to the OCP (MD ‐4.81, 95% CI ‐8.55 to ‐1.06, 5 RCTs, n = 209, I<sup>2</sup> = 0%, <a href="./references#CD005552-fig-0018" title="">Analysis 1.12</a>). </p> <p>Subgroup analysis showed insufficient evidence to suggest a difference in effect by mean study BMI (test for subgroup difference: P = 0.41, I<sup>2</sup> = 0%). </p> <p><b>1.13 Blood pressure ‐ diastolic (mmHg)</b> </p> <p>Four trials including 142 women compared metformin versus the OCP and reported on diastolic blood pressure (<a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0029" title="Luque-RamirezM , Mendieta-AzconaC , Alvarez-BlascoF , Escobar-MorrealeHF . Effects of Metformin versus Ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertility and Sterility2008;91:2527-36. ">Luque‐Ramirez 2009b</a>). </p> <p>Substantial heterogeneity was detected which may be explained by the difference in effect of the interventions between the mean BMI subgroups (test for subgroup difference: P = 0.0009, I<sup>2</sup> = 90.9%) (<a href="./references#CD005552-fig-0019" title="">Analysis 1.13</a>). Therefore, we analysed the results per mean BMI subgroup. </p> <p>Metformin compared to the OCP showed appreciable benefit in the " BMI &gt; 25 kg/m<sup>2</sup>&lt; 30 kg/m<sup>2</sup> " subgroup (MD ‐4.25, 95% CI ‐7.30 to ‐1.20; 3 RCTs; n = 108; I<sup>2</sup> = 0%) and appreciable harm in the BMI ≥ 30kg/m<sup>2</sup> " subgroup (MD 7.50, 95% CI 1.27 to 13.73; 1 RCT; n = 34; I<sup>2</sup> = 0%) </p> <p><b>2. Metformin compared to the combined oral contraceptive pill (OCP) in adult women (hormonal parameters)</b> </p> <p><b>2.1 Serum total testosterone (nmol/L)</b> </p> <p>Seventeen trials including 818 women compared metformin versus the OCP and reported on serum total testosterone (<a href="./references#CD005552-bbs2-0001" title="AghamohammadzadehN , AliasgarzadehA , BaglarL , AbdollahifardS , BahramiA , NajafipourF , et al. Comparison of metformin and cyproterone-estrodiol compound effect on HS C-reactive protein and serum androgen levels in patients with polycystic ovary syndrome. Pakistan Journal of Medical Science2010;26(2):347-51. ">Aghamohammadzadeh 2010</a>; <a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0007" title="ChristakouC , KolliasA , PiperiC , KatsikisI , PanidisD , Diamanti-KandarakisE . The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. Hormones2014;13:488-97. ">Christakou 2014</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0018" title="JinLN , YuQ , Ma LK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/ Ethinyl Estradiol in PCOS patients. Chinese Journal of Postgraduate Medicine2006;29:10-5. ">Jin 2006</a>; <a href="./references#CD005552-bbs2-0023" title="KuekS , Wang W-J, Gui S-Q. Efficacy of chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial. Journal of Chinese Integrative Medicine2011;9:965-72. ">Kuek 2011</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>; <a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0037" title="OzgurtasT , OktenliC , DedeM , TapanS , KenarL , SanisogluSY , et al. Metformin and oral contraceptive treatment reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis2008;200:336-44. ">Ozgurtas 2008</a>; <a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>; <a href="./references#CD005552-bbs2-0042" title="TengYQ , ZhengJH , HanXY . Evaluation of clinical efficacy of Metformin in treating polycystic ovary syndrome. Journal of Harbin Medical University2007;41:405-6. ">Teng 2007</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p>Substantial heterogeneity was detected which may be explained by the difference in effect of the interventions between the mean BMI subgroups (test for subgroup difference: P = 0.006, I<sup>2</sup> = 76.1%). Therefore, we analysed the results per mean BMI subgroup. </p> <p>The effect of metformin compared to the OCP showed a slight benefit for the OCP in all three subgroups: BMI ≤ 25 kg/m<sup>2</sup> (MD 0.48, 95% CI 0.38 to 0.57; 9 RCTs; n = 454; I<sup>2</sup> = 57%); BMI &gt; 25kg/m<sup>2</sup> &lt; 30kg/m<sup>2</sup> (MD 0.21, 95% CI 0.07 to 0.35; 4 RCTs; n = 220; I<sup>2</sup> = 0%); BMI ≥30 kg/m<sup>2</sup>(MD 0.42, 95% CI 0.11 to 0.74; 3 RCTs; n = 119; I<sup>2</sup> = 0%) (<a href="./references#CD005552-fig-0020" title="">Analysis 2.1</a>) </p> <p><b>2.2 Free androgen index (FAI) (%)</b> </p> <p>Ten trials including 433 women compared metformin versus the OCP and reported on FAI (<a href="./references#CD005552-bbs2-0007" title="ChristakouC , KolliasA , PiperiC , KatsikisI , PanidisD , Diamanti-KandarakisE . The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. Hormones2014;13:488-97. ">Christakou 2014</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0023" title="KuekS , Wang W-J, Gui S-Q. Efficacy of chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial. Journal of Chinese Integrative Medicine2011;9:965-72. ">Kuek 2011</a>; <a href="./references#CD005552-bbs2-0028" title="Luque-RamirezM , Alvarez-BlascoF , Uriol RiveraMG , Escobar-MorrealeHF . Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. Human Reproduction2008;23:1594-601. ">Luque‐Ramirez 2008a</a>; <a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>; <a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>). </p> <p>Substantial heterogeneity was detected which may be explained by the difference in effect of the interventions between the mean BMI subgroups (test for subgroup difference: P = 0.006, I<sup>2</sup> = 78%). Therefore, we analysed the results per mean BMI subgroup. </p> <p>The effect of metformin compared to the OCP showed an important benefit for the OCP in all three subgroups: BMI ≤ 25 kg/m<sup>2</sup>(MD 4.48, 95% CI 3.56 to 5.40; 4 RCTs; n = 204; I<sup>2</sup> = 84%); BMI &gt; 25 kg/m<sup>2</sup> &lt; 30 kg/m<sup>2</sup>(MD 3.06, 95% CI 2.14 to 3.97; 3 RCTs; n = 110; I<sup>2</sup> = 78%); BMI ≥30 kg/m<sup>2</sup> (MD 7.12, 95% CI 4.46 to 9.79; 3 RCTs; n = 119; I<sup>2</sup> = 27%) (<a href="./references#CD005552-fig-0021" title="">Analysis 2.2</a>). </p> <p><b>3. Metformin compared to the combined oral contraceptive pill (OCP) in adult women (metabolic parameters)</b> </p> <p><b>3.1 Fasting insulin (mLU/L)</b> </p> <p>Twelve trials including 474 women compared metformin versus the OCP and reported on fasting insulin (<a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>; <a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>; <a href="./references#CD005552-bbs2-0042" title="TengYQ , ZhengJH , HanXY . Evaluation of clinical efficacy of Metformin in treating polycystic ovary syndrome. Journal of Harbin Medical University2007;41:405-6. ">Teng 2007</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p>Overall, metformin resulted in an improvement of fasting insulin compared to the OCP (MD ‐ 3.85, 95% CI ‐4.73 to ‐2.97, 12 RCTs, n = 474, I<sup>2</sup>= 23%, <a href="./references#CD005552-fig-0022" title="">Analysis 3.1</a>). </p> <p>Subgroup analysis showed sufficient evidence to suggest a difference in effect by mean study BMI (test for subgroup difference: P = 0.04, I<sup>2</sup> = 65.1%). </p> <p><b>3.2 Fasting glucose (mmol/L)</b> </p> <p>Twelve trials including 519 women compared metformin versus the OCP and reported on fasting glucose (<a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0023" title="KuekS , Wang W-J, Gui S-Q. Efficacy of chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial. Journal of Chinese Integrative Medicine2011;9:965-72. ">Kuek 2011</a>; <a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0033" title="MoranLJ , MeyerC , HutchisonSK , ZoungasS , TeedeHJ . Novel inflammatory markers in overweight women with or without polycystic ovary syndrome and following pharmacological intervention. Journal of Endocrinological Investigation2010;33:258-65. ">Moran 2010</a>; <a href="./references#CD005552-bbs2-0034" title="Morin-PapunenLC , VauhkonenI , KoivunenRM , RuokonenA , MartikainenHK , TapanainenJS . Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology &amp; Metabolism2000;85(9):3161-8. ">Morin‐Papunen 2000</a>; <a href="./references#CD005552-bbs2-0035" title="Morin-PapunenL , VauhkonenI , KoivunenR , RuokonenA , MartikainenH , TapanainenJS . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology &amp; Metabolism2003;88(1):148-56. ">Morin‐Papunen 2003</a>; <a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>; <a href="./references#CD005552-bbs2-0042" title="TengYQ , ZhengJH , HanXY . Evaluation of clinical efficacy of Metformin in treating polycystic ovary syndrome. Journal of Harbin Medical University2007;41:405-6. ">Teng 2007</a>).<br/>Overall, metformin resulted in an improvement of fasting glucose compared to the OCP (MD ‐0.15, 95% CI ‐0.22 to ‐0.07, 12 RCTs, n = 519; I<sup>2</sup>= 46%, <a href="./references#CD005552-fig-0023" title="">Analysis 3.2</a>). </p> <p>Subgroup analysis showed insufficient evidence to suggest a difference in effect by mean study BMI (test for subgroup difference: P = 0.16, I<sup>2</sup> = 45%). </p> <p><b>3.3 Total cholesterol (mmol/L)</b> </p> <p>Thirteen trials including 610 women compared metformin versus the OCP and reported on total cholesterol (<a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0032" title="MhaoNS , Al-HilliSA , HadiNR , JamilDA , Al-AubaidyHA . A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews2015;10S:S95-S98. ">Mhao 2015</a>; <a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0037" title="OzgurtasT , OktenliC , DedeM , TapanS , KenarL , SanisogluSY , et al. Metformin and oral contraceptive treatment reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis2008;200:336-44. ">Ozgurtas 2008</a>; <a href="./references#CD005552-bbs2-0038" title="RautioK , TapanainenJS , RuokonenA , Morin-PapunenLC . Effects of metformin and ethinyl-estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. European Journal of Endocrinology2005;152:269-75. ">Rautio 2005</a>; <a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>). </p> <p>Substantial heterogeneity was detected which may be explained by the difference in effect of the interventions between the BMI subgroups (test for subgroup difference: P &lt; 0.0001, I<sup>2</sup> = 91.2%). Therefore, we analysed the result per mean BMI subgroup (<a href="./references#CD005552-fig-0024" title="">Analysis 3.3</a>). Metformin decreased total cholesterol compared to the OCP in the subgroup BMI &lt; 25 kg/m<sup>2</sup> (MD ‐0.77, 95% CI ‐1.00 to ‐0.53; 4 RCTs; n = 206; I<sup>2</sup> = 61%). There was insufficient evidence to determine whether there was a difference between metformin and the OCP for total cholesterol in the subgroup BMI &gt; 25 kg/m<sup>2</sup> &lt; 30 kg/m<sup>2</sup> (MD ‐0.14, 95% CI ‐0.30 to 0.01; 7 RCTs; n = 303; I<sup>2</sup> = 0%), and in the subgroup BMI &gt; 30 kg/m<sup>2</sup> (MD ‐0.02, 95% CI ‐0.32 to 0.28; 2 RCTs; n = 101; I<sup>2</sup> = 0%). </p> <p><b>3.4 High‐density lipoprotein (HDL) cholesterol (mmol/L)</b> </p> <p>Thirteen trials including 610 women compared metformin versus the OCP and reported on HDL cholesterol (<a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0032" title="MhaoNS , Al-HilliSA , HadiNR , JamilDA , Al-AubaidyHA . A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews2015;10S:S95-S98. ">Mhao 2015</a>; <a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0037" title="OzgurtasT , OktenliC , DedeM , TapanS , KenarL , SanisogluSY , et al. Metformin and oral contraceptive treatment reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis2008;200:336-44. ">Ozgurtas 2008</a>; <a href="./references#CD005552-bbs2-0038" title="RautioK , TapanainenJS , RuokonenA , Morin-PapunenLC . Effects of metformin and ethinyl-estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. European Journal of Endocrinology2005;152:269-75. ">Rautio 2005</a>; <a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>). </p> <p>Substantial heterogeneity was detected which may be explained by the difference in effect of the interventions between the mean BMI subgroups (test for subgroup difference: P = 0.04, I<sup>2</sup> = 69.5%) (<a href="./references#CD005552-fig-0025" title="">Analysis 3.4</a>).Therefore, we analysed the results per mean BMI subgroup. </p> <p>Metformin compared to the OCP showed no benefit in subgroup BMI ≤ 25 kg/m<sup>2</sup> (MD ‐0.02, 95% CI ‐0.01 to 0.07; 4 RCTs; n = 206; I<sup>2</sup> = 90%) and BMI &gt; 25 kg/m<sup>2</sup> but &lt; 30 kg/m<sup>2</sup> (MD 0.02, 95% CI ‐0.02 to 0.06; 7 RCTs; n = 303; I<sup>2</sup> = 75%), or slight harm in subgroup BMI ≥ 30kg/m<sup>2</sup> (MD 0.20, 95% CI 0.05 to 0.35; 2 RCTs; n = 101; I<sup>2</sup> = 0%) for the metformin in the three subgroups. </p> <p><b>3.5 Low‐density lipoprotein (LDL) cholesterol (mmol/L)</b><br/><br/>Thirteen trials including 610 women compared metformin versus the OCP and reported on LDL cholesterol (<a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0032" title="MhaoNS , Al-HilliSA , HadiNR , JamilDA , Al-AubaidyHA . A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews2015;10S:S95-S98. ">Mhao 2015</a>; <a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0037" title="OzgurtasT , OktenliC , DedeM , TapanS , KenarL , SanisogluSY , et al. Metformin and oral contraceptive treatment reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis2008;200:336-44. ">Ozgurtas 2008</a>; <a href="./references#CD005552-bbs2-0038" title="RautioK , TapanainenJS , RuokonenA , Morin-PapunenLC . Effects of metformin and ethinyl-estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. European Journal of Endocrinology2005;152:269-75. ">Rautio 2005</a>; <a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>).<br/><br/>Substantial heterogeneity was detected which may be explained by the difference in effect of the interventions between the mean BMI subgroups (test for subgroup difference: P &lt; 0.00001, I<sup>2</sup> = 92.7%). Therefore, we analysed the results per mean BMI subgroup. </p> <p>The effect of the metformin compared to the OCP showed a slight harm in subgroup BMI ≥30 kg/m<sup>2</sup> (MD 0.35, 95% CI 0.02 to 0.67; 2 RCTs; n = 101; I<sup>2</sup> = 0%), or benefit in subgroup BMI ≤ 25kg/m<sup>2</sup> (MD ‐0.39, 95% CI ‐0.54 to ‐0.23; 4 RCTs; n = 206; I<sup>2</sup> = 50%), or no important benefit/harm in subgroup BMI &gt; 25 kg/m<sup>2</sup> but &lt; 30 kg/m<sup>2</sup> (MD 0.02, 95% CI ‐0.06 to 0.10; 7 RCTs; n = 303; I<sup>2</sup> = 12%) for metformin in the three subgroups (<a href="./references#CD005552-fig-0026" title="">Analysis 3.5</a>). </p> <p><b>3.6 Triglycerides (mmol/L)</b><br/><br/>Thirteen trials including 610 women compared metformin versus the OCP and reported on triglycerides (<a href="./references#CD005552-bbs2-0006" title="CetinkalpS , KaradenizM , ErdoganM , OzgenG , SaygiliF , YilmazC . The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist2009;19:94-7. ">Cetinkalp 2009</a>; <a href="./references#CD005552-bbs2-0009" title="DardzinskaJA , RachonD , Kuligowska-JakuboswkaM , Aleksandrowicz-WronaE , PloszynskiA , WyrzykowskiB , et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum C-reactive protein, Interleukine-6 and Soluble Vascular Cell Adhesion Molecule-1 concentrations in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2014;122:118-25. ">Dardzinska 2014</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0026" title="Luque-RamirezM , Alvarez-BlascoF , Botella-CarreteroJI , Martinez-BermejoE , LasuncionMA , Escobar-MorrealeHF . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 04/2007;92:2453-61. ">Luque‐Ramirez 2007a</a>; <a href="./references#CD005552-bbs2-0032" title="MhaoNS , Al-HilliSA , HadiNR , JamilDA , Al-AubaidyHA . A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews2015;10S:S95-S98. ">Mhao 2015</a>; <a href="./references#CD005552-bbs2-0031" title="MeyerC , McGrathBP , TeedeHJ . Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care2007;30(3):471-8. ">Meyer 2007</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0037" title="OzgurtasT , OktenliC , DedeM , TapanS , KenarL , SanisogluSY , et al. Metformin and oral contraceptive treatment reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis2008;200:336-44. ">Ozgurtas 2008</a>; <a href="./references#CD005552-bbs2-0038" title="RautioK , TapanainenJS , RuokonenA , Morin-PapunenLC . Effects of metformin and ethinyl-estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. European Journal of Endocrinology2005;152:269-75. ">Rautio 2005</a>; <a href="./references#CD005552-bbs2-0040" title="SahuA , TripathyP , MohantyJ , NagyA . Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction2018;48(5):335-9. ">Sahu 2018</a>). </p> <p>Substantial heterogeneity was detected which may be explained by the difference in effect of the interventions between the mean BMI subgroups (test for subgroup difference: P &lt; 0.00001, I<sup>2</sup> = 93.1%).(<a href="./references#CD005552-fig-0027" title="">Analysis 3.6</a>) Therefore, we analysed the results per BMI subgroup. </p> <p>The effect of metformin compared to the OCP showed slight benefit in subgroup BMI ≤ 25 kg/m<sup>2</sup> (MD ‐0.45, 95% CI ‐0.61 to ‐0.30; 4 RCTs; n = 206; I<sup>2</sup> = 67%), and no improvement in groups BMI &gt; 25k g/m<sup>2</sup> &lt; 30kg/m<sup>2</sup> (MD ‐0.01, 95% CI ‐0.07 to 0.05; 7 RCTs; n = 303; I<sup>2</sup> = 20%), and BMI ≥30 kg/m<sup>2</sup> (MD ‐0.31, 95% CI ‐0.64 to 0.01; 2 RCTs; n = 101; I<sup>2</sup> = 0%). </p> <p><b>4. Metformin compared to metformin combined with the OCP in adult women (clinical parameters)</b> </p> <p><a href="./full#CD005552-tbl-0002">summary of findings Table 2</a> </p> <p>Six trials including 295 adult women compared metformin combined with the OCP compared to metformin (<a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>; <a href="./references#CD005552-bbs2-0018" title="JinLN , YuQ , Ma LK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/ Ethinyl Estradiol in PCOS patients. Chinese Journal of Postgraduate Medicine2006;29:10-5. ">Jin 2006</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0025" title="LiuJX , DangJM , WuYZ , ZhengN , WuXK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/Ethynil Estradiol on PCOS patients. Chinese Journal of Postgraduate Medicine2006;19:530-3. ">Liu 2006</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p><b>Primary outcomes</b> </p> <p><b>4.1 Hirsutism ‐ Clinical Ferriman‐Gallwey</b> (<b>F‐G) score</b> </p> <p>Three trials including 135 women compared metformin versus metformin combined with the OCP and reported hirsutism clinically using the F‐G score (<a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p>Overall, metformin may be less effective in improving hirsutism compared to metformin combined with the OCP (MD 1.36, 95% CI 0.62 to 2.11, 3 RCTs, n = 135, I<sup>2</sup>= 9%, low‐quality evidence, <a href="./references#CD005552-fig-0028" title="">Analysis 4.1</a>). </p> <p>This suggests that for a mean F‐G score of 5.6 following the metformin combined with the OCP, the mean F‐G score following metformin would be between 0.62 higher to 2.11 higher. </p> <p>Subgroup analysis showed insufficient evidence to suggest a difference in effect by mean study BMI (test for subgroup difference: P = 0.18, I<sup>2</sup> = 43.5%). </p> <p>Sensitivity analysis restricting studies to low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>') was unable to be performed due to no RCTs having a low risk of bias. </p> <p><b>Hirsutism ‐ Subjective visual analogue scale (VAS)</b> </p> <p>No RCT reported on this outcome</p> <p><b>Hirsutism ‐ subjective improvement</b> </p> <p>No RCT reported on this outcome</p> <p><b>4.2 Adverse events: severe (requiring stopping of medication) (gastro‐intestinal and others)</b> </p> <p>Three trials compared metformin versus metformin combined with the OCP and reported severe adverse events (<a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>). </p> <p><b>4.2.1 Gastro‐intestinal</b> </p> <p>Three trials including 171 women compared metformin versus metformin combined with the OCP and reported severe gastro‐intestinal adverse events (<a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>). </p> <p>We are uncertain if there was a difference between metformin and metformin combined with the OCP for severe gastro‐intestinal adverse events (OR 0.74, 95% CI 0.21 to 2.53, 3 RCTs, n = 171, I<sup>2</sup> = 0%, low‐quality evidence <a href="./references#CD005552-fig-0029" title="">Analysis 4.2</a>). This suggests that if the severe gastrointestinal adverse event rate following metformin combined with the OCP is 7%, then the severe gastrointestinal adverse event rate after metformin would be between 2% and 17%. </p> <p>Sensitivity analysis restricting studies to low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>') was unable to be performed due to no RCTs having a low risk of bias. </p> <p><b>4.2.2 Others</b> </p> <p>Two trials including 109 women compared metformin versus metformin combined with the OCP and reported severe other adverse events (<a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>). </p> <p>We are uncertain if there was a difference between metformin and metformin combined with the OCP for severe other adverse events (OR 0.56, 95% CI 0.11 to 2.82, 2 RCTs, n = 109, I<sup>2</sup> = 44%, low‐quality evidence <a href="./references#CD005552-fig-0029" title="">Analysis 4.2</a>). This suggests that if the severe other adverse event rate following metformin combined with the OCP is 6%, then the severe other adverse event rate after metformin would between 1% and 15%. </p> <p>Sensitivity analysis restricting studies to low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>') was unable to be performed due to no RCTs having a low risk of bias. </p> <p>One trial including 24 women compared metformin versus metformin combined with the OCP and reported minor adverse events with metformin combined with the OCP and metformin only, but did not report supporting data and therefore could not be included in any meta‐analysis in this review (<a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>). </p> <p><b>Adverse events ‐ minor (gastro‐intestinal and others)</b> </p> <p>No RCT reported on this outcome.</p> <p><b>Secondary outcomes</b> </p> <p><b>Improved menstrual pattern (i.e. shortening of intermenstrual days)</b> </p> <p>No RCT reported on this outcome.</p> <p><b>Improved menstrual pattern (i.e. an initiation of menses or cycle regularity)</b> </p> <p>No RCT reported on this outcome.</p> <p><b>Acne ‐ visual analogue scale (VAS)</b> </p> <p>No RCT reported on this outcome.</p> <p><b>Acne ‐ subjective improvement</b> </p> <p>No RCT reported on this outcome.</p> <p><b>Diagnosis of Type II diabetes mellitus</b> </p> <p>No RCT reported on this outcome.</p> <p><b>4.3 Body weight (kg)</b> </p> <p>Two trials including 101 women compared metformin versus metformin combined with the OCP and reported on body weight (<a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>). </p> <p>Overall, metformin resulted in an improvement of body weight compared to metformin combined with the OCP (MD ‐5.39, 95% CI ‐10.70 to ‐0.08, 2 RCTs, n = 101, I<sup>2</sup>= 0%, <a href="./references#CD005552-fig-0030" title="">Analysis 4.3</a>). </p> <p>Subgroup analysis was not applicable as both RCTs were in the same mean study BMI subgroup. </p> <p><b>4.4 Body mass index (BMI) (kg/m<sup>2</sup>)</b> </p> <p>Five trials including 199 women compared metformin versus metformin combined with the OCP and reported on BMI (<a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0025" title="LiuJX , DangJM , WuYZ , ZhengN , WuXK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/Ethynil Estradiol on PCOS patients. Chinese Journal of Postgraduate Medicine2006;19:530-3. ">Liu 2006</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p>Overall, metformin may improve BMI compared to metformin combined with the OCP (MD ‐1.47, 95% CI ‐2.27 to ‐0.66, 5 RCTs, n = 199, I<sup>2</sup>= 25%, low‐quality evidence, <a href="./references#CD005552-fig-0031" title="">Analysis 4.4</a>). This suggests that for a mean BMI of 25.49 following metformin combined with the OCP, the mean BMI following metformin would be between 2.27 lower to 0.66 lower. </p> <p>Subgroup analysis showed insufficient evidence to suggest a difference in effect by mean study BMI (test for subgroup difference: P = 0.90, I<sup>2</sup> = 0%). </p> <p>Sensitivity analysis restricting studies to low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>') was unable to be performed due to no RCTs having a low risk of bias. </p> <p><b>4.5 Blood pressure ‐ systolic (mmHg)</b> </p> <p>One trial including 42 women compared metformin versus metformin combined with the OCP and reported on systolic blood pressure (<a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>). </p> <p>Metformin resulted in an improvement of systolic blood pressure compared to metformin combined with the OCP (MD ‐10.59, 95% CI ‐15.76 to ‐5.42, 1 RCT, n = 42, <a href="./references#CD005552-fig-0032" title="">Analysis 4.5</a>). </p> <p><b>4.6 Blood pressure ‐ diastolic (mmHg)</b> </p> <p>One trial including 42 women compared metformin versus metformin combined with the OCP and reported on diastolic blood pressure (<a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>). </p> <p>Metformin resulted in an improvement of diastolic blood pressure compared to metformin combined with the OCP (MD ‐7.93, 95% CI ‐14.01 to ‐1.85, 1 RCT, n = 42, <a href="./references#CD005552-fig-0033" title="">Analysis 4.6</a>). </p> <p><b>5. Metformin compared to metformin combined with the OCP in adult women (hormonal parameters)</b> </p> <p><b>5.1 Serum total testosterone (nmol/L)</b> </p> <p>Five trials including 226 women compared metformin versus metformin combined with the OCP and reported on serum total testosterone (<a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0025" title="LiuJX , DangJM , WuYZ , ZhengN , WuXK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/Ethynil Estradiol on PCOS patients. Chinese Journal of Postgraduate Medicine2006;19:530-3. ">Liu 2006</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p>Substantial heterogeneity was detected, which may be explained by the difference in effect of the interventions between the mean BMI subgroups (test for subgroup difference: P &lt; 0.00001, I<sup>2</sup> = 95.9%). (<a href="./references#CD005552-fig-0034" title="">Analysis 5.1</a>). Therefore, we analysed the results per mean BMI subgroup. </p> <p>Metformin compared to metformin combined with the OCP showed no important benefit/harm for metformin in the subgroup BMI ≤ 25 kg/m<sup>2</sup>(MD 0.09, 95% CI ‐0.08 to 0.26; 2 RCTs; n = 74; I<sup>2</sup> = 0%), and important harm in the other subgroup BMI &gt; 25 kg/m<sup>2</sup> &lt; 30kg/m<sup>2</sup> (MD 0.79, 95% CI 0.57 to 1.00; 3 RCTs; n = 152; I<sup>2</sup> = 65%). </p> <p><b>5.2 Free androgen index (FAI) (%)</b> </p> <p>Three trials including 133 women compared metformin versus metformin combined with the OCP and reported on FAI (<a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0025" title="LiuJX , DangJM , WuYZ , ZhengN , WuXK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/Ethynil Estradiol on PCOS patients. Chinese Journal of Postgraduate Medicine2006;19:530-3. ">Liu 2006</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>). </p> <p>Substantial heterogeneity was detected which may be explained by the difference in effect of the interventions between the mean BMI subgroups (test for subgroup difference: P &lt; 0.0001, I<sup>2</sup> = 93.7%) (<a href="./references#CD005552-fig-0035" title="">Analysis 5.2</a>). Therefore, we analysed the results per mean BMI subgroup. </p> <p>Metformin compared to metformin combined with the OCP showed appreciable benefit for the OCP combined with metformin in the " BMI &gt; 25 kg/m<sup>2</sup> &lt; 30 kg/m<sup>2</sup>" subgroup (MD 3.80, 95% CI 2.91 to 4.69; 2 RCTs; n = 93; I<sup>2</sup> = 97%), and no important benefit/harm in the other subgroup (BMI ≤ 25 kg/m<sup>2</sup>) (MD 0.35, 95% CI ‐1.09 to 1.79; 1 RCT; n = 40; I<sup>2</sup> = 0%). </p> <p><b>6. Metformin compared to metformin combined with the OCP in adult women (metabolic parameters)</b> </p> <p><b>6.1 Fasting insulin (mLU/L)</b> </p> <p>Five trials including 199 women compared metformin versus metformin combined with the OCP and reported on fasting insulin (<a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0025" title="LiuJX , DangJM , WuYZ , ZhengN , WuXK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/Ethynil Estradiol on PCOS patients. Chinese Journal of Postgraduate Medicine2006;19:530-3. ">Liu 2006</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p>Overall, metformin resulted in an improvement of fasting insulin compared to metformin combined with the OCP (MD ‐1.32, 95% CI ‐2.63 to ‐0.01, 5 RCTs, n = 199, I<sup>2</sup>= 33%, <a href="./references#CD005552-fig-0036" title="">Analysis 6.1</a>). </p> <p>Subgroup analysis showed insufficient evidence to suggest a difference in effect by mean study BMI (test for subgroup difference: P = 0.72, I<sup>2</sup> = 0%). </p> <p><b>6.2 Fasting glucose (mmol/L)</b> </p> <p>Four trials including 170 women compared metformin versus metformin combined with the OCP and reported on fasting glucose (<a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0025" title="LiuJX , DangJM , WuYZ , ZhengN , WuXK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/Ethynil Estradiol on PCOS patients. Chinese Journal of Postgraduate Medicine2006;19:530-3. ">Liu 2006</a>). </p> <p>Overall, metformin resulted in an improvement of fasting glucose compared to metformin combined with the OCP (MD ‐0.21, 95% CI ‐0.37 to ‐0.06, 4 RCTs, n = 170, I<sup>2</sup>= 49%, <a href="./references#CD005552-fig-0037" title="">Analysis 6.2</a>).<br/>Subgroup analysis showed insufficient evidence to suggest a difference in effect by mean study BMI (test for subgroup difference: P = 0.76, I<sup>2</sup> = 0%). </p> <p><b>6.3 Total cholesterol (mmol/L)</b><br/><br/>Five trials including 216 women compared metformin versus metformin combined with the OCP and reported on total cholesterol (<a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0025" title="LiuJX , DangJM , WuYZ , ZhengN , WuXK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/Ethynil Estradiol on PCOS patients. Chinese Journal of Postgraduate Medicine2006;19:530-3. ">Liu 2006</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>).<br/>Overall, metformin resulted in an improvement of total cholesterol compared to metformin combined with the OCP (MD ‐0.54, 95% CI ‐0.97 to ‐0.11, 5 RCTs, n = 216, I<sup>2</sup>= 65%, <a href="./references#CD005552-fig-0038" title="">Analysis 6.3</a>). </p> <p>Substantial heterogeneity was detected, which was not explained by a difference in effect of the interventions between the BMI subgroups (test for subgroup difference: P = 0.81, I<sup>2</sup> = 0%). </p> <p>Findings were not influenced by sensitivity analyses using a random‐effects model (in the presence of unexplained substantial heterogeneity). </p> <p><b>6.4 High‐density lipoprotein (HDL) cholesterol (mmol/L)</b> </p> <p>Five trials including 216 women compared metformin versus metformin combined with the OCP and reported on HDL cholesterol (<a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0025" title="LiuJX , DangJM , WuYZ , ZhengN , WuXK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/Ethynil Estradiol on PCOS patients. Chinese Journal of Postgraduate Medicine2006;19:530-3. ">Liu 2006</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>). </p> <p>Substantial heterogeneity was detected which may be explained by the difference in effect of the interventions between the mean BMI subgroups (test for subgroup difference: P = 0.0002, I<sup>2</sup> = 93.0%) (<a href="./references#CD005552-fig-0039" title="">Analysis 6.4</a>). Therefore, we analysed the results per mean BMI subgroup. </p> <p>Metformin compared to metformin combined with the OCP showed appreciable benefit for metformin in the "BMI ≤ 2 5kg/m<sup>2</sup> " subgroup (MD ‐0.64, 95% CI ‐0.99 to ‐0.29; n = 40; 1 RCT; I<sup>2</sup> = 0%), and no important benefit/harm in the other subgroup (BMI &gt; 25 kg/m<sup>2</sup> &lt; 30 kg/m<sup>2</sup>) (MD 0.05, 95% CI ‐0.04 to 0.14; n = 176; 4 RCTs; I<sup>2</sup> = 0%) </p> <p><b>6.5 Low‐density lipoprotein (LDL) cholesterol (mmol/L)</b><br/><br/>Four trials including 176 women compared metformin versus metformin combined with the OCP and reported on LDL cholesterol (<a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>).<br/>Overall, there was insufficient evidence to determine whether there was a difference between metformin combined with the OCP and metformin for LDL cholesterol (MD ‐0.13, 95% CI ‐0.32 to 0.06, 4 RCTs, n = 176, I<sup>2</sup> = 40%, <a href="./references#CD005552-fig-0040" title="">Analysis 6.5</a>). </p> <p>Subgroup analysis was not applicable as all four RCTs were in the same mean study BMI subgroup. </p> <p><b>6.6 Triglycerides (mmol/L)</b><br/><br/>Five trials including 216 women compared metformin combined with the OCP versus metformin and reported on triglycerides (<a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0025" title="LiuJX , DangJM , WuYZ , ZhengN , WuXK . The effect of combination therapy with Metformin and combined Cyproterone Acetate/Ethynil Estradiol on PCOS patients. Chinese Journal of Postgraduate Medicine2006;19:530-3. ">Liu 2006</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>).<br/>Overall, metformin resulted in an improvement of triglycerides compared to metformin combined with the OCP (MD ‐0.22, 95% CI ‐0.37 to ‐0.07, 5 RCTs, n = 216, I<sup>2</sup>= 85%, <a href="./references#CD005552-fig-0041" title="">Analysis 6.6</a>). </p> <p>Substantial heterogeneity was detected which could not be explained by the difference in effect of the interventions between the BMI subgroups (test for subgroup difference: P = 0.03, I<sup>2</sup> = 78.6%) but could be explained by the effect of one of the included studies which showed benefit for metformin combined with the OCP (<a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>). </p> <p><b>7. Oral contraceptive pill (OCP) compared with metformin combined with the OCP in adult women (clinical parameters)</b> </p> <p><a href="./full#CD005552-tbl-0003">summary of findings Table 3</a> </p> <p>Sixteen trials including 1043 adult women compared metformin combined with the OCP to the combined OCP (<a href="./references#CD005552-bbs2-0004" title="Bhattacharya SM , BiswasB , BasuA . Comparative study of the therapeutic effects of drospirenone (DRSP, 3mg) with ethinyl estradiol (EE, 20 mcg) pill with or without metformin 500 mg in polycystic ovary syndrome (PCOS). In: Fertility and Sterility. 2016, poster P-401:e257. ">Bhattacharya 2016</a>; <a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0011" title="ElterK , ImirG , DurmusogluF . Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction2002;17(7):1729-37. ">Elter 2002</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0019" title="KayaMG , YildirimS , CalapkorurB , AkpekM , UnluhizarciK , KelestimurF . Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecological Endocrinology2015;31:401-5. ">Kaya 2015</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0021" title="BilgirO , KebapcilarL , TanerC , BilgirF , KebapcilarA , BozkayaG , et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). International Medicine2009;48:1193-9. KebapcilarL , YukselA , BozkayaG , TanerCE , KebapcilarAG , BilgirO , et al. Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome. Central European Journal of Medicine2009;4:423-7. ">Kebapcilar 2009b</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0030" title="LvL , LiuY , SunY , TanK . Effects of Metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. Journal of Huazhong University of Science and Technology2005;25:194-7. ">Lv 2005</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0041" title="SongJ , RuanX , GuM , WangL , WangH , MueckAO . Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological Endocrinology2018;34:413-7. ">Song 2017</a>; <a href="./references#CD005552-bbs2-0039" title="RuanX , SongJ , GuM , WangL , WangH , Mueck AO. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Archives of Gynecology and Obstetrics2018;297:1557-63. ">Ruan 2018</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p><b>Primary outcomes</b> </p> <p><b>7.1 Hirsutism ‐ Clinical Ferriman‐Gallwey</b> (<b>F‐G) score</b> </p> <p>Six trials including 389 women compared the OCP versus metformin combined with the OCP and reported hirsutism clinically using the F‐G score (<a href="./references#CD005552-bbs2-0004" title="Bhattacharya SM , BiswasB , BasuA . Comparative study of the therapeutic effects of drospirenone (DRSP, 3mg) with ethinyl estradiol (EE, 20 mcg) pill with or without metformin 500 mg in polycystic ovary syndrome (PCOS). In: Fertility and Sterility. 2016, poster P-401:e257. ">Bhattacharya 2016</a>; <a href="./references#CD005552-bbs2-0011" title="ElterK , ImirG , DurmusogluF . Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction2002;17(7):1729-37. ">Elter 2002</a>; <a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p>Overall, the OCP may be less effective in improving hirsutism compared to metformin combined with the OCP (MD 0.54, 95% CI 0.20 to 0.89, 6 RCTs, n = 389, I<sup>2</sup>= 1%, low‐quality evidence, <a href="./references#CD005552-fig-0042" title="">Analysis 7.1</a>). This suggests that for a mean F‐G score of 5.57 following metformin combined with the OCP, the mean F‐G score following the OCP would be between 0.20 higher to 0.89 higher. </p> <p>Subgroup analysis showed insufficient evidence to suggest a difference in effect by mean study BMI (test for subgroup difference: P = 0.36, I<sup>2</sup> = 0%). </p> <p>Findings were not influenced by sensitivity analysis restricting to the one study with low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>') (<a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>). </p> <p><b>Hirsutism ‐ subjective visual analogue scale (VAS)</b> </p> <p>No RCT reported on this outcome.</p> <p><b>Hirsutism ‐ Subjective improvement</b> </p> <p>No RCT reported on this outcome.</p> <p><b>7.2 Adverse events: severe (requiring stopping of medication) (gastro‐intestinal and others)</b> </p> <p>Six trials including 387 women compared the OCP versus metformin combined with the OCP and reported severe adverse events (<a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p><b>7.2.1 Gastro‐intestinal</b> </p> <p>Five trials including 228 women compared the OCP versus metformin combined with the OCP and reported severe gastro‐intestinal adverse events (<a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p>The OCP may result in a lower incidence of severe gastro‐intestinal adverse events compared to metformin combined with the OCP (OR 0.20, 95% CI 0.06 to 0.72, 5 RCTs, n = 228, I<sup>2</sup> = 0%, low‐quality evidence <a href="./references#CD005552-fig-0043" title="">Analysis 7.2</a>). This suggests that for severe gastro‐intestinal adverse event rate of 10% following metformin combined with the OCP, the severe gastro‐intestinal adverse event rate following the OCP would be between 1% and 7%. </p> <p>Sensitivity analysis restricting studies to low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>') was unable to be performed due to no RCTs having a low risk of bias. </p> <p><b>7.2.2 Others</b> </p> <p>Four trials including 159 women compared the OCP versus metformin combined with the OCP and reported other severe adverse events (<a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p>We are uncertain if there is a difference between the OCP and metformin combined with the OCP for other severe adverse events (OR 1.61, 95% CI 0.49 to 5.37, 4 RCTs, n = 159, I<sup>2</sup> = 12%, low‐quality evidence, <a href="./references#CD005552-fig-0043" title="">Analysis 7.2</a>). This suggests that for severe other adverse event rate of 4% following metformin combined with the OCP, the severe other adverse event rate following the OCP would be between 1.9% and 17.9%. </p> <p>Sensitivity analysis restricting studies to low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>') was unable to be performed due to no RCTs having a low risk of bias. </p> <p><b>7.3 Adverse events: minor (gastro‐intestinal and others)</b> </p> <p>Two trials including 98 women compared the OCP versus metformin combined with the OCP and reported minor adverse events (<a href="./references#CD005552-bbs2-0011" title="ElterK , ImirG , DurmusogluF . Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction2002;17(7):1729-37. ">Elter 2002</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>). </p> <p><b>7.3.1 Gastro‐intestinal</b> </p> <p>Overall, the OCP may have a lower incidence of minor (gastro‐intestinal) adverse events compared to metformin combined with the OCP (OR 0.06, 95% CI 0.01 to 0.44, 2 RCTs, n = 98, I<sup>2</sup> = 0%,low‐quality evidence; <a href="./references#CD005552-fig-0044" title="">Analysis 7.3</a>). This suggests that for an overall minor (gastro‐intestinal) adverse event rate of 26% following metformin combined with the OCP, the minor (gastro‐intestinal) adverse event rate following the OCP would be between 0.4% and 13%. </p> <p>Subgroup analysis was not applicable as all minor adverse events were gastro‐intestinal in nature. </p> <p>Sensitivity analysis restricting studies to low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>') was unable to be performed due to no RCTs having a low risk of bias. </p> <p>One trial including 24 women compared the OCP versus metformin combined with the OCP and reported minor adverse events with metformin combined with the OCP, but did not report supporting data and therefore could not be included in any meta‐analysis in this review (<a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>). </p> <p><b>Secondary outcomes</b> </p> <p><b>Improved menstrual pattern (i.e. shortening of intermenstrual days)</b> </p> <p>No RCT reported on this outcome.</p> <p><b>Improved menstrual pattern (i.e. an initiation of menses or cycle regularity)</b> </p> <p>No RCT reported on this outcome</p> <p><b>7.4 Acne ‐ clinical acne score</b> </p> <p>One trial including 82 women compared the OCP versus metformin combined with the OCP and reported acne using a clinical acne score. (<a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>). </p> <p>The OCP may improve slightly acne compared to metformin combined with the OCP (MD ‐0.09, 95% CI ‐0.10 to ‐ 0.08, 1 RCT, n = 82, low‐quality evidence, <a href="./references#CD005552-fig-0045" title="">Analysis 7.4</a>). </p> <p>This one RCT had a low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>'). </p> <p><b>7.5 Acne ‐ subjective improvement</b> </p> <p>One trial including 129 women compared the OCP versus metformin combined with the OCP and reported acne subjectively. (<a href="./references#CD005552-bbs2-0004" title="Bhattacharya SM , BiswasB , BasuA . Comparative study of the therapeutic effects of drospirenone (DRSP, 3mg) with ethinyl estradiol (EE, 20 mcg) pill with or without metformin 500 mg in polycystic ovary syndrome (PCOS). In: Fertility and Sterility. 2016, poster P-401:e257. ">Bhattacharya 2016</a>). </p> <p>There was insufficient evidence to determine whether there was a difference between the OCP and metformin combined with the OCP for acne (OR 0.67, 95% CI 0.33 to 1.35, 1 RCT, n = 129, <a href="./references#CD005552-fig-0046" title="">Analysis 7.5</a>). </p> <p><b>Diagnosis of Type II diabetes mellitus</b> </p> <p>No RCT reported on this outcome.</p> <p><b>7.6 Body weight (kg)</b> </p> <p>Seven trials including 387 women compared the OCP versus metformin combined with the OCP and reported on body weight (<a href="./references#CD005552-bbs2-0004" title="Bhattacharya SM , BiswasB , BasuA . Comparative study of the therapeutic effects of drospirenone (DRSP, 3mg) with ethinyl estradiol (EE, 20 mcg) pill with or without metformin 500 mg in polycystic ovary syndrome (PCOS). In: Fertility and Sterility. 2016, poster P-401:e257. ">Bhattacharya 2016</a>; <a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0019" title="KayaMG , YildirimS , CalapkorurB , AkpekM , UnluhizarciK , KelestimurF . Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecological Endocrinology2015;31:401-5. ">Kaya 2015</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>). </p> <p>Overall, there was insufficient evidence to determine whether there was a difference between the OCP and metformin combined with the OCP for body weight (MD ‐0.63, 95% CI ‐1.58 to 0.33, 7 RCTs, n = 387, I<sup>2</sup> = 18%, <a href="./references#CD005552-fig-0047" title="">Analysis 7.6</a>). </p> <p>Subgroup analysis showed insufficient evidence to suggest a difference in effect by mean study BMI (test for subgroup difference: P = 0.80, I<sup>2</sup> = 0%). </p> <p><b>7.7 Body Mass Index (BMI) (kg/m<sup>2</sup>)</b> </p> <p>Thirteen trials including 661 women compared the OCP versus metformin combined with the OCP and reported on BMI (<a href="./references#CD005552-bbs2-0004" title="Bhattacharya SM , BiswasB , BasuA . Comparative study of the therapeutic effects of drospirenone (DRSP, 3mg) with ethinyl estradiol (EE, 20 mcg) pill with or without metformin 500 mg in polycystic ovary syndrome (PCOS). In: Fertility and Sterility. 2016, poster P-401:e257. ">Bhattacharya 2016</a>; <a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>; <a href="./references#CD005552-bbs2-0011" title="ElterK , ImirG , DurmusogluF . Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction2002;17(7):1729-37. ">Elter 2002</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0030" title="LvL , LiuY , SunY , TanK . Effects of Metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. Journal of Huazhong University of Science and Technology2005;25:194-7. ">Lv 2005</a>; <a href="./references#CD005552-bbs2-0019" title="KayaMG , YildirimS , CalapkorurB , AkpekM , UnluhizarciK , KelestimurF . Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecological Endocrinology2015;31:401-5. ">Kaya 2015</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0021" title="BilgirO , KebapcilarL , TanerC , BilgirF , KebapcilarA , BozkayaG , et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). International Medicine2009;48:1193-9. KebapcilarL , YukselA , BozkayaG , TanerCE , KebapcilarAG , BilgirO , et al. Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome. Central European Journal of Medicine2009;4:423-7. ">Kebapcilar 2009b</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p>Overall, there was uncertainty as to whether there was a difference between the OCP and metformin combined with the OCP for BMI (MD ‐0.21, 95% CI ‐0.53 to 0.12, 13 RCTs, n = 661, I<sup>2</sup> = 50%, very low‐quality evidence, <a href="./references#CD005552-fig-0048" title="">Analysis 7.7</a>). </p> <p>Substantial heterogeneity was detected, which was not explained by the difference in effect of the interventions between the BMI subgroups (test for subgroup difference: P = 0.64, I<sup>2</sup> = 0%). </p> <p>Findings were not influenced by sensitivity analysis restricting to the one study with low risk of bias (defined in methods section'<a href="#CD005552-sec-0037">Sensitivity analysis</a>') (<a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>). </p> <p>Findings were not influenced by sensitivity analyses using a random‐effects model (in the presence of unexplained substantial heterogeneity). </p> <p>The funnel plot (n = 13 studies) was symmetrical indicating that our findings might not be influenced by publication bias (funnel plot not shown) </p> <p><b>7.8 Blood pressure ‐ systolic (mmHg)</b> </p> <p>Five trials including 326 women compared the OCP versus metformin combined with the OCP and reported on systolic blood pressure (<a href="./references#CD005552-bbs2-0004" title="Bhattacharya SM , BiswasB , BasuA . Comparative study of the therapeutic effects of drospirenone (DRSP, 3mg) with ethinyl estradiol (EE, 20 mcg) pill with or without metformin 500 mg in polycystic ovary syndrome (PCOS). In: Fertility and Sterility. 2016, poster P-401:e257. ">Bhattacharya 2016</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0019" title="KayaMG , YildirimS , CalapkorurB , AkpekM , UnluhizarciK , KelestimurF . Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecological Endocrinology2015;31:401-5. ">Kaya 2015</a>). </p> <p>Overall, there was insufficient evidence to determine whether there was a difference between the OCP and metformin combined with the OCP for systolic blood pressure (MD ‐1.75, 95% CI ‐4.03 to 0.53, 5 RCTs, n = 326, I<sup>2</sup> = 76%, <a href="./references#CD005552-fig-0049" title="">Analysis 7.8</a>). </p> <p>Substantial heterogeneity was detected which was not explained by a difference in effect of the interventions between the BMI subgroups (test for subgroup difference: P = 0.16, I<sup>2</sup> = 45.8%). </p> <p>Findings were not influenced by sensitivity analyses using a random‐effects model (in the presence of unexplained substantial heterogeneity). </p> <p><b>7.9 Blood pressure ‐ diastolic (mmHg)</b> </p> <p>Five trials including 326 women compared the OCP versus metformin combined with the OCP and reported on diastolic blood pressure (<a href="./references#CD005552-bbs2-0004" title="Bhattacharya SM , BiswasB , BasuA . Comparative study of the therapeutic effects of drospirenone (DRSP, 3mg) with ethinyl estradiol (EE, 20 mcg) pill with or without metformin 500 mg in polycystic ovary syndrome (PCOS). In: Fertility and Sterility. 2016, poster P-401:e257. ">Bhattacharya 2016</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0019" title="KayaMG , YildirimS , CalapkorurB , AkpekM , UnluhizarciK , KelestimurF . Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecological Endocrinology2015;31:401-5. ">Kaya 2015</a>). </p> <p>Overall, there was insufficient evidence to determine whether there was a difference between the OCP and metformin combined with the OCP for diastolic blood pressure (MD ‐1.05, 95% CI ‐2.79 to 0.68, 5 RCTs, n = 326, I<sup>2</sup> = 76%, <a href="./references#CD005552-fig-0050" title="">Analysis 7.9</a>). </p> <p>Substantial heterogeneity was detected which was not explained by a difference in effect of the interventions between the BMI subgroups (test for subgroup difference: P = 0.28, I<sup>2</sup> = 20.8%). </p> <p>Findings were not influenced by sensitivity analyses using a random‐effects model (in the presence of unexplained substantial heterogeneity). </p> <p><b>8. The OCP compared to metformin combined with the OCP in adult women (hormonal parameters)</b> </p> <p><b>8.1 Serum total testosterone (nmol/L)</b> </p> <p>Twelve trials including 715 women compared the OCP versus metformin combined with the OCP and reported on serum total testosterone (<a href="./references#CD005552-bbs2-0004" title="Bhattacharya SM , BiswasB , BasuA . Comparative study of the therapeutic effects of drospirenone (DRSP, 3mg) with ethinyl estradiol (EE, 20 mcg) pill with or without metformin 500 mg in polycystic ovary syndrome (PCOS). In: Fertility and Sterility. 2016, poster P-401:e257. ">Bhattacharya 2016</a>; <a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>; <a href="./references#CD005552-bbs2-0011" title="ElterK , ImirG , DurmusogluF . Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction2002;17(7):1729-37. ">Elter 2002</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0030" title="LvL , LiuY , SunY , TanK . Effects of Metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. Journal of Huazhong University of Science and Technology2005;25:194-7. ">Lv 2005</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0041" title="SongJ , RuanX , GuM , WangL , WangH , MueckAO . Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological Endocrinology2018;34:413-7. ">Song 2017</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p>Overall, the OCP resulted in an increase of serum total testosterone compared to metformin combined with the OCP (MD 0.08, 95% CI 0.01 to 0.16, 12 RCTs, n = 715, I<sup>2</sup> = 0%, <a href="./references#CD005552-fig-0051" title="">Analysis 8.1</a>). </p> <p>Subgroup analysis showed insufficient evidence to suggest a difference in effect by mean study BMI (test for subgroup difference: P = 0.91, I<sup>2</sup> = 0%). </p> <p><b>8.2 Free androgen index (FAI) (%)</b> </p> <p>Seven trials including 482 women compared the OCP versus metformin combined with the OCP and reported on FAI (<a href="./references#CD005552-bbs2-0004" title="Bhattacharya SM , BiswasB , BasuA . Comparative study of the therapeutic effects of drospirenone (DRSP, 3mg) with ethinyl estradiol (EE, 20 mcg) pill with or without metformin 500 mg in polycystic ovary syndrome (PCOS). In: Fertility and Sterility. 2016, poster P-401:e257. ">Bhattacharya 2016</a>; <a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0019" title="KayaMG , YildirimS , CalapkorurB , AkpekM , UnluhizarciK , KelestimurF . Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecological Endocrinology2015;31:401-5. ">Kaya 2015</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0041" title="SongJ , RuanX , GuM , WangL , WangH , MueckAO . Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological Endocrinology2018;34:413-7. ">Song 2017</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>). </p> <p>Overall, the OCP resulted in an increase of FAI compared to metformin combined with the OCP (MD 0.51, 95% CI 0.30 to 0.71, 7 RCTs, n = 482, I<sup>2</sup>= 28%, <a href="./references#CD005552-fig-0052" title="">Analysis 8.2</a>). </p> <p>Subgroup analysis showed insufficient evidence to suggest a difference in effect by mean study BMI (test for subgroup difference: P = 0.90, I<sup>2</sup> = 0%). </p> <p><b>9. The oral contraceptive pill (OCP) compared to metformin combined with the OCP in adult women (metabolic parameters)</b> </p> <p><b>9.1 Fasting insulin (mLU/L)</b> </p> <p>Twelve trials including 602 women compared the OCP versus metformin combined with the OCP and reported on fasting insulin (<a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>; <a href="./references#CD005552-bbs2-0011" title="ElterK , ImirG , DurmusogluF . Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction2002;17(7):1729-37. ">Elter 2002</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0021" title="BilgirO , KebapcilarL , TanerC , BilgirF , KebapcilarA , BozkayaG , et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). International Medicine2009;48:1193-9. KebapcilarL , YukselA , BozkayaG , TanerCE , KebapcilarAG , BilgirO , et al. Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome. Central European Journal of Medicine2009;4:423-7. ">Kebapcilar 2009b</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0030" title="LvL , LiuY , SunY , TanK . Effects of Metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. Journal of Huazhong University of Science and Technology2005;25:194-7. ">Lv 2005</a>; <a href="./references#CD005552-bbs2-0041" title="SongJ , RuanX , GuM , WangL , WangH , MueckAO . Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological Endocrinology2018;34:413-7. ">Song 2017</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>; <a href="./references#CD005552-bbs2-0044" title="WuJ , ZhuY , JiangY , CaoY . Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology2008;24:392-8. ">Wu 2008</a>). </p> <p>Substantial heterogeneity was detected which may be explained by the difference in effect of the interventions between the mean BMI subgroups (test for subgroup difference: P = 0.0006, I<sup>2</sup> = 86.6%). Therefore, we analysed the results per mean BMI subgroup. </p> <p>The OCP compared to metformin combined with the OCP showed appreciable benefit for metformin combined with the OCP in the BMI &lt; 25 kg/m<sup>2</sup> subgroup (MD 4.77, 95% CI 3.26 to 6.28; 5 RCTs; n = 198; I<sup>2</sup> = 0%), and in the BMI &gt; 25 kg/m<sup>2</sup> &lt; 30 kg/m<sup>2</sup> subgroup (MD 0.25, 95% CI 0.14 to 0.36; 4 RCTs; = 305; n = 4; I<sup>2</sup> = 39%). There was no important effect between the OCP and metformin combined with the OCP in the BMI &gt; 30 kg/m<sup>2</sup> subgroup (MD ‐0.30, 95% CI ‐0.81 to 0.21; 1 RCT; n = 19; I<sup>2</sup> = 0%). </p> <p><b>9.2 Fasting glucose (mmol/L)</b> </p> <p>Ten trials including 529 women compared the OCP versus metformin combined with the OCP and reported on fasting glucose (<a href="./references#CD005552-bbs2-0005" title="BodurS , DundarO , Kanat-PektasM , Kinci MF, TutuncuL . The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled study. Taiwanese Journal of Obstetrics and Gynecology2018;57:411-6. ">Bodur 2018</a>; <a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>; <a href="./references#CD005552-bbs2-0011" title="ElterK , ImirG , DurmusogluF . Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction2002;17(7):1729-37. ">Elter 2002</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0030" title="LvL , LiuY , SunY , TanK . Effects of Metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. Journal of Huazhong University of Science and Technology2005;25:194-7. ">Lv 2005</a>; <a href="./references#CD005552-bbs2-0041" title="SongJ , RuanX , GuM , WangL , WangH , MueckAO . Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological Endocrinology2018;34:413-7. ">Song 2017</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>). </p> <p>Subgroup analysis showed sufficient evidence to suggest a difference in effect by mean study BMI (test for subgroup difference: P = 0.06, I<sup>2</sup> = 64.1%), and therefore we did not pool the results and performed the analysis per BMI subgroup. (<a href="./references#CD005552-fig-0054" title="">Analysis 9.2</a>). The OCP compared to metformin combined with the OCP showed insufficient evidence of a difference in effect in the BMI ≤ 25 kg/m<sup>2</sup> subgroup (MD 0.11, 95% CI ‐0.07 to 0.29; 5 RCTs; n = 205; I<sup>2</sup> = 42%), and in the BMI ≥30 kg/m<sup>2</sup> subgroup (MD ‐0.30, 95% CI ‐0.81 to 0.21; participants = 19; studies = 1; I<sup>2</sup> = 0%). The OCP compared to metformin combined with the OCP showed an increase in fasting glucose levels in subgroup BMI &gt; 25 kg/m<sup>2</sup> &lt; 30 kg/m<sup>2</sup> (MD 1.37, 95% CI 0.42 to 2.32; participants = 385; studies = 7; I<sup>2</sup> = 51%). </p> <p><b>9.3 Total cholesterol (mmol/L)</b><br/><br/>Thirteen trials including 668 women compared the OCP versus metformin combined with the OCP and reported on total cholesterol (<a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>; <a href="./references#CD005552-bbs2-0011" title="ElterK , ImirG , DurmusogluF . Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction2002;17(7):1729-37. ">Elter 2002</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0019" title="KayaMG , YildirimS , CalapkorurB , AkpekM , UnluhizarciK , KelestimurF . Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecological Endocrinology2015;31:401-5. ">Kaya 2015</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0021" title="BilgirO , KebapcilarL , TanerC , BilgirF , KebapcilarA , BozkayaG , et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). International Medicine2009;48:1193-9. KebapcilarL , YukselA , BozkayaG , TanerCE , KebapcilarAG , BilgirO , et al. Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome. Central European Journal of Medicine2009;4:423-7. ">Kebapcilar 2009b</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0030" title="LvL , LiuY , SunY , TanK . Effects of Metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. Journal of Huazhong University of Science and Technology2005;25:194-7. ">Lv 2005</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0041" title="SongJ , RuanX , GuM , WangL , WangH , MueckAO . Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological Endocrinology2018;34:413-7. ">Song 2017</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>).<br/>Overall, there was insufficient evidence to determine whether there was a difference between the OCP and metformin combined with the OCP for total cholesterol (MD 0.07, 95% CI ‐0.05 to 0.17, 13 RCTs, n = 668, I<sup>2</sup> = 55%, <a href="./references#CD005552-fig-0055" title="">Analysis 9.3</a>). </p> <p>Substantial heterogeneity was detected which was not explained by a difference in effect of the interventions between the BMI subgroups (test for subgroup difference: P = 0.43, I<sup>2</sup> = 0%). </p> <p>Findings were not influenced by sensitivity analyses using a random‐effects model (in the presence of unexplained substantial heterogeneity). </p> <p><b>9.4 High‐density lipoprotein (HDL) cholesterol (mmol/L)</b> </p> <p>Thirteen trials including 668 women compared the OCP versus metformin combined with the OCP and reported on HDL cholesterol (<a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>; <a href="./references#CD005552-bbs2-0011" title="ElterK , ImirG , DurmusogluF . Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction2002;17(7):1729-37. ">Elter 2002</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0019" title="KayaMG , YildirimS , CalapkorurB , AkpekM , UnluhizarciK , KelestimurF . Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecological Endocrinology2015;31:401-5. ">Kaya 2015</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0021" title="BilgirO , KebapcilarL , TanerC , BilgirF , KebapcilarA , BozkayaG , et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). International Medicine2009;48:1193-9. KebapcilarL , YukselA , BozkayaG , TanerCE , KebapcilarAG , BilgirO , et al. Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome. Central European Journal of Medicine2009;4:423-7. ">Kebapcilar 2009b</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0030" title="LvL , LiuY , SunY , TanK . Effects of Metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. Journal of Huazhong University of Science and Technology2005;25:194-7. ">Lv 2005</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0041" title="SongJ , RuanX , GuM , WangL , WangH , MueckAO . Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological Endocrinology2018;34:413-7. ">Song 2017</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>). </p> <p>Overall, the OCP resulted in a slight worsening of HDL cholesterol compared to metformin combined with the OCP (MD 0.05, 95% CI 0.01 to 0.09, 13 RCTs, n = 668, I<sup>2</sup>= 70%, <a href="./references#CD005552-fig-0056" title="">Analysis 9.4</a>). </p> <p>Substantial heterogeneity was detected which was not explained by a difference in effect of the interventions between the BMI subgroups (test for subgroup difference: P = 0.40, I<sup>2</sup> = 0%). </p> <p>Findings were not influenced by sensitivity analyses using a random‐effects model (in the presence of unexplained substantial heterogeneity). </p> <p><b>9.5 Low‐density lipoprotein (LDL) cholesterol (mmol/L)</b> </p> <p>Thirteen trials including 668 women compared the OCP versus metformin combined with the OCP and reported on LDL cholesterol (<a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>; <a href="./references#CD005552-bbs2-0011" title="ElterK , ImirG , DurmusogluF . Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction2002;17(7):1729-37. ">Elter 2002</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0019" title="KayaMG , YildirimS , CalapkorurB , AkpekM , UnluhizarciK , KelestimurF . Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecological Endocrinology2015;31:401-5. ">Kaya 2015</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0021" title="BilgirO , KebapcilarL , TanerC , BilgirF , KebapcilarA , BozkayaG , et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). International Medicine2009;48:1193-9. KebapcilarL , YukselA , BozkayaG , TanerCE , KebapcilarAG , BilgirO , et al. Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome. Central European Journal of Medicine2009;4:423-7. ">Kebapcilar 2009b</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0030" title="LvL , LiuY , SunY , TanK . Effects of Metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. Journal of Huazhong University of Science and Technology2005;25:194-7. ">Lv 2005</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0041" title="SongJ , RuanX , GuM , WangL , WangH , MueckAO . Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological Endocrinology2018;34:413-7. ">Song 2017</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>).<br/>Overall, there was insufficient evidence to determine whether there was a difference between the OCP and metformin combined with the OCP for LDL cholesterol (MD 0.04, 95% CI ‐0.05 to 0.14, 13 RCTs, n = 668, I<sup>2</sup> = 25%, <a href="./references#CD005552-fig-0057" title="">Analysis 9.5</a>). </p> <p>Subgroup analysis showed insufficient evidence to suggest a difference in effect by mean study BMI (test for subgroup difference: P = 0.65, I<sup>2</sup> = 0%). </p> <p><b>9.6 Triglycerides (mmol/L)</b><br/><br/>Thirteen trials including 668 women compared the OCP versus metformin combined with the OCP and reported on triglycerides (<a href="./references#CD005552-bbs2-0008" title="CibulaD , FantaM , VrbikovaJ , StanickaS , DvorakovaK , HillM , et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction2005;20(1):180-4. ">Cibula 2005</a>; <a href="./references#CD005552-bbs2-0011" title="ElterK , ImirG , DurmusogluF . Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction2002;17(7):1729-37. ">Elter 2002</a>; <a href="./references#CD005552-bbs2-0012" title="EssahPA , ArrowoodA , CheangKI , AdawadkarSS , StovallDW , NestlerJE . Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility2011;96(2):501-4. ">Essah 2011</a>; <a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0014" title="GlintborgD , AltinokML , MummH , HermannAP , RavnP , AndersenM . Body composition is improved during 12 month's treatment with Metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Endocrine Research2014;99:2584-91. ">Glintborg 2014a</a>; <a href="./references#CD005552-bbs2-0019" title="KayaMG , YildirimS , CalapkorurB , AkpekM , UnluhizarciK , KelestimurF . Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecological Endocrinology2015;31:401-5. ">Kaya 2015</a>; <a href="./references#CD005552-bbs2-0020" title="KebapcilarL , TanerCE , KebapcilarAG , AlacaciogluA , SariI . Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics2009;281:35-42. ">Kebapcilar 2009a</a>; <a href="./references#CD005552-bbs2-0021" title="BilgirO , KebapcilarL , TanerC , BilgirF , KebapcilarA , BozkayaG , et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). International Medicine2009;48:1193-9. KebapcilarL , YukselA , BozkayaG , TanerCE , KebapcilarAG , BilgirO , et al. Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome. Central European Journal of Medicine2009;4:423-7. ">Kebapcilar 2009b</a>; <a href="./references#CD005552-bbs2-0024" title="KumarY , KotwalN , SinghY , UpretiV , SomaniS , Hari KumarKV . A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care2018;7:551-6. ">Kumar 2018</a>; <a href="./references#CD005552-bbs2-0030" title="LvL , LiuY , SunY , TanK . Effects of Metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. Journal of Huazhong University of Science and Technology2005;25:194-7. ">Lv 2005</a>; <a href="./references#CD005552-bbs2-0036" title="MoroF , MorcianoA , TropeaA , SagnellaF , PallaC , ScarinciE , et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4+ CD28 null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Science2013;20(12):1508-17. ">Moro 2013</a>; <a href="./references#CD005552-bbs2-0041" title="SongJ , RuanX , GuM , WangL , WangH , MueckAO . Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological Endocrinology2018;34:413-7. ">Song 2017</a>; <a href="./references#CD005552-bbs2-0043" title="WeiW , ZhaoH , WangA , SuiM , LiangK , DengH , et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology2012;166:99-105. ">Wei 2012</a>).<br/>Overall, there was insufficient evidence to determine whether there was a difference between the OCP and metformin combined with the OCP for total cholesterol (MD ‐0.02, 95% CI ‐0.09 to 0.04, 13 RCTs, n = 668, I<sup>2</sup> = 45%, <a href="./references#CD005552-fig-0058" title="">Analysis 9.6</a>). </p> <p>Subgroup analysis showed insufficient evidence to suggest a difference in effect by mean study BMI (test for subgroup difference: P = 0.43, I<sup>2</sup> = 0%). </p> <p><b>10. Metformin compared to the combined oral contraceptive pill (OCP) in adolescent women (clinical parameters)</b> </p> <p><a href="./full#CD005552-tbl-0004">summary of findings Table 4</a> </p> <p>Four trials including 42 adolescent women compared metformin to the OCP (<a href="./references#CD005552-bbs2-0003" title="Al-ZubeidiH , KleinKO . Randomized clinical trial evaluating Metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome. Journal of Pediatric Endocrinology and Metabolism2015;28:853-8. ">Al‐Zubeidi 2015</a>; <a href="./references#CD005552-bbs2-0002" title="AllenHF , MazzoniC , HeptullaRA , MurrayMA , MillerN , KoenigsL , et al. Randomized controlled trial evaluating response to Metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism2005;18:761-8. ">Allen 2005</a>; <a href="./references#CD005552-bbs2-0010" title="El MaghrabyHA , NafeeT , GuiziryD , ElnasharA . Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 months follow up period. Middle East Fertility Society Journal2015;20:131-7. ">El Maghraby 2015</a>; <a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>). </p> <p><b>Primary outcomes</b> </p> <p><b>10.1 Hirsutism ‐ Clinical Ferriman‐Gallwey (F‐G) score</b> </p> <p>One trial including 16 adolescent women compared metformin versus the OCP and reported hirsutism clinically using the F‐G score (<a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>). </p> <p>There was uncertainty as to whether there was a difference between metformin and the OCP for hirsutism (MD ‐0.40, 95% CI ‐3.42 to 2.62, 1 RCT, n = 16, very low‐quality evidence, <a href="./references#CD005552-fig-0059" title="">Analysis 10.1</a>). This suggests that for a mean F‐G score of 8.6 following the OCP, the mean F‐G score following metformin would be between 3.42 lower to 2.62 higher. </p> <p>Sensitivity analysis restricting studies to low risk of bias (defined in methods section <a href="#CD005552-sec-0037">Sensitivity analysis</a>') was unable to be performed due to no RCTs having a low risk of bias. </p> <p><b>Hirsutism ‐ Subjective visual analogue scale (VAS)</b> </p> <p>No RCT reported on this outcome.</p> <p><b>10.2</b> <b>Hirsutism ‐ Subjective improvement</b> </p> <p>One trial including 80 adolescent women compared metformin versus the OCP and reported hirsutism subjectively (not reported if patient self‐assessed or clinician assessed) (<a href="./references#CD005552-bbs2-0010" title="El MaghrabyHA , NafeeT , GuiziryD , ElnasharA . Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 months follow up period. Middle East Fertility Society Journal2015;20:131-7. ">El Maghraby 2015</a>). </p> <p>There was insufficient evidence to determine whether there was a difference between metformin and the OCP for hirsutism (Peto OR 0.50, 95% CI 0.19 to 1.30, 1 RCT, n = 80, <a href="./references#CD005552-fig-0060" title="">Analysis 10.2</a>). </p> <p><b>10.3 Adverse events: severe (requiring stopping of medication) (gastro‐intestinal and others)</b> </p> <p><b>10.3.1 Others</b> </p> <p>One trial including 80 adolescent women compared metformin versus the OCP and reported severe other adverse events (<a href="./references#CD005552-bbs2-0010" title="El MaghrabyHA , NafeeT , GuiziryD , ElnasharA . Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 months follow up period. Middle East Fertility Society Journal2015;20:131-7. ">El Maghraby 2015</a>). </p> <p>There was uncertainty as to whether there was a difference between metformin and the OCP for severe other adverse events (OR 0.63, 95% CI 0.16 to 2.43, 1 RCT, n = 80, very low‐quality evidence, <a href="./references#CD005552-fig-0061" title="">Analysis 10.3</a>). </p> <p>This suggests that for a severe other adverse event rate of 1.5% following the OCP, the severe other adverse event rate following metformin would be between 2.7% and 30%. </p> <p><b>10.4 Adverse events: minor (gastro‐intestinal and others)</b> </p> <p><b>10.4.1 Gastro‐intestinal</b> </p> <p>One trial including 22 adolescent women compared metformin versus the OCP and reported minor gastro‐intestinal adverse events (<a href="./references#CD005552-bbs2-0003" title="Al-ZubeidiH , KleinKO . Randomized clinical trial evaluating Metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome. Journal of Pediatric Endocrinology and Metabolism2015;28:853-8. ">Al‐Zubeidi 2015</a>). </p> <p>There was uncertainty as to whether there was a difference between metformin and the OCP for minor gastro‐intestinal adverse events (OR 11.67, 95% CI 0.53 to 258.56, 1 RCT, n = 12, very low‐quality evidence, <a href="./references#CD005552-fig-0062" title="">Analysis 10.4</a>). This suggests that for a minor (gastro‐intestinal) adverse event rate of 0% following the OCP, the minor (gastro‐intestinal) adverse event rate following metformin would be between 0% and 0%. </p> <p><b>Secondary outcomes</b> </p> <p><b>Improved menstrual pattern (i.e. shortening of intermenstrual days)</b> </p> <p>No RCT reported on this outcome.</p> <p><b>10.5 Improved menstrual pattern (i.e. an initiation of menses or cycle regularity)</b> </p> <p>One trial including 80 adolescent women compared metformin versus the OCP and reported improvement in menstrual pattern (<a href="./references#CD005552-bbs2-0010" title="El MaghrabyHA , NafeeT , GuiziryD , ElnasharA . Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 months follow up period. Middle East Fertility Society Journal2015;20:131-7. ">El Maghraby 2015</a>). </p> <p>There was uncertainty as to whether there was a difference between metformin and the OCP for improvement of menstrual pattern (OR 0.10, 95% CI 0.01 to 1.92, 1 RCT, n = 80, very low‐quality evidence, <a href="./references#CD005552-fig-0063" title="">Analysis 10.5</a>). </p> <p>Sensitivity analysis restricting studies to low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>') was unable to be performed due to no RCTs having a low risk of bias. </p> <p>One trial including 34 adolescent women compared metformin versus the OCP and reported improvement in menstrual pattern but did not report supporting data, and therefore could not be included in any meta‐analysis in this review (<a href="./references#CD005552-bbs2-0003" title="Al-ZubeidiH , KleinKO . Randomized clinical trial evaluating Metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome. Journal of Pediatric Endocrinology and Metabolism2015;28:853-8. ">Al‐Zubeidi 2015</a>). </p> <p><b>Acne ‐ visual analogue scale (VAS)</b> </p> <p>No RCT reported on this outcome.</p> <p><b>Acne ‐ Subjective improvement</b> </p> <p>No RCT reported on this outcome.</p> <p><b>Diagnosis of type II diabetes mellitus</b> </p> <p>No RCT reported on this outcome.</p> <p><b>10.6 Body weight (kg)</b> </p> <p>Two trials including 111 adolescent women compared metformin versus the OCP and reported on body weight (<a href="./references#CD005552-bbs2-0002" title="AllenHF , MazzoniC , HeptullaRA , MurrayMA , MillerN , KoenigsL , et al. Randomized controlled trial evaluating response to Metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism2005;18:761-8. ">Allen 2005</a>; <a href="./references#CD005552-bbs2-0010" title="El MaghrabyHA , NafeeT , GuiziryD , ElnasharA . Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 months follow up period. Middle East Fertility Society Journal2015;20:131-7. ">El Maghraby 2015</a>). </p> <p>Substantial heterogeneity was detected which may be explained by the difference in effect of the interventions between the mean BMI subgroups (test for subgroup difference: P = 0.04, I<sup>2</sup> = 77.1%) (<a href="./references#CD005552-fig-0064" title="">Analysis 10.6</a>) . Therefore, we analysed the results per mean BMI subgroup. The effect of metformin compared to the OCP showed an appreciable benefit for metformin in subgroup, mean BMI not stated (MD ‐19.00, 95% CI ‐20.81 to ‐17.19; 1 RCT; n = 80; I<sup>2</sup> = 0%), and no appreciable benefit/harm in subgroup BMI ≥30 kg/m<sup>2</sup> (MD ‐2.60, 95% CI ‐17.87 to 12.67; 1 RCT; n = 31; I<sup>2</sup> = 0%). </p> <p><b>10.7 Body Mass Index (kg/m<sup>2</sup>)</b> </p> <p>Three trials including 69 adolescent women compared metformin versus the OCP and reported on BMI (<a href="./references#CD005552-bbs2-0003" title="Al-ZubeidiH , KleinKO . Randomized clinical trial evaluating Metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome. Journal of Pediatric Endocrinology and Metabolism2015;28:853-8. ">Al‐Zubeidi 2015</a>; <a href="./references#CD005552-bbs2-0002" title="AllenHF , MazzoniC , HeptullaRA , MurrayMA , MillerN , KoenigsL , et al. Randomized controlled trial evaluating response to Metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism2005;18:761-8. ">Allen 2005</a>; <a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>). </p> <p>Overall, there was uncertainty as to whether there was a difference between metformin and the OCP for BMI (MD ‐1.45, 95% CI ‐5.08 to 2.17, 3 RCTs, n = 69, I<sup>2</sup> = 0%, very low‐quality evidence, <a href="./references#CD005552-fig-0065" title="">Analysis 10.7</a>). This suggests that for a mean BMI of 36 following the OCP, the mean BMI following metformin would be between 5.08 lower to 2.17 higher. </p> <p>Subgroup analysis was not applicable as all three RCTs were in the same mean study BMI subgroup. </p> <p>Sensitivity analysis restricting studies to low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>') was unable to be performed due to no RCTs having a low risk of bias. </p> <p><b>10.8 Blood pressure ‐ systolic (mmHg)</b> </p> <p>One trial including 16 adolescent women compared metformin versus the OCP and reported on systolic blood pressure (<a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>). </p> <p>There was insufficient evidence to determine whether there was a difference between metformin and the OCP for systolic blood pressure (MD ‐1.40, 95% CI ‐12.87 to 10.07, 1 RCT, n = 16, <a href="./references#CD005552-fig-0066" title="">Analysis 10.8</a>). </p> <p><b>10.9 Blood pressure ‐ diastolic (mmHg)</b> </p> <p>One trial including 16 adolescent women compared metformin versus the OCP and reported on diastolic blood pressure (<a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>). </p> <p>There was insufficient evidence to determine whether there was a difference between metformin and the OCP for diastolic blood pressure (MD ‐5.10, 95% CI ‐13.69 to 3.49, 1 RCT, n = 16, <a href="./references#CD005552-fig-0067" title="">Analysis 10.9</a>). </p> <p><b>11. Metformin compared to the combined oral contraceptive pill (OCP) in adolescent women (hormonal parameters)</b> </p> <p><b>11.1 Serum total testosterone (nmol/L)</b> </p> <p>Three trials including 69 adolescent women compared metformin versus the OCP and reported on serum total testosterone (<a href="./references#CD005552-bbs2-0003" title="Al-ZubeidiH , KleinKO . Randomized clinical trial evaluating Metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome. Journal of Pediatric Endocrinology and Metabolism2015;28:853-8. ">Al‐Zubeidi 2015</a>; <a href="./references#CD005552-bbs2-0002" title="AllenHF , MazzoniC , HeptullaRA , MurrayMA , MillerN , KoenigsL , et al. Randomized controlled trial evaluating response to Metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism2005;18:761-8. ">Allen 2005</a>; <a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>). </p> <p>There was insufficient evidence to determine whether there was a difference between metformin and the OCP for serum total testosterone (MD 0.23, 95% CI ‐0.21 to 0.68, 3 RCTs, n = 69, I<sup>2</sup>= 0%, <a href="./references#CD005552-fig-0068" title="">Analysis 11.1</a>). </p> <p>Subgroup analysis was not applicable as all three RCTs were in the same mean study BMI subgroup. </p> <p><b>11.2 Free androgen index (FAI) (%)</b> </p> <p>One trial including 16 adolescent women compared metformin versus the OCP and reported on FAI (<a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>). </p> <p>Metformin resulted in an increase of FAI compared to the OCP (MD 8.50, 95% CI 1.99 to 15.01, 1 RCT, n = 16, <a href="./references#CD005552-fig-0069" title="">Analysis 11.2</a>). </p> <p><b>12. Metformin compared to the combined oral contraceptive pill (OCP) in adolescent women (metabolic parameters)</b> </p> <p><b>12.1 Fasting insulin (mLU/L)</b> </p> <p>Two trials including 53 adolescent women compared metformin versus the OCP and reported on fasting insulin (<a href="./references#CD005552-bbs2-0003" title="Al-ZubeidiH , KleinKO . Randomized clinical trial evaluating Metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome. Journal of Pediatric Endocrinology and Metabolism2015;28:853-8. ">Al‐Zubeidi 2015</a>; <a href="./references#CD005552-bbs2-0002" title="AllenHF , MazzoniC , HeptullaRA , MurrayMA , MillerN , KoenigsL , et al. Randomized controlled trial evaluating response to Metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism2005;18:761-8. ">Allen 2005</a>). </p> <p>Overall, there was insufficient evidence to determine whether there was a difference between metformin and the OCP for fasting insulin (MD 4.55, 95% CI ‐4.82 to 13.92, 2 RCTs, n = 53, I<sup>2</sup>= 21%, <a href="./references#CD005552-fig-0070" title="">Analysis 12.1</a>). </p> <p>Subgroup analysis was not applicable as both RCTs were in the same mean study BMI subgroup. </p> <p><b>12.2 Fasting glucose (mmol/L)</b><br/><br/>One trial including 16 adolescent women compared metformin versus the OCP and reported on fasting glucose (<a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>). </p> <p>There was insufficient evidence to determine whether there was a difference between metformin and the OCP for fasting glucose (MD 0.11, 95% CI ‐0.55 to 0.77, 1 RCT, n = 16, <a href="./references#CD005552-fig-0071" title="">Analysis 12.2</a>). </p> <p><b>12.3 Total cholesterol (mmol/L)</b><br/><br/>Two trials including 47 adolescent women compared metformin versus the OCP and reported on total cholesterol (<a href="./references#CD005552-bbs2-0002" title="AllenHF , MazzoniC , HeptullaRA , MurrayMA , MillerN , KoenigsL , et al. Randomized controlled trial evaluating response to Metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism2005;18:761-8. ">Allen 2005</a>; <a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>). </p> <p>Overall, metformin resulted in an improvement of total cholesterol compared to the OCP (MD ‐1.12, 95% CI ‐1.66 to ‐0.58, 2 RCTs, n = 47, I<sup>2</sup>= 0%, <a href="./references#CD005552-fig-0072" title="">Analysis 12.3</a>). </p> <p>Subgroup analysis was not applicable as both RCTs were in the same mean study BMI subgroup. </p> <p><b>12.4 High‐density lipoprotein (HDL) cholesterol (mmol/L)</b> </p> <p>Two trials including 47 adolescent women compared metformin versus the OCP and reported on HDL cholesterol (<a href="./references#CD005552-bbs2-0002" title="AllenHF , MazzoniC , HeptullaRA , MurrayMA , MillerN , KoenigsL , et al. Randomized controlled trial evaluating response to Metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism2005;18:761-8. ">Allen 2005</a>; <a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>). </p> <p>Overall, there was insufficient evidence to determine whether there was a difference between metformin and the OCP for HDL cholesterol (MD 0.12, 95% CI ‐0.10 to 0.34, 2 RCTs, n = 47, I<sup>2</sup>= 6%, <a href="./references#CD005552-fig-0073" title="">Analysis 12.4</a>). </p> <p>Subgroup analysis was not applicable as both RCTs were in the same mean study BMI subgroup. </p> <p><b>12.5 Low‐density lipoprotein ( LDL) cholesterol (mmol/L)</b><br/><br/>Two trials including 47 adolescent women compared metformin versus the OCP and reported on LDL cholesterol (<a href="./references#CD005552-bbs2-0002" title="AllenHF , MazzoniC , HeptullaRA , MurrayMA , MillerN , KoenigsL , et al. Randomized controlled trial evaluating response to Metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism2005;18:761-8. ">Allen 2005</a>; <a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>). </p> <p>Overall, metformin resulted in an improvement of LDL cholesterol compared to the OCP (MD ‐0.92, 95% CI ‐1.49 to ‐0.35, 2 RCTs, n = 47, I<sup>2</sup>= 0%, <a href="./references#CD005552-fig-0074" title="">Analysis 12.5</a>). </p> <p>Subgroup analysis was not applicable as both RCTs were in the same mean study BMI subgroup. </p> <p><b>12.6 Triglycerides (mmol/L)</b><br/><br/>Three trials including 69 adolescent women compared metformin versus the OCP and reported on triglycerides (<a href="./references#CD005552-bbs2-0004" title="Bhattacharya SM , BiswasB , BasuA . Comparative study of the therapeutic effects of drospirenone (DRSP, 3mg) with ethinyl estradiol (EE, 20 mcg) pill with or without metformin 500 mg in polycystic ovary syndrome (PCOS). In: Fertility and Sterility. 2016, poster P-401:e257. ">Bhattacharya 2016</a>; <a href="./references#CD005552-bbs2-0002" title="AllenHF , MazzoniC , HeptullaRA , MurrayMA , MillerN , KoenigsL , et al. Randomized controlled trial evaluating response to Metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism2005;18:761-8. ">Allen 2005</a>; <a href="./references#CD005552-bbs2-0016" title="HoegerK , DavidsonK , KochmanL , CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008a</a>). </p> <p>Overall, there was insufficient evidence to determine whether there was a difference between metformin and the OCP for triglycerides (MD ‐0.13, 95% CI ‐0.37 to 0.10, 3 RCTs, n = 69, I<sup>2</sup>= 9%, <a href="./references#CD005552-fig-0075" title="">Analysis 12.6</a>). </p> <p>Subgroup analysis was not applicable as all three RCTs were in the same mean study BMI subgroup. </p> <p><b>Metformin compared to metformin combined with the oral contraceptive pill (OCP) in adolescent women</b> </p> <p>There were no trials identified comparing metformin with metformin combined with the OCP in adolescent women on the selected outcomes for this review. </p> <p><b>13. The oral contraceptive pill (OCP) compared to metformin combined with the OCP in adolescent women (clinical parameters)</b> </p> <p><a href="./full#CD005552-tbl-0006">summary of findings Table 6</a> </p> <p>One trial including 36 adolescent women compared metformin combined with the OCP compared to the OCP (<a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>). </p> <p><b>Primary outcomes</b> </p> <p><b>13.1 Hirsutism ‐ Clinical Ferriman‐Gallwey (F‐G)</b> <b>score</b> </p> <p>One trial including 32 women compared the OCP versus metformin combined with the OCP and reported hirsutism clinically using the F‐G score (<a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>). </p> <p>There was uncertainty as to whether there was a difference between the OCP and metformin combined with the OCP for hirsutism (MD 0.80, 95% CI ‐1.19 to 2.79, 1 RCT, n = 32, very low‐quality evidence, <a href="./references#CD005552-fig-0076" title="">Analysis 13.1</a>). This suggests that for a mean F‐G score of 6.2 following metformin combined with the OCP, the mean F‐G score following the OCP would be between 1.19 lower to 2.79 higher. </p> <p>Sensitivity analysis restricting studies to low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>') was unable to be performed due to no RCTs having a low risk of bias. </p> <p><b>Hirsutism ‐ subjective visual analogue scale (VAS)</b> </p> <p>No RCT reported on this outcome.</p> <p><b>Hirsutism ‐ subjective improvement</b> </p> <p>No RCT reported on this outcome.</p> <p><b>13.2 Adverse events: severe (requiring stopping of medication) (gastro‐intestinal and others)</b> </p> <p><b>13.2.1 Gastro‐intestinal</b> </p> <p>One trial including 36 women compared the OCP versus metformin combined with the OCP and reported severe gastro‐intestinal adverse events (<a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>). </p> <p>There was uncertainty as to whether there was a difference between the OCP and metformin combined with the OCP for severe gastro‐intestinal adverse event (OR 1.00, 95% CI 0.06 to 17.33, 1 RCT, n = 36, very low‐quality evidence, <a href="./references#CD005552-fig-0077" title="">Analysis 13.2</a>). This suggests that for a severe gastro‐intestinal adverse event rate of 5.6% following metformin combined with the OCP, the severe gastro‐intestinal adverse event rate following the OCP would be between 0.4% and 50.5%. </p> <p><b>Adverse events ‐</b> <b>minor (gastro‐intestinal and others)</b> </p> <p>No RCT reported on this outcome.</p> <p><b>Secondary outcomes</b> </p> <p><b>Improved menstrual pattern (i.e. shortening of intermenstrual days)</b> </p> <p>No RCT reported on this outcome.</p> <p><b>Improved menstrual pattern (i.e. an initiation of menses or cycle regularity)</b> </p> <p>No RCT reported on this outcome.</p> <p><b>Acne ‐ visual analogue scale (VAS)</b> </p> <p>No RCT reported on this outcome.</p> <p><b>Acne ‐ subjective improvement</b> </p> <p>No RCT reported on this outcome.</p> <p><b>Diagnosis of Type II diabetes mellitus</b> </p> <p>No RCT reported on this outcome.</p> <p><b>Body weight (kg)</b> </p> <p>No RCT reported on this outcome.</p> <p><b>13.3 Body mass index (kg/m<sup>2</sup>)</b> </p> <p>One trial including 32 women compared the OCP versus metformin combined with the OCP and reported BMI (<a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>). </p> <p>There was uncertainty as to whether there was a difference between the OCP and metformin combined with the OCP for BMI (MD 1.50, 95% CI ‐1.63 to 4.63, 1 RCT, n = 32, very low‐quality evidence, <a href="./references#CD005552-fig-0078" title="">Analysis 13.3</a>). This suggests that for a mean BMI of 32.4 following metformin combined with the OCP, the mean BMI following the OCP would be between 1.63 lower to 4.63 higher. </p> <p>Sensitivity analysis restricting studies to low risk of bias (defined in methods section '<a href="#CD005552-sec-0037">Sensitivity analysis</a>') was unable to be performed due to no RCTs having a low risk of bias. </p> <p><b>13.4 Blood pressure ‐ systolic (mmHg)</b> </p> <p>One trial including 32 women compared the OCP versus metformin combined with the OCP and reported systolic blood pressure (<a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>). </p> <p>There was insufficient evidence to determine whether there was a difference between the OCP and metformin combined with the OCP for systolic blood pressure (MD ‐3.50, 95% CI ‐12.65 to 5.65, 1 RCT, n = 32, <a href="./references#CD005552-fig-0079" title="">Analysis 13.4</a>). </p> <p><b>13.5 Blood pressure ‐ diastolic (mmHg)</b> </p> <p>One trial including 32 women compared the OCP versus metformin combined with the OCP and reported diastolic blood pressure (<a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>). </p> <p>There was insufficient evidence to determine whether there was a difference between the OCP and metformin combined with the OCP for diastolic blood pressure (MD ‐1.00, 95% CI ‐6.94 to 4.94, 1 RCT, n = 32, <a href="./references#CD005552-fig-0080" title="">Analysis 13.5</a>). </p> <p><b>14 The oral contraceptive pill (OCP) compared to metformin combined with the OCP in adolescent women (hormonal parameters)</b> </p> <p><b>14.1 Serum total testosterone (nmol/L)</b> </p> <p>One trial including 32 women compared the OCP versus metformin combined with the OCP and reported serum total testosterone (<a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>) </p> <p>There was insufficient evidence to determine whether there was a difference between the OCP and metformin combined with the OCP for serum total testosterone (MD 0.37, 95% CI ‐0.29 to 1.03, 1 RCT, n = 32, <a href="./references#CD005552-fig-0081" title="">Analysis 14.1</a>). </p> <p><b>14.2 Free androgen index (FAI) (%)</b> </p> <p>One trial including 32 women compared the OCP versus metformin combined with the OCP and reported FAI (<a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>). </p> <p>There was insufficient evidence to determine whether there was a difference between the OCP and metformin combined with the OCP for FAI (MD 0.70, 95% CI ‐0.32 to 1.72, 1 RCT, n = 32, <a href="./references#CD005552-fig-0082" title="">Analysis 14.2</a>). </p> <p><b>15 The oral contraceptive pill (OCP) compared to metformin combined with the OCP in adolescent women (metabolic parameters)</b> </p> <p><b>Fasting insulin (mLU/L)</b> </p> <p>No RCT reported on this outcome.</p> <p><b>15.1 Fasting glucose (mmol/L)</b> </p> <p>One trial including 32 women compared the OCP versus metformin combined with the OCP and reported fasting glucose (<a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>). </p> <p>There was insufficient evidence to determine whether there was a difference between the OCP and metformin combined with the OCP for fasting glucose (MD 0.03, 95% CI ‐0.23 to 0.29, 1 RCT, n = 32, <a href="./references#CD005552-fig-0083" title="">Analysis 15.1</a>). </p> <p><b>15.2 Total cholesterol (mmol/L)</b> <br/>One trial including 32 women compared the OCP versus metformin combined with the OCP and reported total cholesterol (<a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>). </p> <p>There was insufficient evidence to determine whether there was a difference between the OCP and metformin combined with the OCP for total cholesterol (MD ‐0.50, 95% CI ‐1.32 to 0.32, 1 RCT, n = 32, <a href="./references#CD005552-fig-0084" title="">Analysis 15.2</a>). </p> <p><b>15.3 High‐density lipoprotein (HDL) cholesterol (mmol/L)</b> </p> <p>One trial including 32 women compared the OCP versus metformin combined with the OCP and reported HDL cholesterol (<a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>) </p> <p>There was insufficient evidence to determine whether there was a difference between the OCP and metformin combined with the OCP for HDL cholesterol (MD 0.23, 95% CI ‐0.00 to 0.46, 1 RCT, n = 32, <a href="./references#CD005552-fig-0085" title="">Analysis 15.3</a>). </p> <p><b>15.4 Low‐density lipoprotein (LDL) cholesterol (mmol/L)</b><br/><br/>One trial including 32 women compared metformin combined with the OCP versus the OCP and reported LDL cholesterol (<a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>). </p> <p>There was insufficient evidence to determine whether there was a difference between the OCP and metformin combined with the OCP for LDL cholesterol (MD ‐0.29, 95% CI ‐0.99 to 0.41, 1 RCT, n = 32, <a href="./references#CD005552-fig-0086" title="">Analysis 15.4</a>). </p> <p><b>15.5 Triglycerides (mmol/L)</b><br/><br/>One trial including 32 women compared metformin combined with the OCP versus the OCP and reported triglycerides (<a href="./references#CD005552-bbs2-0017" title="HoegerK , Davidson K Kochman L, CherryT , KopinL , GuzickS . The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism2008;93:4299-306. ">Hoeger 2008b</a>). </p> <p>There was insufficient evidence to determine whether there was a difference between the OCP and metformin combined with the OCP for triglycerides (MD 0.02, 95% CI ‐0.68 to 0.72, 1 RCT, n = 32, <a href="./references#CD005552-fig-0087" title="">Analysis 15.5</a>). </p> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005552-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005552-sec-0050"></div> <section id="CD005552-sec-0051"> <h3 class="title" id="CD005552-sec-0051">Summary of main results</h3> <p><b>Metformin compared to the oral contraceptive pill (OCP) in adult women</b> </p> <p><i>Main outcomes</i> </p> <p>Metformin, when compared with the OCP, may be less effective in improving hirsutism in the subgroup BMI &gt; 25/kg2 &lt; BMI 30kg/m<sup>2</sup> but we are uncertain of the effect of metformin compared to the OCP on hirsutism in subgroups body mass index (BMI) &lt; 25 kg/m<sup>2</sup> and BMI &gt; 30 kg/m<sup>2</sup>. Metformin may result in a higher incidence of severe gastro‐intestinal side‐effects and a lower incidence of severe other side effects compared to the OCP. There were no trials reporting on minor adverse events. Metformin may be less effective in improving menstrual pattern compared to the OCP by lengthening of intermenstrual days. In terms of an initiation of menses or cycle regularity, Metformin compared to the OCP may be less effective in improving menstrual pattern in subgroup BMI ≤ 25 kg/m<sup>2</sup> but we are uncertain if metformin is less effective in improving menstrual pattern in subgroup BMI &gt; 25 kg/m<sup>2</sup> &lt; 30kg/m<sup>2</sup> and uncertain of the effect of metformin compared to the OCP in subgroup BMI ≥ 30 kg/m<sup>2</sup> and subgroup BMI not stated. There was uncertainty as to whether there was a difference between metformin and the OCP for acne. We are uncertain if metformin decreases BMI compared to the OCP in subgroup BMI &lt; 25 kg/m<sup>2</sup> and subgroup BMI &gt; 30 kg/m<sup>2</sup>,whist there is uncertainty in the effect of metformin compared to the OCP on BMI in subgroup BMI &gt; 25 kg/m<sup>2</sup> &lt; 30 kg/m<sup>2</sup>. The quality of the evidence for all reported main outcomes between these two interventions were either low (indicating that our confidence in the effect estimate is limited and that the true effect may be substantially different from the estimate of the effect), or very low (indicating that we have very little confidence in the effect estimate and that the true effect is likely to be substantially different from the estimate of effect). </p> <p><i>Other outcomes</i> </p> <p>Metformin, when compared to the OCP, resulted in an improvement of the clinical parameters systolic blood pressure with insufficient evidence to determine whether there was a difference in diagnosis of type 2 diabetes mellitus, diastolic blood pressure and body weight. Metformin was less effective in improving hormonal parameters serum total testosterone and free androgen index (FAI) compared to the OCP. In terms of metabolic parameters, metformin resulted in an improvement in fasting insulin, glucose, total cholesterol and triglycerides with insufficient evidence to determine whether there was a difference in fasting high‐density lipoprotein (HDL) or low‐density lipoprotein (LDL) cholesterol when compared to the OCP. </p> <p><b>Metformin compared to metformin combined with the OCP in adult women</b> </p> <p><i>Main outcomes</i> </p> <p>Metformin alone when compared with <i>m</i>etformin combined with the OCP, may be less effective in improving hirsutism, but we are uncertain as to whether there is a difference between these two interventions for severe gastro‐intestinal adverse events and severe other adverse events requiring stopping medication. There were no trials reporting on minor adverse events, menstrual pattern or acne. Metformin may improve BMI compared to metformin combined with the OCP. The quality of the evidence for all reported main outcomes between these two interventions was low. </p> <p><i>Other outcomes</i> </p> <p>Metformin, when compared to metformin combined with the OCP, resulted in an improvement of the clinical parameters body weight, systolic blood pressure, and diastolic blood pressure with no randomised controlled trials (RCTs) reporting on diagnosis of type 2 diabetes mellitus. Metformin alone was less effective in improving hormonal parameters serum total testosterone and FAI compared to metformin combined with the OCP. In terms of metabolic parameters, metformin resulted in an improvement in fasting insulin, glucose, total cholesterol (in the presence of unexplained substantial heterogeneity), and triglycerides with insufficient evidence to determine whether there was a difference in fasting HDL or LDL cholesterol when compared to metformin combined with the OCP. </p> <p><b>The OCP compared to metformin combined with the OCP in adult women</b> </p> <p><i>Main outcomes</i> </p> <p>The OCP alone when compared with metformin combined with the OCP, may be less effective in improving hirsutism. The OCP may result in a lower incidence of severe gastro‐intestinal side effects, but there is uncertainty as to whether there is a difference for other severe adverse events when compared to metformin combined with the OCP. The OCP may have a lower incidence of minor (gastro‐intestinal) adverse events compared to metformin combined with the OCP. There were no trials reporting on menstrual pattern. The OCP alone may slightly improve acne compared to metformin combined with the OCP. We are uncertain as to whether there is a difference between these two interventions for BMI. The quality of the evidence for all reported main outcomes between these two interventions were low except for the outcome of BMI which had very low‐quality evidence . </p> <p><i>Other outcomes</i> </p> <p>There was insufficient evidence to determine whether there was a difference in the clinical parameters body weight, systolic blood pressure, and diastolic blood pressure when comparing the OCP to metformin combined with the OCP, with no RCTs reporting on diagnosis of type 2 diabetes mellitus. The OCP was less effective in improving hormonal parameters serum total testosterone and FAI compared to metformin combined with the OCP. In terms of metabolic parameters, the OCP was less effective in improving fasting insulin and glucose with insufficient evidence to determine whether there was a difference in fasting lipids (total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides) when compared to metformin combined with the OCP. </p> <p><b>Metformin compared to the OCP in adolescent women</b> </p> <p><i>Main outcomes</i> </p> <p>We are uncertain as to whether there is a difference between metformin, when compared to the OCP, in the outcomes hirsutism, adverse events (severe other requiring stopping medication and minor gastro‐intestinal), menstrual pattern, acne (no trials reporting this outcome) and BMI. The quality of the evidence for all reported main outcomes between these two interventions were very low due primarily to very serious imprecision as the evidence for all reported main outcomes derived from a single RCT. </p> <p><i>Other outcomes</i> </p> <p>Metformin, when compared to the OCP, resulted in an improvement of the clinical parameter body weight with insufficient evidence to determine whether there was a difference in systolic or diastolic blood pressure and no RCTs reporting on diagnosis of type 2 diabetes mellitus. Metformin was less effective in improving the hormonal parameter FAI when compared to the OCP, with insufficient evidence to determine whether there was a difference in serum total testosterone. In terms of metabolic parameters, metformin resulted in an improvement in fasting total and LDL cholesterol with insufficient evidence to determine whether there was a difference in fasting insulin, glucose, HDL cholesterol and triglycerides when compared to the OCP. </p> <p><b>Metformin compared to metformin combined with the OCP in adolescent women</b> </p> <p>There were no trials identified comparing metformin versus metformin combined with the OCP in adolescent women reporting on the outcomes for this review. </p> <p><b>The OCP compared to metformin combined with the OCP in adolescent women</b> </p> <p><i>Main outcomes</i> </p> <p>We are uncertain as to whether there is a difference between the OCP alone when compared with metformin combined with the OCP, in the outcomes hirsutism, adverse events (both severe requiring stopping medication and minor (no trials reporting this latter outcome)), menstrual pattern (no trials reporting this outcome), acne (no trials reporting this outcome), and BMI. The quality of the evidence for all reported main outcomes between these two interventions were very low due primarily to very serious imprecision as the evidence for all reported main outcomes derived from a single RCT. </p> <p><i>Other outcomes</i> </p> <p>There was insufficient evidence to determine whether there was a difference in the clinical parameters systolic and diastolic blood pressure with no RCTs reporting on diagnosis of type 2 diabetes mellitus and body weight. There was insufficient evidence to determine whether there was a difference in the hormonal parameters serum total testosterone and FAI when comparing the OCP with metformin combined with the OCP. In terms of metabolic parameters, there was also insufficient evidence to determine whether there was a difference in fasting glucose and lipids (total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides) when comparing the OCP with metformin combined with the OCP, with no RCTs reporting fasting insulin. </p> </section> <section id="CD005552-sec-0052"> <h3 class="title" id="CD005552-sec-0052">Overall completeness and applicability of evidence</h3> <p>In adult women with PCOS, we found sufficient studies reporting on our main clinical outcomes of hirsutism, menstrual pattern and adverse events to answer our main review questions for our main comparison of metformin compared to the OCP. However, there were only two RCTs reporting on the other main clinical outcome of acne for this comparison. For the other comparisons for this review (metformin versus metformin in combination with the OCP; and the OCP versus metformin in combination with the OCP), there was only a small number of RCTs reporting on our main clinical outcomes. In adolescent women with PCOS, there was only a small number of RCTs reporting on our main clinical outcomes for all three comparisons. Unfortuately, the predominantly low or very low quality of the evidence provided by the included studies limited the confidence we have in the effect estimate for our main clinical outcomes for all three comparisons in both adult and adolescent women with PCOS. </p> <p>In terms of the applicability of the evidence with respect to the participants, this review includes 44 RCTs with 2253 PCOS women who met the Rotterdam diagnostic criteria for PCOS (<a href="./references#CD005552-bbs2-0114" title="The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction2004;19:41-7.">Rotterdam ESHRE 2004</a>) in 43/44 studies as 1/44 studies did not described any diagnostic criteria. 2047 adult women were recruited in 39/44 studies and 206 adolescent women were recruited in 5/44 studies. The women with PCOS were recruited in and thus representative of a number of continents around the world including Europe (see section on description of studies for list of European countries), North America (USA), Africa (Egypt), Asia (Iran, Iraq and Turkey) and Australia. </p> <p>In terms of the applicability of the evidence with respect to reporting results per pre‐specified population mean BMI subgroups (e.g. BMI ≤ 25kg/m<sup>2</sup>, BMI &gt; 25kg/m<sup>2</sup> but &lt; 30kg/m<sup>2</sup>, BMI ≥30kg/m<sup>2</sup>) in the presence of explained (by the BMI subgroup) significant heterogeneity, it is important to note that when interpreting these subgroup findings that the subgroups were defined on this basis of mean BMI, rather than on the basis of a population restricted to a certain BMI range according to strict study inclusion criteria. Participants in the particular subgroup may be very heterogeneous with some having a BMI much lower or higher than the mean BMI and thus does not imply that participants in the study generally have a BMI close to that value. Therefore, caution is required in that the translation of findings into treatment recommendations from a population with a particular mean BMI is different from saying that this is the effect in a population restricted to a given BMI range and thus should not be misinterpreted as showing the latter. </p> <p>In terms of the applicability of the evidence with respect to the interventions, all the studies compared the relevant interventions of metformin versus the OCP (alone or in combination). There were no trials identified comparing metformin with metformin combined with the OCP in adolescent women on the selected outcomes for this review. The daily dose of metformin ranged from 500 mg to 2000 mg in the included studies. This review compared OCPs as a group, however, different types and doses of oestrogen and progesterone were used. Indeed, 31 trials used ethinyl estradiol (EE) 35 µg combined with cyproterone acetate (CPA) 2 mg (EE 35/CPA2) as the OCP, four trials used EE 35 µg combined with drospirenone 3 mg, three trials used EE 35 µg combined with desogestrel 150, three trials used EE 35 µg combined with norgestimate 0.25, one trial used EE 30 µg with norethisterone 1mg, one trial used EE 20 µg with drospirenone 3 µg, and one trial used EE 30 µg with progestin 15 mg. Therefore, the results of this review are generally applicable to these specific types of the OCP. </p> <p>In terms of the applicability of the evidence with respect to the outcomes, the review investigated the main clinically important outcomes of hirsutism, acne, improvement of menstrual pattern, BMI and adverse events for the three comparisons (the OCP versus metformin, metformin versus metformin combined with the OCP, and the OCP versus metformin combined with the OCP) in both adolescent and adult women with PCOS separately. The majority of the outcomes reported in the studies were hirsutism, improvement of menses (the OCP versus metformin), BMI and adverse outcomes with only two studies reporting on acne. There was only one study identified reporting on the diagnosis of type 2 diabetes mellitus (the OCP versus metformin). The review also investigated the important surrogate outcomes related to the clinically important outcomes including hormonal (serum total testosterone and FAI) and metabolic (fasting insulin, glucose and lipids [total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides) parameters. </p> <p>There were four studies, all recruiting adult women with PCOS, that measured outcomes but had no 'usable' data. Two of these studies were for the comparison of metformin versus the OCP, one study was for the outcome of 'Hirsutism ‐ Subjective improvement' and the other study was for the outcome of 'Acne ‐ Subjective improvement'. One study was for the comparison of metformin versus metformin combined with the OCP for the outcome of severe adverse events. The last such study was for the comparison of the OCP versus metformin combined with the OCP for the comparison of minor adverse events. </p> <p>The review findings both support and will help guide the current common practice of using the OCP and metformin, either alone or in combination, in the long‐term treatment of both adult and adolescent women with PCOS. </p> </section> <section id="CD005552-sec-0053"> <h3 class="title" id="CD005552-sec-0053">Quality of the evidence</h3> <p>Evidence quality for the main outcomes of the review ranged from very low to low based on GRADE assessment. The main limitations were risk of bias (very few studies at low risk of bias defined as low risk of selection bias (both random sequence generation and allocation concealment) and not at high risk of bias in any domain), imprecision and inconsistency. Only two of 44 studies in total were judged to be at low risk of bias (<a href="./references#CD005552-bbs2-0013" title="FengW , Jia Y-Y, Zhang D-Y, Shi H-R. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology2016;32(2):147-50. ">Feng 2016</a>; <a href="./references#CD005552-bbs2-0015" title="HarborneL , FlemingR , LyallH , SattarN , NormanJ . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2003;88(9):4116-23. ">Harborne 2003</a>). This review had six comparisons as follows. </p> <p>1. Metformin compared to the OCP in adult women.</p> <p>The quality of the evidence for all reported main outcomes between these two interventions was either low (indicating that our confidence in the effect estimate is limited and that the true effect may be substantially different from the estimate of the effect) or very low (indicating that we have very little confidence in the effect estimate and that the true effect is likely to be substantially different from the estimate of effect). </p> <p>2. Metformin compared to metformin combined with the OCP in adult women.</p> <p>The quality of the evidence for all reported main outcomes between these two interventions was low . </p> <p>3. The OCP compared to metformin combined with the OCP in adult women.</p> <p>The quality of the evidence for all reported main outcomes between these two interventions was low except for the outcome of BMI which had very low‐quality evidence. </p> <p>4. Metformin compared to the OCP in adolescent women.</p> <p>The quality of the evidence for all reported main outcomes between these two interventions was very low due primarily to very serious imprecision as the evidence for all reported main outcomes derived from a single RCT. </p> <p>5. Metformin compared to metformin combined with the OCP in adolescent women.</p> <p>There were no trials identified comparing metformin versus metformin combined with the OCP in adolescent women reporting on the outcomes for this review. </p> <p>6. The OCP compared to metformin combined with the OCP in adolescent women.</p> <p>The quality of the evidence for all reported main outcomes between these two interventions was very low due primarily to very serious imprecision as the evidence for all reported main outcomes derived from a single RCT. </p> <p>We observed significant (substantial) heterogeneity in many of the analyses, which was explained in most cases by the pre‐defined subgroup analysis of mean study BMI. Unexplained substantial heterogeneity was observed for the outcomes of BMI (the OCP versus metformin combined with the OCP in adults), systolic and diastolic blood pressure (the OCP versus metformin combined with the OCP in adults), fasting total cholesterol (metformin versus metformin combined with the OCP in adults), fasting total cholesterol (the OCP versus metformin combined with the OCP in adults) and fasting HDL cholesterol (the OCP versus metformin combined with the OCP in adults). Of these outcomes, all showed insufficient evidence to determine whether there was a difference between the interventions except for fasting total cholesterol (metformin versus metformin combined with the OCP in adults), which favoured the intervention of metformin and the result being unchanged with random‐effects meta‐analysis. Unexplained substantial heterogeneity resulted in the downgrading of evidence quality for the main review outcome of BMI (the OCP versus metformin combined with the OCP in adults). </p> </section> <section id="CD005552-sec-0054"> <h3 class="title" id="CD005552-sec-0054">Potential biases in the review process</h3> <p>We conducted a comprehensive search with the help of an experienced Information Specialist, and ran extensive manual searches in order to identify all relevant studies and in an effort to minimise the risk of publication bias. At the review level, we performed funnel plots for the main review outcomes if there were 10 or more studies in an analysis in order to explore the possibility of small‐study effects that may indicate incomplete identification of studies (publication bias). Four funnel plots were performed in total (metformin versus the OCP in adult women for the outcomes of hirsutism ‐ Clinical Ferriman‐Gallwey (F‐G) score, severe adverse events and BMI; the OCP versus metformin combined with the OCP for the outcome of BMI). Two of the funnel plots were symmetrical (metformin versus the OCP in adult women for the outcome of severe adverse events; the OCP versus metformin combined with the OCP for the outcome of BMI), indicating that our findings might not be influenced by publication bias. The other two funnel plots (metformin versus the OCP in adult women for the outcomes of hirsutism ‐ Clinical F‐G score and BMI) were asymmetrical indicating that our findings might be influenced by publication bias although the asymmetrical funnel plots for these two outcomes may also be due to the substantial heterogeneity (explained by mean study BMI subgroups) observed for these two outcomes. </p> <p>We followed Cochrane guidelines to search for and identify all the studies eligible for this review, extract data and assess the quality and potential risks of different types of biases in all our included studies, in order to minimise the chance of error and bias by the review authors. Subjective judgements are involved in the assessment of risk of bias. This potential limitation is minimised by following the procedures in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005552-bbs2-0106" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 5.2 (updated 2017). The Cochrane Collaboration, 2011. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>), with review authors independently assessing studies and resolving any disagreement through discussion, and if required involving a third review author in the decision. </p> <p>There are four studies awaiting classification (<a href="./references#CD005552-bbs2-0083" title="FruzzettiF , PeriniD , LazzariniV , ParriniD , GambaccianiM , GenazzaniRA . Comparison of effects of 3 mg drospirenone plus 20 µg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertility and Sterility2009;94:1793-8. ">Fruzzeti 2009</a>; <a href="./references#CD005552-bbs2-0084" title="">NCT01573377</a>; <a href="./references#CD005552-bbs2-0085" title="Spremovic-RadjenovicS , SreckovicS , GudovicA , DjakonovicM , BilaJ , Radonjic-LazovicG . Comparison of the effects of dianogest/ethinyl estradiol and metformin on metabolic parameters in non-obese women with polycystic ovary syndrome. In: Poster, European Society of Contraception and Reproductive Health, S207. 2014. ">Spremovic‐Radjenovic 2014</a>; <a href="./references#CD005552-bbs2-0086" title="VieiraCS , FernandesJB , SoaresGM , MartinsWP , Silva-de-SàMF , FerrianiRA . Addition of low dose of metformin to the oral contraceptive has no great advantage in terms of cardiovascular risk markers in women with polycystic ovary syndrome regardless insulin resistance. Fertility and Sterility2010;94(4 Suppl 1):S63-4. [Oral communication O-217]">Vieira 2010</a>), and three ongoing clinical trials (<a href="./references#CD005552-bbs2-0087" title="OCP vs metformin for Improvement in clinical symptoms and metabolic markers in Indian PCOS women (OCP). Ongoing study. 04/2016. Contact author for more information.">NCT02744131</a>; <a href="./references#CD005552-bbs2-0088" title="Comparing the effects of oral contraceptive pills versus metformin (COMET-PCOS). Ongoing study. Juillet 2017. Contact author for more information.">NCT03229057</a>; <a href="./references#CD005552-bbs2-0089" title="Relative desirability of metformin vs. birth control pill in treating PCOS in women of later reproductive age. Ongoing study. March 2020. Contact author for more information.">NCT03905941</a>) that are likely to provide further useful information. </p> </section> <section id="CD005552-sec-0055"> <h3 class="title" id="CD005552-sec-0055">Agreements and disagreements with other studies or reviews</h3> <p>A recent systematic review and meta‐analysis of RCTs assessed the efficacy and safety of therapeutic approaches for adult patients with PCOS not seeking fertility including OCPs, antiandrogens (AA) and/or insulin sensitisers including metformin (<a href="./references#CD005552-bbs2-0110" title="Luque-RamirezM , Nattero-ChavezL , Ortiz FloresAE , Escobar-MorrealeHF . Combined oral contraceptive and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update2018;24:225-41.">Luque‐Ramirez 2018</a>). This review did not compare metformin versus the OCP as such, but compared metformin versus the OCP and/or AAs, and agreed with our main outcome findings of a reduction in hirsutism and an improved menstrual pattern for the OCP and/or AAs along with a reduction in BMI for metformin. The outcomes of acne and adverse events were not reported. The global quality of evidence was low for the review, which was consistent with our findings. This review also compared the OCP and/or AAs versus metformin combined with the OCP and/or AAs, and reported on only one of our main outcomes for our review which was BMI. The review found a reduction in BMI with the addition of metformin to the OCP and/or AAs (low‐quality evidence), which disagreed with our findings, although our review did not compare exactly the same interventions as we did not include studies combining AA's with the OCP. </p> <p>A more recent systematic review and meta‐analysis of RCTs aimed to investigate the effect of the OCP and/or metformin in the management of hormonal and clinical features of PCOS in order to inform the recent international guidelines on PCOS (<a href="./references#CD005552-bbs2-0117" title="TeedeHJ , MissoML , CostelloMF , DokrasA , LavenJ , MoranL , et al, International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction2018;33(9):1602-18.">Teede 2018</a>; <a href="./references#CD005552-bbs2-0118" title="TeedeH , TassoneEC , PiltonenT , MalhotraJ , MolBW , PenaA , et al. Effect of the combined oral contraceptive pill and/or Metformin in the management of polycystique ovary syndrome: a systematic review with meta-analyses. Clinical Endocrinology2019;91:479-89.">Teede 2019</a>). This review restricted studies to those published in English language, used stricter study selection criteria in terms of including a RCT in terms of random sequence generation and allocation concealment and different methods for data synthesis (random‐effects model), and grading the quality of evidence (according to risk of bias with each study being allocated a risk of bias rating of either low, moderate of high) compared to our review, and did not report on the outcome of acne. For the comparison metformin versus the OCP, this review's findings agreed with our main outcomes findings with respect to an improvement in menstrual pattern with the OCP, but differed by finding no statistically significant difference between the two interventions for hirsutism, BMI, gastro‐intestinal side effects (all i.e. minor and severe) and other side effects (all i.e. minor and severe). The majority of included studies for this comparison were judged to be of moderate quality, and therefore, the authors recommended that the findings should be interpreted with some degree of caution. </p> <p>The review by Teede and colleagues also compared metformin versus metformin + the OCP and reported on only one of our review main outcomes, BMI, and found no statistically significant difference between the two interventions and thus differed from our review. There were no RCTs reporting on adverse events (<a href="./references#CD005552-bbs2-0118" title="TeedeH , TassoneEC , PiltonenT , MalhotraJ , MolBW , PenaA , et al. Effect of the combined oral contraceptive pill and/or Metformin in the management of polycystique ovary syndrome: a systematic review with meta-analyses. Clinical Endocrinology2019;91:479-89.">Teede 2019</a>). The authors advised caution when interpreting the results due to moderate risk of bias across all studies. The same review also compared the OCP versus metformin + the OCP and found, in terms of the main outcomes for our review, no statistically significant difference between the two interventions for BMI (agreement with our review), gastro‐intestinal severe side effects (disagreement with our review) and gastro‐intestinal minor side effects (disagreement with our review). The RCTs were of moderate quality with small sample sizes (only 1 RCT reporting on gastro‐intestinal severe or minor side‐effects) with the authors advising that the results should be interpreted with caution. </p> <p>The recently published international guideline on PCOS made recommendations based on Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework covering evidence quality, balance between desirable versus undesirable effects (direction and magnitude), feasibility, acceptability, cost, implementation and ultimately recommendation strength (<a href="./references#CD005552-bbs2-0117" title="TeedeHJ , MissoML , CostelloMF , DokrasA , LavenJ , MoranL , et al, International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction2018;33(9):1602-18.">Teede 2018</a>). In terms of pharmacological treatment for non‐fertility indications in adult women with PCOS, the guideline, based on low‐quality evidence, made a strong recommendation for the use of the OCP alone for management of hyperandrogenism and/or irregular menstrual cycles, conditional recommendation for the use of metformin (in addition to lifestyle) for the treatment of weight, hormonal and metabolic outcomes, and a strong recommendation for the use of the OCP combined with metformin for management of metabolic features where the OCP and lifestyle changes do not achieve desired goals. Our review findings are likely to be consistent with these recommendations given that the recommendations are based on more factors than just the evidence (both direction and magnitude in addition to quality), but also take into consideration the balance between desirable versus undesirable consequences, feasibility, acceptability, cost, and implementation. </p> <p>In terms of specifically adolescents with PCOS, two recent systematic review and meta‐analysis of RCTs have evaluated the use of metformin versus the OCP (but not combinations of metformin and/or the OCP) for the treatment of PCOS in adolescents (<a href="./references#CD005552-bbs2-0090" title="Al KhalifahRA , FlorezID , DennisB , ThsbsnrL , BassiliousE . Metformin or oral contraceptives for adolescents with polycystic ovarian syndrome: a meta-analysis. Peditrics2016;137(5):e20154089.">Al Khalifah 2016</a>, <a href="./references#CD005552-bbs2-0118" title="TeedeH , TassoneEC , PiltonenT , MalhotraJ , MolBW , PenaA , et al. Effect of the combined oral contraceptive pill and/or Metformin in the management of polycystique ovary syndrome: a systematic review with meta-analyses. Clinical Endocrinology2019;91:479-89.">Teede 2019</a>). Both of these reviews included the same RCTs that were included for our review and both assessed the quality of evidence as very low or low, and as a result identified the need for future high‐quality RCTs to address several questions for the treatment of adolescents with PCOS, which is in accordance with our conclusions. The latter review also advised caution in the interpretation of the results due to the low quality of the evidence, whilst the former review, in light of the very low/low‐quality evidence, concluded that treatment choice should be guided by patient values and preferences while balancing potential adverse events. This conclusion was performed in order to formulate the recommendations in the recently published international guideline on PCOS which resulted in conditional recommendations (low‐quality evidence) to consider the use of both metformin alone or the OCP alone in adolescents with PCOS as pharmacological treatment for non‐fertility indications (<a href="./references#CD005552-bbs2-0117" title="TeedeHJ , MissoML , CostelloMF , DokrasA , LavenJ , MoranL , et al, International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction2018;33(9):1602-18.">Teede 2018</a>). These conditional recommendations of the international guideline in PCOS reflect our review's findings of there being uncertainty as to whether there is a difference between metformin, when compared to the OCP, in the main outcomes in adolescents with PCOS. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005552-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD005552-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies" data-id="CD005552-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study ." data-id="CD005552-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study . </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Adult ‐ metformin versus OCP (Clinical parameters), outcome: 1.1 Hirsutism ‐ Clinical F‐G score." data-id="CD005552-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Adult ‐ metformin versus OCP (Clinical parameters), outcome: 1.1 Hirsutism ‐ Clinical F‐G score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Adult ‐ metformin versus OCP (Clinical parameters), outcome: 1.1 Hirsutism ‐ Clinical F‐G score." data-id="CD005552-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Adult ‐ metformin versus OCP (Clinical parameters), outcome: 1.1 Hirsutism ‐ Clinical F‐G score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Adult ‐ metformin versus OCP (Clinical parameters), outcome: 1.4 Adverse events ‐ severe." data-id="CD005552-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Adult ‐ metformin versus OCP (Clinical parameters), outcome: 1.4 Adverse events ‐ severe. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 1: Hirsutism ‐ Clinical F‐G score" data-id="CD005552-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 1: Hirsutism ‐ Clinical F‐G score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 2: Hirsutism ‐ Subjective visual analogue scale" data-id="CD005552-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 2: Hirsutism ‐ Subjective visual analogue scale </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 3: Hirsutism ‐ Subjective improvement" data-id="CD005552-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 3: Hirsutism ‐ Subjective improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 4: Adverse events ‐ severe" data-id="CD005552-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 4: Adverse events ‐ severe </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 5: Improved menstrual pattern (ie. shortening of intermenstrual days)" data-id="CD005552-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 5: Improved menstrual pattern (ie. shortening of intermenstrual days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 6: Improved menstrual pattern (ie. an initiation of menses or cycle regularity)" data-id="CD005552-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 6: Improved menstrual pattern (ie. an initiation of menses or cycle regularity) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 7: Acne ‐ Visual analogue scale" data-id="CD005552-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 7: Acne ‐ Visual analogue scale </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 8: Acne ‐ Subjective improvement" data-id="CD005552-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 8: Acne ‐ Subjective improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 9: Diagnosis of Type II diabetes mellitus" data-id="CD005552-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 9: Diagnosis of Type II diabetes mellitus </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 10: Body weight (kg)" data-id="CD005552-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 10: Body weight (kg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 11: Body Mass Index (kg/m2)" data-id="CD005552-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 11: Body Mass Index (kg/m<sup>2</sup>) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 12: Blood pressure ‐ systolic (mm Hg)" data-id="CD005552-fig-0018" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 12: Blood pressure ‐ systolic (mm Hg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 13: Blood pressure ‐ diastolic (mm Hg)" data-id="CD005552-fig-0019" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Adult ‐ Metformin versus OCP (Clinical parameters), Outcome 13: Blood pressure ‐ diastolic (mm Hg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Adult ‐ Metformin versus OCP (Hormonal parameters), Outcome 1: Serum total testosterone (nmol/L)" data-id="CD005552-fig-0020" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Adult ‐ Metformin versus OCP (Hormonal parameters), Outcome 1: Serum total testosterone (nmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Adult ‐ Metformin versus OCP (Hormonal parameters), Outcome 2: Free androgen index (FAI) (%)" data-id="CD005552-fig-0021" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Adult ‐ Metformin versus OCP (Hormonal parameters), Outcome 2: Free androgen index (FAI) (%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Adult ‐ Metformin versus OCP (Metabolic parameters), Outcome 1: Fasting insulin (mIU/L)" data-id="CD005552-fig-0022" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Adult ‐ Metformin versus OCP (Metabolic parameters), Outcome 1: Fasting insulin (mIU/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Adult ‐ Metformin versus OCP (Metabolic parameters), Outcome 2: Fasting glucose (mmol/L)" data-id="CD005552-fig-0023" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Adult ‐ Metformin versus OCP (Metabolic parameters), Outcome 2: Fasting glucose (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Adult ‐ Metformin versus OCP (Metabolic parameters), Outcome 3: Total Cholesterol (mmol/L)" data-id="CD005552-fig-0024" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Adult ‐ Metformin versus OCP (Metabolic parameters), Outcome 3: Total Cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Adult ‐ Metformin versus OCP (Metabolic parameters), Outcome 4: HDL Cholesterol (mmol/L)" data-id="CD005552-fig-0025" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Adult ‐ Metformin versus OCP (Metabolic parameters), Outcome 4: HDL Cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Adult ‐ Metformin versus OCP (Metabolic parameters), Outcome 5: LDL Cholesterol (mmol/L)" data-id="CD005552-fig-0026" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Adult ‐ Metformin versus OCP (Metabolic parameters), Outcome 5: LDL Cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Adult ‐ Metformin versus OCP (Metabolic parameters), Outcome 6: Triglycerides (mmol/L)" data-id="CD005552-fig-0027" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Adult ‐ Metformin versus OCP (Metabolic parameters), Outcome 6: Triglycerides (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Adult ‐ Metformin versus Metformin combined with OCP (Clinical parameters), Outcome 1: Hirsutism ‐ Clinical F‐G score" data-id="CD005552-fig-0028" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Adult ‐ Metformin versus Metformin combined with OCP (Clinical parameters), Outcome 1: Hirsutism ‐ Clinical F‐G score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Adult ‐ Metformin versus Metformin combined with OCP (Clinical parameters), Outcome 2: Adverse events ‐severe" data-id="CD005552-fig-0029" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Adult ‐ Metformin versus Metformin combined with OCP (Clinical parameters), Outcome 2: Adverse events ‐severe </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Adult ‐ Metformin versus Metformin combined with OCP (Clinical parameters), Outcome 3: Body weight (kg)" data-id="CD005552-fig-0030" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Adult ‐ Metformin versus Metformin combined with OCP (Clinical parameters), Outcome 3: Body weight (kg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Adult ‐ Metformin versus Metformin combined with OCP (Clinical parameters), Outcome 4: Body Mass Index (kg/m2)" data-id="CD005552-fig-0031" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Adult ‐ Metformin versus Metformin combined with OCP (Clinical parameters), Outcome 4: Body Mass Index (kg/m2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Adult ‐ Metformin versus Metformin combined with OCP (Clinical parameters), Outcome 5: Blood pressure ‐ systolic (mm Hg)" data-id="CD005552-fig-0032" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Adult ‐ Metformin versus Metformin combined with OCP (Clinical parameters), Outcome 5: Blood pressure ‐ systolic (mm Hg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Adult ‐ Metformin versus Metformin combined with OCP (Clinical parameters), Outcome 6: Blood pressure ‐ diastolic (mm Hg)" data-id="CD005552-fig-0033" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Adult ‐ Metformin versus Metformin combined with OCP (Clinical parameters), Outcome 6: Blood pressure ‐ diastolic (mm Hg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Adult ‐ Metformin versus Metformin combined with OCP (Hormonal parameters), Outcome 1: Serum total testosterone (nmol/L)" data-id="CD005552-fig-0034" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Adult ‐ Metformin versus Metformin combined with OCP (Hormonal parameters), Outcome 1: Serum total testosterone (nmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Adult ‐ Metformin versus Metformin combined with OCP (Hormonal parameters), Outcome 2: FAI (%)" data-id="CD005552-fig-0035" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Adult ‐ Metformin versus Metformin combined with OCP (Hormonal parameters), Outcome 2: FAI (%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Adult ‐ Metformin versus Metformin combined with OCP (Metabolic parameters), Outcome 1: Fasting insulin (mIU/L)" data-id="CD005552-fig-0036" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Adult ‐ Metformin versus Metformin combined with OCP (Metabolic parameters), Outcome 1: Fasting insulin (mIU/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Adult ‐ Metformin versus Metformin combined with OCP (Metabolic parameters), Outcome 2: Fasting glucose (mmol/L)" data-id="CD005552-fig-0037" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Adult ‐ Metformin versus Metformin combined with OCP (Metabolic parameters), Outcome 2: Fasting glucose (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Adult ‐ Metformin versus Metformin combined with OCP (Metabolic parameters), Outcome 3: Total Cholesterol (mmol/L)" data-id="CD005552-fig-0038" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Adult ‐ Metformin versus Metformin combined with OCP (Metabolic parameters), Outcome 3: Total Cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Adult ‐ Metformin versus Metformin combined with OCP (Metabolic parameters), Outcome 4: HDL Cholesterol (mmol/L)" data-id="CD005552-fig-0039" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Adult ‐ Metformin versus Metformin combined with OCP (Metabolic parameters), Outcome 4: HDL Cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Adult ‐ Metformin versus Metformin combined with OCP (Metabolic parameters), Outcome 5: LDL Cholesterol (mmol/L)" data-id="CD005552-fig-0040" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Adult ‐ Metformin versus Metformin combined with OCP (Metabolic parameters), Outcome 5: LDL Cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Adult ‐ Metformin versus Metformin combined with OCP (Metabolic parameters), Outcome 6: Triglycerides (mmol/L)" data-id="CD005552-fig-0041" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Adult ‐ Metformin versus Metformin combined with OCP (Metabolic parameters), Outcome 6: Triglycerides (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 1: Hirsutism ‐ Clinical F‐G score" data-id="CD005552-fig-0042" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 1: Hirsutism ‐ Clinical F‐G score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 2: Adverse events ‐ severe" data-id="CD005552-fig-0043" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 2: Adverse events ‐ severe </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 3: Adverse events ‐ minor" data-id="CD005552-fig-0044" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 3: Adverse events ‐ minor </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 4: Acne ‐ Clinical acne score" data-id="CD005552-fig-0045" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 4: Acne ‐ Clinical acne score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 5: Acne ‐ Subjective improvement" data-id="CD005552-fig-0046" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 5: Acne ‐ Subjective improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-007.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 6: Body weight (kg)" data-id="CD005552-fig-0047" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-007.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-007.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 6: Body weight (kg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-007.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-007.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 7: Body Mass Index (kg/m2)" data-id="CD005552-fig-0048" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-007.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-007.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7: Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 7: Body Mass Index (kg/m2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-007.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-007.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 8: Blood Pressure ‐ Systolic (mmHg)" data-id="CD005552-fig-0049" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-007.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-007.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7: Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 8: Blood Pressure ‐ Systolic (mmHg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-007.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-007.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 9: Blood Pressure ‐ Diastolic (mmHg)" data-id="CD005552-fig-0050" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-007.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-007.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7: Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 9: Blood Pressure ‐ Diastolic (mmHg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-007.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Adult ‐ OCP versus Metformin combined with OCP (Hormonal parameters), Outcome 1: Serum total testosterone (nmol/L)" data-id="CD005552-fig-0051" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Adult ‐ OCP versus Metformin combined with OCP (Hormonal parameters), Outcome 1: Serum total testosterone (nmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Adult ‐ OCP versus Metformin combined with OCP (Hormonal parameters), Outcome 2: Free androgen index (FAI) (%)" data-id="CD005552-fig-0052" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Adult ‐ OCP versus Metformin combined with OCP (Hormonal parameters), Outcome 2: Free androgen index (FAI) (%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Adult ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 1: Fasting insulin (mIU/L)" data-id="CD005552-fig-0053" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Adult ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 1: Fasting insulin (mIU/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Adult ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 2: Fasting glucose (mmol/L)" data-id="CD005552-fig-0054" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Adult ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 2: Fasting glucose (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Adult ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 3: Total Cholesterol (mmol/L)" data-id="CD005552-fig-0055" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Adult ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 3: Total Cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Adult ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 4: HDL Cholesterol (mmol/L)" data-id="CD005552-fig-0056" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Adult ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 4: HDL Cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-009.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Adult ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 5: LDL Cholesterol (mmol/L)" data-id="CD005552-fig-0057" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-009.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-009.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9: Adult ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 5: LDL Cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-009.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-009.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Adult ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 6: Triglycerides (mmol/L)" data-id="CD005552-fig-0058" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-009.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-009.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9: Adult ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 6: Triglycerides (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-009.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Adolescent ‐ Metformin versus OCP (Clinical parameters), Outcome 1: Hirsutism ‐ Clinical F‐G score" data-id="CD005552-fig-0059" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Adolescent ‐ Metformin versus OCP (Clinical parameters), Outcome 1: Hirsutism ‐ Clinical F‐G score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Adolescent ‐ Metformin versus OCP (Clinical parameters), Outcome 2: Hirsutism ‐ Subjective improvement" data-id="CD005552-fig-0060" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Adolescent ‐ Metformin versus OCP (Clinical parameters), Outcome 2: Hirsutism ‐ Subjective improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Adolescent ‐ Metformin versus OCP (Clinical parameters), Outcome 3: Adverse event ‐ severe" data-id="CD005552-fig-0061" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Adolescent ‐ Metformin versus OCP (Clinical parameters), Outcome 3: Adverse event ‐ severe </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-010.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Adolescent ‐ Metformin versus OCP (Clinical parameters), Outcome 4: Adverse event ‐ minor" data-id="CD005552-fig-0062" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-010.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-010.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10: Adolescent ‐ Metformin versus OCP (Clinical parameters), Outcome 4: Adverse event ‐ minor </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-010.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-010.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Adolescent ‐ Metformin versus OCP (Clinical parameters), Outcome 5: Improved menstrual pattern (ie. an initiation of menses or cycle regularity)" data-id="CD005552-fig-0063" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-010.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-010.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10: Adolescent ‐ Metformin versus OCP (Clinical parameters), Outcome 5: Improved menstrual pattern (ie. an initiation of menses or cycle regularity) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-010.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-010.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Adolescent ‐ Metformin versus OCP (Clinical parameters), Outcome 6: Body Weight (kg)" data-id="CD005552-fig-0064" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-010.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-010.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10: Adolescent ‐ Metformin versus OCP (Clinical parameters), Outcome 6: Body Weight (kg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-010.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-010.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Adolescent ‐ Metformin versus OCP (Clinical parameters), Outcome 7: Body Mass Index (kg/m2)" data-id="CD005552-fig-0065" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-010.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-010.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.7</div> <div class="figure-caption"> <p>Comparison 10: Adolescent ‐ Metformin versus OCP (Clinical parameters), Outcome 7: Body Mass Index (kg/m<sup>2</sup>) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-010.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-010.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Adolescent ‐ Metformin versus OCP (Clinical parameters), Outcome 8: Blood pressure ‐ systolic (mm Hg)" data-id="CD005552-fig-0066" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-010.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-010.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.8</div> <div class="figure-caption"> <p>Comparison 10: Adolescent ‐ Metformin versus OCP (Clinical parameters), Outcome 8: Blood pressure ‐ systolic (mm Hg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-010.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-010.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Adolescent ‐ Metformin versus OCP (Clinical parameters), Outcome 9: Blood pressure ‐ diastolic (mm Hg)" data-id="CD005552-fig-0067" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-010.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-010.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.9</div> <div class="figure-caption"> <p>Comparison 10: Adolescent ‐ Metformin versus OCP (Clinical parameters), Outcome 9: Blood pressure ‐ diastolic (mm Hg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-010.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Adolescent ‐ Metformin versus OCP (Hormonal parameters), Outcome 1: Serum total testosterone (nmol/L)" data-id="CD005552-fig-0068" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Adolescent ‐ Metformin versus OCP (Hormonal parameters), Outcome 1: Serum total testosterone (nmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Adolescent ‐ Metformin versus OCP (Hormonal parameters), Outcome 2: Free androgen index (FAI) (%)" data-id="CD005552-fig-0069" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Adolescent ‐ Metformin versus OCP (Hormonal parameters), Outcome 2: Free androgen index (FAI) (%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Adolescent ‐ Metformin versus OCP (Metabolic parameters), Outcome 1: Fasting insulin (mIU/L)" data-id="CD005552-fig-0070" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Adolescent ‐ Metformin versus OCP (Metabolic parameters), Outcome 1: Fasting insulin (mIU/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Adolescent ‐ Metformin versus OCP (Metabolic parameters), Outcome 2: Fasting glucose (mmol/L)" data-id="CD005552-fig-0071" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Adolescent ‐ Metformin versus OCP (Metabolic parameters), Outcome 2: Fasting glucose (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Adolescent ‐ Metformin versus OCP (Metabolic parameters), Outcome 3: Total Cholesterol (mmol/L)" data-id="CD005552-fig-0072" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: Adolescent ‐ Metformin versus OCP (Metabolic parameters), Outcome 3: Total Cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-012.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Adolescent ‐ Metformin versus OCP (Metabolic parameters), Outcome 4: HDL Cholesterol (mmol/L)" data-id="CD005552-fig-0073" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-012.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-012.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12: Adolescent ‐ Metformin versus OCP (Metabolic parameters), Outcome 4: HDL Cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-012.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-012.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Adolescent ‐ Metformin versus OCP (Metabolic parameters), Outcome 5: LDL Cholesterol (mmol/L)" data-id="CD005552-fig-0074" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-012.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-012.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.5</div> <div class="figure-caption"> <p>Comparison 12: Adolescent ‐ Metformin versus OCP (Metabolic parameters), Outcome 5: LDL Cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-012.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-012.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Adolescent ‐ Metformin versus OCP (Metabolic parameters), Outcome 6: Triglycerides (mmol/L)" data-id="CD005552-fig-0075" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-012.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-012.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.6</div> <div class="figure-caption"> <p>Comparison 12: Adolescent ‐ Metformin versus OCP (Metabolic parameters), Outcome 6: Triglycerides (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-012.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Adolescent ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 1: Hirsutism ‐ Clinical F‐G score" data-id="CD005552-fig-0076" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Adolescent ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 1: Hirsutism ‐ Clinical F‐G score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Adolescent ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 2: Adverse events ‐ severe" data-id="CD005552-fig-0077" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: Adolescent ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 2: Adverse events ‐ severe </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Adolescent ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 3: Body Mass Index (kg/m2)" data-id="CD005552-fig-0078" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: Adolescent ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 3: Body Mass Index (kg/m2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-013.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Adolescent ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 4: Blood Pressure ‐ Systolic (mmHg)" data-id="CD005552-fig-0079" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-013.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-013.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13: Adolescent ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 4: Blood Pressure ‐ Systolic (mmHg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-013.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-013.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Adolescent ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 5: Blood Pressure ‐ Diastolic (mmHg)" data-id="CD005552-fig-0080" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-013.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-013.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.5</div> <div class="figure-caption"> <p>Comparison 13: Adolescent ‐ OCP versus Metformin combined with OCP (Clinical parameters), Outcome 5: Blood Pressure ‐ Diastolic (mmHg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-013.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Adolescent ‐ OCP versus Metformin combined with OCP (Hormonal parameters), Outcome 1: Serum total testosterone (nmol/L)" data-id="CD005552-fig-0081" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: Adolescent ‐ OCP versus Metformin combined with OCP (Hormonal parameters), Outcome 1: Serum total testosterone (nmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Adolescent ‐ OCP versus Metformin combined with OCP (Hormonal parameters), Outcome 2: Free androgen index (FAI) (%)" data-id="CD005552-fig-0082" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: Adolescent ‐ OCP versus Metformin combined with OCP (Hormonal parameters), Outcome 2: Free androgen index (FAI) (%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Adolescent ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 1: Fasting glucose (mmol/L)" data-id="CD005552-fig-0083" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: Adolescent ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 1: Fasting glucose (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-015.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Adolescent ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 2: Total Cholesterol (mmol/L)" data-id="CD005552-fig-0084" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-015.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-015.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15: Adolescent ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 2: Total Cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-015.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-015.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Adolescent ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 3: HDL Cholesterol (mmol/L)" data-id="CD005552-fig-0085" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-015.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-015.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15: Adolescent ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 3: HDL Cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-015.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-015.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Adolescent ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 4: LDL Cholesterol (mmol/L)" data-id="CD005552-fig-0086" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-015.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-015.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.4</div> <div class="figure-caption"> <p>Comparison 15: Adolescent ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 4: LDL Cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-015.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005552-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/urn:x-wiley:14651858:media:CD005552:CD005552-CMP-015.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Adolescent ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 5: Triglycerides (mmol/L)" data-id="CD005552-fig-0087" src="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-015.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_t/tCD005552-CMP-015.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.5</div> <div class="figure-caption"> <p>Comparison 15: Adolescent ‐ OCP versus Metformin combined with OCP (Metabolic parameters), Outcome 5: Triglycerides (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/media/CDSR/CD005552/image_n/nCD005552-CMP-015.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005552-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Metformin compared to oral contraceptive pill (OCP) for hirsutism, acne, and menstrual pattern in adult women with polycystic ovary syndrome (PCOS)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Metformin compared to OCP for hirsutism, acne, and menstrual pattern in adult women with PCOS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult women with PCOS<br/><b>Setting:</b> Hospital or University Clinics<br/><b>Intervention:</b> metformin<br/><b>Comparison:</b> OCP </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with OCP</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with metformin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Hirsutism ‐ Clinical F‐G score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI ≤ 25kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean hirsutism ‐ Clinical F‐G score was 7.5</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.38 higher<br/>(0.44 lower to 1.19 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI &gt; 25 kg/m<sup>2</sup> &lt; 30 kg/m<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean hirsutism ‐ Clinical F‐G score was 6.44</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 1.92 higher<br/>(1.21 higher to 2.64 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>254 (5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>LOW<sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI ≥ 30 kg/m<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean hirsutism ‐ Clinical F‐G score was 6.05</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 0.38 lower<br/>(1.93 lower to 1.17 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>LOW<sup>1,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events ‐ Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1 000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1 000<br/>(10 to 45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 6.42<br/>(2.98 to 13.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>602<br/>(11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>122 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>27 per 1000</p> <p>(12 to 57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.20<br/>(0.09 to 0.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>363<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>6,7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse events ‐ Minor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse events ‐ Minor ‐ Gastro‐intestinal"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse events ‐ Minor ‐ Others"</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Improved menstrual pattern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shortening of intermenstrual days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improved menstrual pattern (ie. shortening of intermenstrual days) was 32.4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 6.05 higher<br/>(2.37 higher to 9.74 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝⊝<br/>LOW <sup>4,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An initiation of menses or cycle regularity) ‐ ≤<br/>25 kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1 000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1 000<br/>(1000 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.07<br/>(0.01 to 0.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An initiation of menses or cycle regularity)‐ BMI &gt; 25 kg/m<sup>2</sup> &lt; 30 kg/m<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>931 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>669 per 1000 (486 to 817)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.15 (0.07 to 0.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>VERY LOW <sup>7,8,9</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An initiation of menses or cycle regularity) ‐ BMI ≥ 30 kg/m<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1000 per 1 000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1000 per 1 000<br/>(1000 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.09 (0.01 to 1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>6,10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An initiation of menses or cycle regularity) ‐ BMI not stated</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>500 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>661 per 1000 (281 to 906)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.95 (0.39 to 9.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>VERY LOW <sup>8,10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne ‐ Visual analogue scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean acne ‐ Visual analogue scale was 1</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.90 higher<br/>(0.40 lower to 2.20 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>11</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>BMI (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI ≤ 25 kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BMI (kg/m<sup>2</sup>) was 22.7 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.59 lower<br/>(1.02 lower to 0.17 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>451<br/>(9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>VERY LOW</p> <p><sup>1,12,13</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI &gt; 25 kg/m<sup>2</sup> &lt; 30 kg/m<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean BMI (kg/m<sup>2</sup>) was 27.4 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 0.11 higher<br/>(0.48 lower to 0.7 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>353 (8 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>VERY LOW</p> <p><sup>1,14,15</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI ≥ 30 kg/m<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean BMI (kg/m<sup>2</sup>) was 35.1 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 2.31 lower<br/>(4.40 lower to 0.21 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>VERY LOW</p> <p><sup>1, 15,16</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI:</b> body mass index; <b>CI:</b> Confidence interval; <b>F‐G:</b> Ferriman‐Gallwey score; <b>MD:</b> Mean difference; <b>OR:</b> Odds ratio; <b>RCT:</b> Randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Evidence downgraded by one level for serious risk of bias ‐ the majority of the RCTs have unclear or high risk of bias<br/><sup>2</sup> Evidence downgraded by one level for serious inconsistency (I<sup>2</sup> = 50%) as unexplained heterogeneity (i.e. heterogeneity not explained by subgrouping of data according to mean study BMI) </p> <p><sup>3</sup> Evidence downgraded by one level for serious imprecision – 95% CI includes both appreciable effect and little or no effect and low number of participants (total number of participants &lt; 400) </p> <p><sup>4</sup> Evidence downgraded by one level for serious imprecision – low number of participants (total number of participants &lt; 400) </p> <p><sup>5</sup> Evidence downgraded by one level for serious imprecision ‐ low number of participants (total number of participants &lt; 400) and 95% CI includes both appreciable benefit and harm </p> <p><sup>6</sup> Evidence downgraded by one level for serious risk of bias ‐ the majority of the RCTs have unclear risk of bias </p> <p><sup>7</sup> Evidence downgraded by one level for serious imprecision – low number of events (total number of events &lt; 300) </p> <p><sup>8</sup> Evidence downgraded by one level for serious risk of bias ‐ the majority of the RCTs have high risk of bias </p> <p><sup>9</sup> Evidence downgraded by one level for serious inconsistency (I<sup>2</sup> = 51%) as unexplained heterogeneity (i.e. heterogeneity not explained by subgrouping of data according to mean study BMI) </p> <p><sup>10</sup> Evidence downgraded by two levels for very serious imprecision – 95% CI includes both appreciable benefit and harm or no effect and very low number of events (total number of events &lt; 300) </p> <p><sup>11</sup> Evidence downgraded by two levels for serious imprecision – 95% CI includes both appreciable benefit and harm or no effect and low number of participants (total number of participants &lt; 400) </p> <p><sup>12</sup> Evidence downgraded by one level for serious inconsistency (I<sup>2</sup> = 76%) as unexplained heterogeneity (i.e. heterogeneity not explained by subgrouping of data according to mean study BMI) </p> <p><sup>13</sup> Evidence downgraded by one level for serious imprecision – 95% CI includes both appreciable effect and little or no effect </p> <p><sup>14</sup> Evidence downgraded by one level for serious inconsistency (I<sup>2</sup> = 72%) as unexplained heterogeneity (i.e. heterogeneity not explained by subgrouping of data according to mean study BMI) </p> <p><sup>15</sup> Evidence downgraded by one level for serious imprecision ‐ low number of participants (total number of participants &lt; 400) and 95% CI includes both appreciable effect and little or no effect </p> <p><sup>16</sup> Evidence downgraded by one level for serious inconsistency (I<sup>2</sup> = 52%) as unexplained heterogeneity (i.e. heterogeneity not explained by subgrouping of data according to mean study BMI) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Metformin compared to oral contraceptive pill (OCP) for hirsutism, acne, and menstrual pattern in adult women with polycystic ovary syndrome (PCOS)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005552-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Metformin compared to metformin combined with oral contraceptive pill (OCP) for hirsutism, acne, and menstrual pattern in adult women with polycystic ovary syndrome (PCOS)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Metformin compared to metformin combined with OCP for hirsutism, acne, and menstrual pattern in adult women with PCOS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population: a</b> dult women with PCOS<br/><b>Setting:</b> Hospital or University Clinics<br/><b>Intervention:</b> metformin<br/><b>Comparison:</b> metformin combined with OCP </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Metformin combined with OCP</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with metformin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hirsutism ‐ Clinical F‐G score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean hirsutism ‐ Clinical F‐G score was 5.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.36 higher<br/>(0.62 higher to 2.11 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events ‐ Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1 000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1 000<br/>(17 to 168) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.74<br/>(0.21 to 2.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>60 per 1 000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>35 per 1 000<br/>(7 to 153) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.56<br/>(0.11 to 2.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>109<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse events ‐ Minor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse events ‐ Minor ‐ Gastro‐intestinal"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse events ‐ Minor ‐ Others"</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Improved menstrual pattern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shortening of intermenstrual days</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trials reported on outcome "Improved menstrual pattern (i.e. shortening of intermenstrual days)" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An initiation of menses or cycle regularity</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trials reported on outcome "Improved menstrual pattern (i.e. an initiation of menses or cycle regularity)" </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne ‐ Visual analogue scale/Clinical acne score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trials reported either on outcome "Acne ‐ Visual analogue scale" or "Acne ‐ Clinical acne score" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean Body Mass Index (kg/m<sup>2</sup>) was 25.49 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 1.47 lower<br/>(2.27 lower to 0.66 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>199<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI: Body mass index; CI:</b> Confidence interval; <b>F‐G:</b> Ferriman‐Gallwey score; <b>MD:</b> Mean difference; <b>OR:</b> Odds ratio; <b>RCT:</b> Randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Evidence downgraded by one level for serious risk of bias ‐ the majority of the RCTs have unclear risk of bias<br/><sup>2</sup> Evidence downgraded by one level for serious imprecision – low number of participants (total number of participants &lt; 400)<br/><sup>3</sup> Evidence downgraded by one level for serious imprecision – low number of events (total number of events &lt; 300) and 95% CI includes both appreciable benefit and harm </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Metformin compared to metformin combined with oral contraceptive pill (OCP) for hirsutism, acne, and menstrual pattern in adult women with polycystic ovary syndrome (PCOS)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005552-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oral contraceptive pill (OCP) compared to metformin combined with OCP for hirsutism, acne, and menstrual pattern in adult women with polycystic ovary syndrome (PCOS)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>OCP compared to Metformin combined with OCP for hirsutism, acne, and menstrual pattern in adult women with polycystic ovary syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> aAdult women with PCOS<br/><b>Setting:</b> Hospital or University Clinics<br/><b>Intervention:</b> OCP<br/><b>Comparison:</b> metformin combined with OCP </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with metformin combined with OCP</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with OCP</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hirsutism ‐ Clinical F‐G score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean hirsutism ‐ Clinical F‐G score was 5.57</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.54 higher<br/>(0.20 higher to 0.89 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>389<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse events ‐ Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>98 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>21 per 1000<br/>(6 to 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.20<br/>(0.06 to 0.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>228<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000<br/>(19 to 179) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.61<br/>(0.49 to 5.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events ‐ Minor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>260 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/>(4 to 134) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.06<br/>(0.01 to 0.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse events ‐ Minor ‐ Others"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Improved menstrual pattern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shortening of inter menstrual days</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Improved menstrual pattern (i.e. shortening of inter menstrual days)" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An initiation of menses or cycle regularity</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Improved menstrual pattern (i.e. an initiation of menses or cycle regularity)" </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne ‐ Clinical acne score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean acne ‐ Clinical acne score was 0.54</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.09 lower<br/>(0.10 lower to 0.08 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMI (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BMI (kg/m<sup>2</sup>) was 28.6 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.21 lower<br/>(0.53 lower to 0.12 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>661<br/>(13 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI:</b> body mass index; <b>CI:</b> Confidence interval; <b>F‐G:</b> Ferriman‐Gallwey score; <b>MD:</b> Mean difference; <b>OR:</b> Odds ratio; <b>RCT:</b> Randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Evidence downgraded by one level for serious risk of bias ‐ the majority of the RCTs have unclear risk of bias<br/><sup>2</sup> Evidence downgraded by one level for serious imprecision – low number of participants (total number of participants &lt; 400) and 95% CI includes both appreciable effect and little or no effect<br/><sup>3</sup> Evidence downgraded by one level for serious imprecision ‐ low number of events (total number of events &lt; 300)<br/><sup>4</sup> Evidence downgraded by one level for serious imprecision – low number of events (total number of events &lt; 300) and 95% CI includes both appreciable benefit and harm<br/><sup>5</sup> Evidence downgraded by one level for serious risk of bias ‐ the majority of the RCTs have high risk of bias<br/><sup>6</sup> Evidence downgraded by one level for serious imprecision – low number of events (total number of events &lt; 300)<br/><sup>7</sup>Evidence downgraded by one level for serious imprecision – very low number of participants (total number of participants &lt; 400; i.e n = 82; single RCT) and/or 95% CI includes both appreciable effect and little or no effect<br/><sup>8</sup>Evidence downgraded by one level for serious inconsistency ‐ substantial heterogeneity was detected which was not explained by the difference in effect of the interventions between the BMI subgroups (test for subgroup difference: P = 0.64, I<sup>2</sup> = 0%) </p> <p><sup>9</sup> Evidence downgraded by one level for serious imprecision ‐ 95% CI includes both appreciable effect and little or no effect </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oral contraceptive pill (OCP) compared to metformin combined with OCP for hirsutism, acne, and menstrual pattern in adult women with polycystic ovary syndrome (PCOS)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005552-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Metformin compared to oral contraceptive pill (OCP) for hirsutism, acne, and menstrual pattern in adolescent women with polycystic ovary syndrome (PCOS)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Metformin compared to OCP for hirsutism, acne, and menstrual pattern in adolescent women with PCOS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> adolescent women with PCOS<br/><b>Setting:</b> Hospital or University Clinics<br/><b>Intervention: m</b> etformin<br/><b>Comparison:</b> OCP </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with OCP</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with metformin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hirsutism ‐ Clinical F‐G score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean hirsutism ‐ Clinical F‐G score was 8.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.40 lower<br/>(3.42 lower to 2.62 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse event ‐ Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse event ‐ Severe ‐ Gastro‐intestinal"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1 000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1 000<br/>(27 to 300) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.63<br/>(0.16 to 2.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse event ‐ Minor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1 000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1 000<br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 11.67<br/>(0.53 to 258.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were only 3 events in the arm metformin and 0 in the arm OCP</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse event ‐ Minor ‐ Others"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Improved menstrual pattern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shortening of inter menstrual days</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Improved menstrual pattern (i.e. shortening of inter menstrual days)" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An initiation of menses or cycle regularity</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 000 per 1 000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1 000<br/>(1 000 to 1 000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.10<br/>(0.01 to 1.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>3,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 out of 40 participants had improved menstrual patter in the OCP group compared to 36 out of 40 in the metformin group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne ‐ Visual analogue scale or Clinical acne score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported either on outcome "Acne ‐ Visual analogue scale" or "Acne ‐ Clinical acne score" </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMI (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BMI (kg/m<sup>2</sup>) was 36 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.45 lower<br/>(5.08 lower to 2.17 </p> <p>higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>7,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI:</b> body mass index; <b>CI:</b> Confidence interval; <b>F‐G:</b> Ferriman‐Gallwey score; <b>MD:</b> Mean difference; <b>OR:</b> Odds ratio; <b>RCT:</b> Randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Evidence downgraded by one level for serious risk of bias – a single RCT which has unclear risk of bias<br/><sup>2</sup> Evidence downgraded by two levels for very serious imprecision – very low number of participants (total number of participants &lt; 400 i.e. n = 16 participants) and 95% CI includes both appreciable benefit and appreciable harm<br/><sup>3</sup> Evidence downgraded by one level for serious risk of bias – a single RCT which has high risk of bias<br/><sup>4</sup> Evidence downgraded by two levels for very serious imprecision – very low number of events (total number of events &lt; 300 i.e. n = 10 events) and 95% CI includes both appreciable benefit and appreciable harm<br/><sup>5</sup> Evidence downgraded by two levels for very serious imprecision – very low number of events (total number of events &lt; 300 i.e. n = 3 events) and 95% CI includes both appreciable benefit and appreciable harm<br/><sup>6</sup> Evidence downgraded by two levels for very serious imprecision – very low number of events (total number of events &lt; 300 i.e. n = 76 events) and 95% CI includes both appreciable benefit and appreciable harm<br/><sup>7</sup> Evidence downgraded by one level for serious risk of bias ‐ the majority of the RCTs have unclear risk of bias<br/><sup>8</sup> Evidence downgraded by two levels for very serious imprecision – very low number of participants (total number of participants &lt; 400 i.e. n = 69 participants) and 95% CI includes both appreciable benefit and appreciable harm </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Metformin compared to oral contraceptive pill (OCP) for hirsutism, acne, and menstrual pattern in adolescent women with polycystic ovary syndrome (PCOS)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005552-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Metformin compared to metformin combined with oral contraceptive pill (OCP) for hirsutism, acne and menstrual pattern in adolescent women with polycystic ovary syndrome (PCOS)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Metformin compared to metformin combined with OCP for hirsutism, acne and menstrual pattern in adolescent women with PCOS</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> adolescent women with PCOS<br/><b>Setting:</b> Hospital or University Clinics<br/><b>Intervention:</b> metformin<br/><b>Comparison:</b> metformin combined with OCP </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with metformin combined with OCP</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with metformin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hirsutism ‐ Clinical F‐G score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Hirsutism ‐ Clinical F‐G score"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse event ‐ Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse event ‐ Severe ‐ Gastro‐intestinal"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse event ‐ Severe ‐ Others"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse event ‐ Minor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse event ‐ Minor ‐ Gastro‐intestinal"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse event ‐ Minor ‐ Others"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Improved menstrual pattern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shortening of inter menstrual day</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Improved menstrual pattern (i.e. shortening of intermenstrual days)" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An initiation of menses or cycle regularity</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Improved menstrual pattern (i.e. an initiation of menses or cycle regularity)" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne ‐ Visual analogue scale or Clinical acne score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported either on outcome "Acne ‐ Visual analogue scale" or "Acne ‐ Clinical acne score" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "BMI"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI:</b> body mass index; <b>CI:</b> Confidence interval; <b>F‐G:</b> Ferriman‐Gallwey score; <b>MD:</b> Mean difference; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Metformin compared to metformin combined with oral contraceptive pill (OCP) for hirsutism, acne and menstrual pattern in adolescent women with polycystic ovary syndrome (PCOS)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005552-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Oral contraceptive pill (OCP) compared to metformin combined with OCP for hirsutism, acne, and menstrual pattern in adolescent women with polycystic ovary syndrome PCOS</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>OCP compared to metformin combined with OCP for hirsutism, acne, and menstrual pattern in adolescent women with PCOS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> adolescent women with PCOS<br/><b>Setting:</b> Hospital or University Clinics<br/><b>Intervention:</b> OCP<br/><b>Comparison:</b> metformin combined with OCP </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with metformin combined with OCP</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with OCP</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hirsutism ‐ Clinical F‐G score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean hirsutism ‐ Clinical F‐G score was 6.2</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.80 higher<br/>(1.19 lower to 2.79 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events ‐ Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1 000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1 000<br/>(4 to 505) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00<br/>(0.06 to 17.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse events ‐ Severe ‐ Others"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse events ‐ Minor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastro‐intestinal</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse events ‐ Minor ‐ Gastro‐intestinal"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Adverse events ‐ Minor ‐ Others"</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Improved menstrual pattern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shortening of intermenstrual days</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Improved menstrual pattern (i.e. shortening of intermenstrual days)" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An initiation of menses or cycle regularity</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported on outcome "Improved menstrual pattern (i.e. an initiation of menses or cycle regularity)" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne ‐ Visual analogue scale or Clinical acne score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported either on outcome "Acne ‐ Visual analogue scale" or "Acne ‐ Clinical acne score" </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMI (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BMI (kg/m<sup>2</sup>) was 32.4 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.5 higher<br/>(1.63 lower to 4.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI:</b> body mass index; <b>CI:</b> Confidence interval; <b>F‐G:</b> Ferriman‐Gallwey score; <b>MD:</b> Mean difference; <b>OR:</b> Odds ratio; <b>RCT:</b> Randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Evidence downgraded by one level for serious risk of bias – a single RCT which has unclear risk of bias<br/><sup>2</sup> Evidence downgraded by two levels for very serious imprecision – very low number of participants (total number of participants &lt; 400 i.e. n = 32 participants) and 95% CI includes both appreciable benefit and appreciable harm<br/><sup>3</sup> Evidence downgraded by two levels for very serious imprecision – very low number of events (total number of events &lt; 300 i.e. n = 2 events) and 95% CI includes both appreciable benefit and appreciable harm </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Oral contraceptive pill (OCP) compared to metformin combined with OCP for hirsutism, acne, and menstrual pattern in adolescent women with polycystic ovary syndrome PCOS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005552-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Conversion Factors</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Convert from</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Convert to</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Conversion factor</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Androstenedione</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cholesterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.026</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence intervals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence intervals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(upper limit ‐ lower limit)/3.92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glucose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.056</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mIU/L (= microIU/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1667</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sex hormone‐binding globulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mcg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sqrt n</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Testosterone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pg/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Triglycerides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.011</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Conversion Factors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/full#CD005552-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005552-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Adult ‐ Metformin versus OCP (Clinical parameters)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Hirsutism ‐ Clinical F‐G score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.57, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [‐0.44, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [1.21, 2.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐1.93, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Hirsutism ‐ Subjective visual analogue scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Hirsutism ‐ Subjective improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Mean BMI not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Adverse events ‐ severe <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Gastro‐intestinal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.42 [2.98, 13.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.09, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Improved menstrual pattern (ie. shortening of intermenstrual days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.05 [2.37, 9.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 BMI &gt; 25 kg/m2&lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.10 [2.40, 9.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.10 [‐55.47, 49.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Improved menstrual pattern (ie. an initiation of menses or cycle regularity) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.11, 0.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.01, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.07, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.4 Mean BMI not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.39, 9.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Acne ‐ Visual analogue scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Acne ‐ Subjective improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.11, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.16, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.03, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 Mean BMI not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Diagnosis of Type II diabetes mellitus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Body weight (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.93 [‐2.93, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.02 [‐0.22, 8.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.96 [‐6.32, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.50 [‐5.16, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Body Mass Index (kg/m<sup>2</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>923</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.74, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 BMI ≤ 25kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.59 [‐1.02, ‐0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 BMI &gt; 25kg/m2&lt; 30kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.48, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.31 [‐4.40, ‐0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Blood pressure ‐ systolic (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.81 [‐8.55, ‐1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 BMI &gt; 25 kg/m2&lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.48 [‐9.56, ‐1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.11 [‐10.62, 8.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Blood pressure ‐ diastolic (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.98 [‐4.72, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 BMI &gt; 25 kg/m2&lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.25 [‐7.30, ‐1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.50 [1.27, 13.73]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Adult ‐ Metformin versus OCP (Clinical parameters)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005552-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Adult ‐ Metformin versus OCP (Hormonal parameters)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Serum total testosterone (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.32, 0.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.38, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 BMI &gt; 25 kg/m2&lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.07, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.11, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 Mean BMI not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.69 [‐2.02, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Free androgen index (FAI) (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.95 [3.32, 4.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.48 [3.56, 5.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 BMI &gt; 25 kg/m2&lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.06 [2.14, 3.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.12 [4.46, 9.79]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Adult ‐ Metformin versus OCP (Hormonal parameters)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005552-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Adult ‐ Metformin versus OCP (Metabolic parameters)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Fasting insulin (mIU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.85 [‐4.73, ‐2.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.91 [‐5.40, ‐2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 BMI &gt; 25 kg/m2&lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.08 [‐5.25, ‐2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.00 [‐8.48, ‐1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.4 Mean BMI not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.35 [‐1.64, 8.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Fasting glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.22, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.23, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 BMI &gt; 25 kg/m2&lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.31, ‐0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.22, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Total Cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.40, ‐0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.77 [‐1.00, ‐0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 BMI &gt; 25 kg/m2&lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.30, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.32, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 HDL Cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.01, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.10, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 BMI &gt; 25 kg/m2&lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.02, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.05, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 LDL Cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.12, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.54, ‐0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 BMI &gt; 25 kg/m2&lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.06, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.02, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Triglycerides (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.12, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.61, ‐0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 BMI &gt; 25 kg/m2&lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.07, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.64, 0.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Adult ‐ Metformin versus OCP (Metabolic parameters)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005552-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Adult ‐ Metformin versus Metformin combined with OCP (Clinical parameters)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Hirsutism ‐ Clinical F‐G score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.62, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.21, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 BMI &gt; 25k g/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [0.75, 3.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Adverse events ‐severe <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Gastro‐intestinal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.21, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.11, 2.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Body weight (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.39 [‐10.70, ‐0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.39 [‐10.70, ‐0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Body Mass Index (kg/m2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.47 [‐2.27, ‐0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐2.44, ‐0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.38 [‐2.94, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Blood pressure ‐ systolic (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Blood pressure ‐ diastolic (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Adult ‐ Metformin versus Metformin combined with OCP (Clinical parameters)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005552-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Adult ‐ Metformin versus Metformin combined with OCP (Hormonal parameters)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Serum total testosterone (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.22, 0.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.08, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.57, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 FAI (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [2.08, 3.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [‐1.09, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.80 [2.91, 4.69]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Adult ‐ Metformin versus Metformin combined with OCP (Hormonal parameters)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005552-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Adult ‐ Metformin versus Metformin combined with OCP (Metabolic parameters)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Fasting insulin (mIU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.32 [‐2.63, ‐0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.58 [‐3.47, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.09 [‐2.91, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Fasting glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.37, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.54, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.38, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Total Cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.54 [‐0.97, ‐0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐1.56, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐1.02, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 HDL Cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.08, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.64 [‐0.99, ‐0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.04, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 LDL Cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.32, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.1 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.32, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Triglycerides (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.37, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.69 [‐1.14, ‐0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.32, ‐0.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Adult ‐ Metformin versus Metformin combined with OCP (Metabolic parameters)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005552-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Hirsutism ‐ Clinical F‐G score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.20, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.33, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 BMI &gt; 25 kg/m2&lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.24, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Adverse events ‐ severe <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 Gastro‐intestinal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.06, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 Others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.49, 5.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Adverse events ‐ minor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.01, 0.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 Gastro‐intestinal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.01, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Acne ‐ Clinical acne score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.1 BMI &gt; 25 kg/m2&lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Acne ‐ Subjective improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 Body weight (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.63 [‐1.58, 0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐1.55, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.2 BMI &gt; 25 kg/m2&lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.67 [‐6.46, 3.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.30 [‐23.46, 12.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.7 Body Mass Index (kg/m2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.53, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.52, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐1.29, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.10 [‐9.61, 3.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.8 Blood Pressure ‐ Systolic (mmHg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.75 [‐4.03, 0.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8.1 BMI ≤ 25kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [‐3.42, 4.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.29 [‐5.24, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.80 [‐17.94, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.9 Blood Pressure ‐ Diastolic (mmHg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.05 [‐2.79, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐3.75, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.61 [‐2.84, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.20 [‐10.60, 0.20]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Adult ‐ OCP versus Metformin combined with OCP (Clinical parameters)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005552-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Adult ‐ OCP versus Metformin combined with OCP (Hormonal parameters)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Serum total testosterone (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.01, 0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.01, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.04, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [‐4.23, 6.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Free androgen index (FAI) (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.30, 0.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [‐0.12, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.29, 0.73]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Adult ‐ OCP versus Metformin combined with OCP (Hormonal parameters)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005552-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Adult ‐ OCP versus Metformin combined with OCP (Metabolic parameters)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Fasting insulin (mIU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [1.49, 3.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.77 [3.26, 6.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>385</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.42, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.63 [‐9.67, 6.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Fasting glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.11, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.07, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.14, 0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.81, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Total Cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.05, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.20, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.04, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.31, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 HDL Cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.01, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.00, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.02, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.02, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.5 LDL Cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.05, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.18, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.07, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.27, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.6 Triglycerides (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.09, 0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6.1 BMI ≤ 25 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.08, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6.2 BMI &gt; 25 kg/m2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.15, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6.3 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.67, 1.27]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Adult ‐ OCP versus Metformin combined with OCP (Metabolic parameters)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005552-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Adolescent ‐ Metformin versus OCP (Clinical parameters)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Hirsutism ‐ Clinical F‐G score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Hirsutism ‐ Subjective improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 Mean BMI not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Adverse event ‐ severe <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.1 Others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.4 Adverse event ‐ minor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4.1 Gastro‐intestinal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.5 Improved menstrual pattern (ie. an initiation of menses or cycle regularity) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.1 Mean BMI not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.6 Body Weight (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐18.77 [‐20.57, ‐16.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.60 [‐17.87, 12.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6.2 Mean BMI not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐19.00 [‐20.81, ‐17.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.7 Body Mass Index (kg/m<sup>2</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.45 [‐5.08, 2.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.7.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.45 [‐5.08, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.8 Blood pressure ‐ systolic (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.8.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.9 Blood pressure ‐ diastolic (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.9.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Adolescent ‐ Metformin versus OCP (Clinical parameters)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005552-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Adolescent ‐ Metformin versus OCP (Hormonal parameters)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Serum total testosterone (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [‐0.21, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [‐0.21, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Free androgen index (FAI) (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Adolescent ‐ Metformin versus OCP (Hormonal parameters)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005552-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Adolescent ‐ Metformin versus OCP (Metabolic parameters)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Fasting insulin (mIU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.55 [‐4.82, 13.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.55 [‐4.82, 13.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Fasting glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Total Cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.12 [‐1.66, ‐0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.12 [‐1.66, ‐0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.4 HDL Cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.10, 0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.10, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.5 LDL Cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.92 [‐1.49, ‐0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.92 [‐1.49, ‐0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.6 Triglycerides (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.37, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.6.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.37, 0.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Adolescent ‐ Metformin versus OCP (Metabolic parameters)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005552-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Adolescent ‐ OCP versus Metformin combined with OCP (Clinical parameters)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Hirsutism ‐ Clinical F‐G score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Adverse events ‐ severe <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.1 Gastro‐intestinal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 Body Mass Index (kg/m2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.4 Blood Pressure ‐ Systolic (mmHg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.5 Blood Pressure ‐ Diastolic (mmHg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Adolescent ‐ OCP versus Metformin combined with OCP (Clinical parameters)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005552-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Adolescent ‐ OCP versus Metformin combined with OCP (Hormonal parameters)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Serum total testosterone (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 Free androgen index (FAI) (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Adolescent ‐ OCP versus Metformin combined with OCP (Hormonal parameters)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005552-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Adolescent ‐ OCP versus Metformin combined with OCP (Metabolic parameters)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Fasting glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.2 Total Cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.3 HDL Cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.4 LDL Cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.5 Triglycerides (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Adolescent ‐ OCP versus Metformin combined with OCP (Metabolic parameters)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005552.pub3/references#CD005552-tbl-0022">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005552.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD005552-note-0020">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005552-note-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005552-note-0019">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD005552-note-0017">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD005552-note-0016">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD005552-note-0014">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD005552-note-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD005552-note-0012">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD005552-note-0013">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD005552-note-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD005552-note-0011">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005552\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005552\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005552\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005552\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005552\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005552\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005552\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005552\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005552\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005552\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005552\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005552\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005552\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005552\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005552\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005552\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005552\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005552\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=JmNqPX1V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005552.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005552.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005552.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005552.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005552.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716061584"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005552.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716061588"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005552.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d9649daf8f409',t:'MTc0MDcxNjA2Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 